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Abstract 
Haemophilus influenzae type b (Hib) was a main cause of bacterial meningitis. 
Together with Neisseria meningitidis and Streptococcus pneumoniae, it occurred 
with comparable frequency prior to the introduction of conjugated polysaccharide 
vaccines against Hib. Despite the fact that the introduction of conjugated vaccines 
against Hib has virtually eradicated infection in many areas of the globe, this 
pathogen still causes many infections in developing countries and a number of 
cases of infection have been reported in fully vaccinated children in developed 
countries. Recent studies have focused on the mechanisms by which these 
pathogens invade the central nervous system through the blood brain barrier 
(BBB). One study revealed that the outer membrane protein OmpP2 of H. 
influenzae interacted with the 37/67-kDa non-integrin laminin receptor (LamR) of 
human brain microvascular endothelial cells (HBMECs). In this study, OmpP2 of 
H. influenzae was expressed and purified and its interactions with purified 
recombinant LamR (rLamR) were analysed. OmpP2, which is predicted to contain 
eight H[WUDFHOOXODUORRSVZDVH[SUHVVHGLQWZRSDUWV2PS3ǻ-4, lacking loops 
1-DQG2PS3ǻ-8, lacking loops 5-8. The protein fragments were purified and 
their interaction with rLamR was investigated by ELISA. The LamR binding site 
of OmpP2 was found to be restricted to loops 1-4. Therefore, ompP2 derivatives 
encoding OmpP2 lacking loops 1, 2, 3 and 4 individually, were constructed. The 
OmpP2 derivatives were expressed and tested in rLamR-binding assays to 
GHWHUPLQHZKLFKRI WKHVH ORRSV LV UHTXLUHGIRU/DP5ELQGLQJ2QO\2PS3¨/
showed dramatically decreased binding to rLamR. Accordingly, loop 2 of OmpP2 
may play an important role in the interaction of H. influenzae with LamR. 
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Therefore, ompP2 and oPS3ǻ/ null mutants were generated in H. influenzae 
strain Rd KW20 and utilized in subsequent characterization experiments to 
facilitate a study of the potential role of OmpP2 and its second loop in the 
pathogenesis of H. influenzae. The interaction of H. influenzae and its derivative 
mutants to LamR was investigated using a combination of molecular and 
immunological techniques, including ELISA, whole cell lysate pull-down assays, 
invasion and association assays and flow cytometry. H. influenzae cells either 
lacking OmpP2 or expressing 2PS3¨/showed significantly reduced rLamR-
binding compared to the wild type. Furthermore, synthetic peptides based on the 
loop 2 sequence coupled to micro-beads mediated adherence of the beads to 
HBMECs. The amino acid sequence of OmpP2 loop 2 was found to be highly 
conserved in Hib isolates, but not in non-typeable H. influenzae, which rarely 
cause invasive disease. The potential roles of OmpP2 and Loop 2 in H. influenzae 
pathogenesis are discussed. 
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CHAPTER ONE 
1. GENERAL INTRODUCTION 
1.1  Meningitis  
Meningitis is an inflammation of the meninges: the pia mater, the arachnoid mater 
and the dura mater. It is characterised by the presence of polymorphonuclear cells 
in the cerebrospinal fluid (CSF). Inflammation of these membranes may be caused 
by a number of pathogenic microbes including viruses, fungi, parasites and 
bacteria, which are capable of entry into the central nervous system (CNS). 
Although several bacteria are able to invade the CNS and cause meningitis, the 
majority of cases are caused by Neisseria meningitidis, Haemophilus influenzae, 
and Streptococcus pneumoniae and, in newborns, Escherichia coli K1 and Group 
B streptococcus (1999; Harvey et al., 1999; Huang et al., 2000). 
1.2  Clinical Presentation of Bacterial Meningitis 
The signs and symptoms among patients with bacterial meningitis can be variable, 
subtle, non-specific, or even absent and somewhat dependent on the age (Kim, 
2010; Mace, 2008). They are more subtle and atypical in the younger patient 
(Saez-Llorens & McCracken, 2003). The common manifestations noted at any age 
are fever (85% of patients) which is more common in adults than in children, 
headache, neck stiffness, nausea and altered mental status (Kaplan, 1999; 
Rosenstein et al., 2001). Other symptoms which can be seen in older children and 
adults including: vomiting, irritability, neck or back pain, photophobia, anorexia, 
lethargy, malaise and PD\EH DFFRPSDQLHG E\ .HUQLJ¶V IOH[LQJ WKH KLS DQG
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H[WHQGLQJWKHNQHHWRHOLFLWSDLQLQWKHEDFNDQGOHJVDQGRU%UXG]LQVNL¶VVLJQV
(passive flexion of the neck elicits flexion of the hips) (Kaplan, 1999; Tunkel & 
Scheld, 1995). In addition, signs include cerebral dysfunction (confusion, 
delirium, or declining consciousness) which are found in 85% of patients who 
present with acute bacterial meningitis, cranial nerve palsies and focal cerebral 
signs occur in 10-20% of cases. Buccal or periorbital cellulitis, delirium, 
drowsiness, and coma can also develop (Kaplan, 1999; Tunkel & Scheld, 1995). 
Seizures occur more commonly in children (20% to 30%) than in adults (0-12%) 
and occur more frequently with S. pneumoniae or H. influenzae type b (Hib) than 
with meningitis caused by N. meningitidis (Tunkel & Scheld, 1995; Geiseler et 
al., 1980; Kaplan, 1999; Saez-Llorens & McCracken, 2003). Occasionally, 
hearing loss or balance disorder were found as initial symptoms in older patients. 
Petechiae or purpura are noted in adults with N. meningitidis, S. pneumoniae and 
Hib. Arthritis, pneumonia, and pericarditis are examples of other suppurative 
signs of bacterial meningitis (Kaplan, 1999). The signs and symptoms in infants 
who have meningitis are often non-specific and include irritability, diarrhoea, 
lethargy, fever, stiff neck, poor feeding, seizures, apnea, a rash, or bulging 
fontanelles (Galiza & Heath, 2009; Kim, 2010). 
1.3  Laboratory Diagnosis of Bacterial Meningitis  
Blood and CFS (from lumbar puncture) cultures along with morphologic and 
chemical examination of CSF (cell count, glucose and protein concentrations) are 
used for WKHURXWLQH ODERUDWRU\GLDJQRVLVRIEDFWHULDOPHQLQJLWLV*UDP¶VVWDLQ LV
employed for initial assessment of CSF; other stains, such as Acridine orange and 
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Wayson stain also can be used (Daly et al., 1985). CSF findings suggestive of 
bacterial meningitis are: Glucose less than 40 mg/dL or ratio of CSF/blood 
glucose less than 0.40, protein greater than 200 mg/dL, white blood cells (WBC) 
greater than 1000/µL, greater than 80% polymorphonuclear neutrophils, opening 
pressure (OP) of greater than 300 mm (Mace, 2008). In addition, many non-
culture tests are used, such as latex agglutination (Gray & Fedorko, 1992), loop-
mediated isothermal amplification (Kim et al., 2011), microarray or biochip (Ben 
et al., 2008). PCR has been used to detect microbial DNA in the CSF of a patient 
with suspected bacterial meningitis (primers are available for detection of the 
most common organisms, such as N. meningitidis, S. pneumoniae, and Hib (Chiba 
et al., 2009; Kotilainen et al., 1998; Poppert et al., 2005). Leukocyte aggregation 
score (LAS) in the CSF was described as a cheap, simple and rapid method to 
detect and differentiate diagnosis of bacterial or meningitis (Garty et al., 1997). 
Computerised tomographic (CT) scans or magnetic resonance (MR) imaging of 
the head are being used to detect a number of anatomic abnormalities in patients 
with bacterial meningitis (Kline & Kaplan, 1988; Steele et al., 1985; Chen & 
Jiang, 2011). The presence of S. pneumoniae, N. meningitidis, or Hib can be 
confirmed using the Quellung procedure by mixing drop of CSF with antisera 
specific for the capsular polysaccharides of each of these three bacteria; the 
presence of the bacterial capsules can be detected under microscopic examination 
(Gray & Fedorko, 1992). Furthermore, Counter-immunoelectrophoresis (CIE) 
(Naiman & Albritton, 1980), Gas-liquid chromatography (GLC) (Thadepalli et 
al., 1982), EIA Enzyme immunoassays (EIAs) (Salih et al., 1989) have been used 
for the detection of suspected bacterial meningitis. 
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1.4  Epidemiology and Incidence of Bacterial Meningitis  
In spite of the introduction and widespread use of antibiotics and other advances 
in medical care, meningitis still has a high morbidity and mortality (Durand et al., 
1993). Bacterial meningitis is an even more significant problem in many areas of 
the world, especially in developing countries. Despite the fact that many microbes 
that are pathogenic to humans have the potential to cause meningitis, relatively 
few of them are responsible for most cases of bacterial meningitis; these include 
S. pneumoniae, N. meningitidis, group B streptococcus, Hib, E. coli K1, 
Mycobacterium tuberculosis, and Listeria monocytogenes (Thigpen et al., 2011). 
Between 1998 and 2007, more than 3000 patients with bacterial meningitis were 
identified in eight surveillance area in the United States (about 17.4 million 
persons), 14.8% of them died (Thigpen et al., 2011). Of the 1670 cases reported in 
the same study during 2003±2007, S. pneumoniae was the predominant infective 
species (58.0%), followed by group B streptococci (18.1%), N. meningitidis 
(13.9%), H. influenzae (6.7%), and L. monocytogenes (3.4%) (Thigpen et al., 
2011).  
More generally, S. pneumoniae, N. meningitidis, and Hib are the most common 
etiologic agents, which account for 90% of reported cases of acute bacterial 
meningitis (Peltola, 2000; CDC, 2002). In England and Wales, these three 
pathogens counted for 60% of the episodes (Bedford et al., 2001). In the United 
States during the 1950s, 1960s, and 1970s they were identified to be responsible 
for the majority of the incidence of bacterial meningitis cases (70%) (Brouwer et 
al., 2010).  
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Despite the change in the range of causative infecting bacteria, the rate of 
incidence has not changed dramatically around the world, in England and Wales 
from 1985 through 1987, the incidence was 0.22 per 1,000 live births (de Louvois 
et al., 1991), 0.25 to 2.66 cases per 1,000 live births in Costa Rica (Odio, 1995), 
and 0.25 per 1,000 in Philadelphia and 0.36 to 1.11 in South Africa (Adhikari et 
al., 1995). Between 1986 and 2001 in Kaohsiung-Taiwan, H. influenzae, 
Salmonella species, Strep. agalactiae, and E. coli were identified as the most 
causative agents of bacterial meningitis (about 59%) in 80 cases of reported 
bacterial meningitis in children of 1 month to one year of age (Chang et al., 2004). 
The annual incidence in children younger than 5 years of age between 1995 and 
2000 in Kenyans increased from 120 to 202 per 100,000 (Mwangi et al., 2002). 
The predominant causes were S. pneumoniae (43.1%) and H. influenzae (41.9%) 
(Mwangi et al., 2002). Recently, in a study performed in Turkey, 408 CSF 
samples were collected for a one year period (2005-2006) from children aged 1-17 
months. Bacterial meningitis was identified in 243 samples. N. meningitidis was 
the most common causative bacterial agent (56.5%) followed by S. pneumoniae 
(22.5%) then Hib (20.5%). Among N. meningitidis±positive CSF samples, 42.7%, 
31.1%, 2.2%, and 0.7% belonged to serogroups W-135, B, Y, and A, respectively 
(Ceyhan et al., 2008). From 1981 to 1996, 7078 cases of bacterial meningitis were 
identified in Niger (lies within the African meningitis belt), the majority were 
caused by N. meningitidis (57.7%), followed by S. pneumoniae (13.2%) and Hib 
(9.5%) (Campagne et al., 1999). Between 2002 and 2005, a surveillance study 
was performed to determine the incidence of childhood bacterial meningitis in 
children between 2 months to 5 years of age in Ulaanbaatar, Mongolia. 201 
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suspected meningitis cases were identified in residents of Ulaanbaatar. The 
average annual incidence rate for confirmed and probable bacterial meningitis was 
68 cases per 100,000 children aged 2 months to 5 years. The average annual 
incidence rate of confirmed cases was 28 cases per 100,000 children for Hib 
meningitis, 11 cases per 100,000 children for pneumococcal meningitis, and 13 
cases per 100,000 children for meningococcal meningitis (Mendsaikhan et al., 
2009). 
1.5  Epidemiology and Incidence of H. influenzae 
Before the advent of H. influenzae type b (Hib) conjugate vaccines, H. influenzae 
type b meningitis was the leading cause of bacterial meningitis in childhood 
(Mendsaikhan et al., 2009; Howie et al., 2007). The incidence of Hib meningitis 
was 26-43/100,000 per year in Denmark, Norway, Finland, Sweden and Iceland 
(Claesson, 1993). The highest rates of Hib meningitis occur in the first year of 
life. Most cases were in children aged 3 months to 3 years, as most infants are 
protected by passively acquired maternal antibodies during the first few months of 
life and they naturally develop immunity to H. influenzae after 3 years of age 
(Munson et al., 1989b; Saez-Llorens & McCracken, 2003). Prior to the 
availability of H. influenzae type b conjugate vaccines in the United States, Hib 
was the most frequent cause of bacterial meningitis (45 to 48%) (peak incidence, 
6 to 12 months of age) (Schlech et al., 1985). A prospective, laboratory-based 
surveillance project obtained accurate data on meningitis in a population of 34 
million people during 1986; H. influenzae was the most common cause of 
bacterial meningitis (45%), followed by S. pneumoniae (18%), and N. 
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meningitidis (14%) (Wenger et al., 1990). The annual incidence for Hib 
meningitis in the Oxford region between 1985 and 1990 was 25.1 per 100,000 
children aged less than 5 years with overall mortality was 4.3% and the majority 
of cases (71%) occurred in children younger than 2 years of age (Booy et al., 
1993). In the Republic of Ireland (1991 to 1993), the mean annual incidence rate 
of H. influenzae meningitis in children under five years was 25.4 per 100,000 with 
peak incidence (65-8 per 100,000) in the 6-11 months age-group (Fogarty et al., 
1995). 
During the past 25 years and due to the introduction of programs for immunizing 
infants with conjugate Hib vaccines, the incidence of bacterial meningitis and 
other forms of invasive disease caused by Hib have greatly reduced in several 
parts of the world (Bisgard et al., 1998; Schuchat et al., 1997; van Alphen et al., 
1997; Slack et al., 1998; Wenger, 1998; Garpenholt et al., 2000; Daza et al., 
2006; Cowgill et al., 2006; Lagos et al., 1998; Robbins et al., 1996; Dery & 
Hasbun, 2007). Since the introduction of the Hib conjugate vaccine in 1990 in the 
United States, the incidence of bacterial meningitis has declined by 55% (Dery & 
Hasbun, 2007; Thigpen et al., 2011). Most industrialised countries use a 3-dose 
schedule in early infancy (2, 3, and 4 months) with a further dose at 11±18 months 
(Campbell et al., 2009; Peltola et al., 2005; Rijkers et al., 2003). Following three 
doses of conjugate Hib vaccines; polyribosyl-ribitol-phosphate (PRP) conjugated 
to tetanus toxoid (PRP-T), diphtheria toxoid (PRP-D), the non-toxic variant of 
diphtheria toxin CRM197 (HbOC), in infancy showed 83±100% protection against 
invasive Hib infections (Black et al., 1991; Vadheim et al., 1993; Booy et al., 
1994). Higher estimates of efficacy were obtained after a booster dose in the 
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second year of life (Trotter et al., 2008; Fitzgerald et al., 2005). After the 
introduction of Hib vaccines into the routine infant immunization schedule, the 
median age of persons with bacterial meningitis increased greatly, from 15 
months in 1986 to 25 years in 1995 and recently increased to 39 years of age in 
the United States (Bisgard et al., 1998; Schuchat et al., 1997). 
1.6  Bacterial Meningitis Vaccines 
Available vaccines against Hib, N. meningitidis (except N. meningitidis serogroup 
B) and S. pneumoniae are based on the polysaccharide capsule of the bacteria 
(Trotter et al., 2008). The polysaccharide capsules of these pathogens are 
composed of repeating saccharide units, the chemical nature of which defines the 
capsular type of the organism (Pollard et al., 2009). The disadvantages of 
polysaccharide vaccines are that they generally produce weak T-cell-independent 
immune responses which provide short-term protection and they are not generally 
immunogenic in infants (Trotter et al., 2008; Smith et al., 1973; Coutinho & 
Moller, 1973). In order to improve immunogenicity, polysaccharide vaccines were 
conjugated to different carrier proteins, such as tetanus toxoid or mutated 
diphtheria toxin CRM197 (which contains a glycine to glutamic acid point 
mutation at position 52 in the A subunit of diphtheria toxoid). These conjugate 
vaccines are immunogenic in children aged under 2 years and are able to induce a 
T-cell dependent immune response which provides long-term immunity through 
the production of new memory B cells (Bulkow et al., 1993; Trotter & Ramsay, 
2007; Bar-Zeev & Buttery, 2006). 
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1.6.1  H. influenzae Type b (Hib) Conjugate Vaccine Use and 
Effectiveness 
Newborn babies and infants are protected until approximately 6 months of age by 
maternal antibodies which were supplied through transplacental transfer; after this 
age they become susceptible to invasive Hib disease (Ulanova & Tsang, 2009). 
The Hib capsular polysaccharide was the first vaccine to be licensed for use 
against Hib in 1985. It was composed of polyribosyl ribitol phosphate (PRP) 
(Morris et al., 2008). Despite the fact that the PRP vaccine provided adequate 
protection in children above 2 years, it provided little protection in infants 
younger than 18 months (Peltola et al., 1977). Polysaccharides are not recognized 
by T cells in children < 18 months, and therefore this cohort has poor immune 
responses to T-cell-independent antigens (McVernon et al., 2004b; Pollard et al., 
2009; Coutinho & Moller, 1973). Consequently, new vaccines based on PRP 
chemically conjugated to a carrier protein were developed, such as diphtheria 
toxoid PRP-D, tetanus toxoid PRP-T or outer membrane protein of N. 
meningitidis PRP-OMP (Trotter et al., 2008; Pollard et al., 2009).  
Helper T cells are needed to generate an anamnestic response, and also to induce 
class switching, are able to recognise a peptide linked to the antigen recognised by 
a B cell (McVernon et al., 2004a). These new Hib vaccines have the ability to 
induce immunological memory B cells; such cells induce the secondary immune 
response on re-exposure to Hib antigen (McVernon et al., 2003b). These vaccines 
are highly immunogenic in young children; anti-PRP antibody is induced in 
infants as young as 2 months of age (Trollfors et al., 1992).  
  
 
 
11 
 
Immunisation with Hib conjugate vaccines was introduced in the United Kingdom 
and the Republic of Ireland (ROI) in 1992. In the UK, it was recommended at 2, 
3, and 4 months of age and in the ROI, it is recommended at 2, 4, and 6 months of 
age (Heath et al., 2000). There was also a catch-up campaign, in which a single 
dose was given to those aged < 4 years (Ramsay et al., 2003). The vaccination 
program enhanced the control of Hib infection in England and Wales (Ramsay et 
al., 2003). In England and Wales the incidence of invasive Hib disease has 
dramatically declined in children < 5 years of age since the annual incidence was 
20.5±22.9 per 100,000 in 1990 and by 1998 it had fallen to 0.65 per 100,000 
(Johnson et al., 2006).  
The most commonly used Hib conjugated vaccines consist of PRP conjugated to 
tetanus toxoid (PRP-T), diphtheria toxoid (PRP-D), the non-toxic variant of 
diphtheria toxin CRM197 (HbOC), or an outer membrane protein of N. 
meningitidis (PRP-OMP) (Heath, 1998). H. influenzae vaccines, PRP±T, PRP±
OMP and HbOC are highly efficacious (WHO, 2006). Two injections are needed 
for such vaccines to induce protective antibody response, except for PRP-OMP 
which induces a protective response in 2-month-old infants after a single dose 
(Ulanova & Tsang, 2009). Singleton et al. indicated that in addition to decreasing 
Hib disease in Alaska, by using PRP-OMP in children > 5 years of age, Hib 
carriage also decreased in unvaccinated children, thus revealing a herd immunity 
effect (Singleton et al., 2006). Herd immunity is a consequence of unvaccinated 
children deriving benefit from lower carriage rates in the community and hence 
reduced risk of exposure to Hib. Hib vaccines are now routinely administrated in 
119 countries; however, just 42% of the population in developing countries and 
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only 8% of the population in the poorest developing countries are routinely 
vaccinated (Morris et al., 2008; WHO, 2008).  
Despite the remarkable efficacy of Hib conjugate vaccines, failures were reported 
in different areas of the world (Rijkers et al., 2003; McVernon et al., 2003b; 
Garpenholt et al., 2000). Furthermore, Hib vaccines are not effective against non-
type b H. influenzae. Recent studies showed that Hib bacterial meningitis is still 
causing high rates of incidence and mortality throughout the world (Mendsaikhan 
et al., 2009; Pelkonen et al., 2009). Since 1999, the incidence of Hib infection 
increased predominantly in vaccinated children (Trotter et al., 2003; McVernon et 
al., 2004c). There have been reports of true Hib disease vaccine failures cases in 
children in United Kingdom (Garner & Weston, 2003; Heath et al., 2000). 
Between 1993 and 2001, 363 cases of Hib infection were reported in fully 
vaccinated children in England and Wales (Ramsay et al., 2003). The increase in 
invasive Hib disease incidence in the UK was believed to be due to the 
combination of Hib vaccines with acellular pertussis (DTaP-Hib) (McVernon et 
al., 2003a). In Ireland from 1996 to 2005, the annually reported cases of Hib 
disease in fully vaccinated children were increased from 1 to 10 cases respectively 
(Fitzgerald et al., 2005) and acellular pertussis combinations were not used prior 
to 2005. In the Gambia, a recent report suggests that the number of cases of Hib 
disease may be increasing 8 years after vaccine introduction, highlighting the need 
for continued surveillance (Howie et al., 2007). Therefore, improved vaccines 
containing additional well conserved antigens may lead to a greater reduction in 
H. influenzae disease burden; OmpP2 as a non-capsular outer membrane antigen 
is might be candidate vaccine against Hib infection. 
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1.7  The Genus Haemophilus 
The genus Haemophilus is classified as a member of the family Pasteurellaceae. 
This family, together with another two families (Enterobacteriaceae and 
Vibrionaceae), belong to the facultatively anaerobic Gram-negative rods group 
(Holt et al., 1994). The family Pasteurelleceae contains two main genera of 
interest to human disease; Haemophilus and Actinobacillus (Holt et al., 1994). 
Haemophilus are Gram negative pleomorphic, rod-shaped bacteria, which are 
non-motile, aerobic but facultatively anaerobic and generally oxidase and catalase 
positive. Haemophilus species reduce nitrate, ferment sugars and grow optimally 
at 37°C in an environment supplemented with CO2, on enriched media such as 
nutrient or chocolate agar. The genus name is derived from the Greek word 
³EORRG-ORYLQJ´ DOOXGLQJ WR WKHLU UHTXLUHPHQW IRU KHPH Haemophilus species 
require one or both of two growth fDFWRUV ; IDFWRU KHPLQ RU 9 IDFWRU ȕ-
nicotinamide adenine dinucleotide). These growth factors are required because 
VWUDLQVDUHXQDEOHWRFRQYHUWį-aminolaevulinic acid to protoporphyrin (Collee et 
al., 1996; Cown & Talaro, 2009; Tortora & Case, 2009). Some species of 
Haemophilus, such as H. influenzae, H. aegyptius and H. haemolyticus require 
both of these growth factors. In contrast, H. ducreyi requires only X factor, whilst 
H. parainfluenzae and H. parahymolyticus needs only V factor for survival (Ward 
et al., 2009; William et al., 2005).  
1.7.1  Haemophilus Species 
Haemophilus species are obligate commensals of the mucous membranes of 
humans and animals. Ten species are associated with humans: H. influenzae; H. 
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parainfluenzae; H. haemolyticus; H. parahymolyticus; H. aprophilus; H. 
paraphrophilus; H. paraphrohaemolyticus; H. aegyptius; H. segnis; and H. 
ducreyi (Mahon & Manuselis, 2000). Haemophilus species constitute 
approximately 10% of the total bacterial flora in the human upper respiratory trac, 
with the majority being H. parainfluenzae and non-encapsulated H. influenzae. 
Six species are associated with animals: H. parasuis (swine); H. paragallinarum 
(poultry); H. paracuniculus (rabbits); H. haemoglobinophilus (dogs); and H. felis 
(cats) amongst others (Mahon & Manuselis, 2000). 
1.7.1.1 H. influenzae  
H. influenzae forms part of the normal commensal flora of the throat and 
nasopharynx of between 25-75% of healthy people and acts opportunistically as a 
secondary invader in a variety of respiratory tract infections (Collee et al., 1996). 
H. influenzae transmission is believed to occur from person to person by contact 
with infected respiratory droplets (Marrs et al., 2001). H. influenzae species are 
divided into two groups: encapsulated and non-encapsulated. Encapsulated H. 
influenzae can cause severe systemic infections including epiglottitis, pneumonia, 
meningitis, osteomyelitis, septic arthritis and orbital cellulitis. Non-encapsulated 
H. influenzae are often associated with localised infections including acute otitis 
media in children, sinusitis in adults and children, and community-acquired 
pneumonia, especially in the elderly and in those with chronic obstructive 
pulmonary disease [COPD] (Goering et al., 2008; Marrs et al., 2001). The H. 
influenzae capsule is composed of polysaccharide and six antigenically distinct 
capsular types are recognized (a-f). Using an animal infection model with 
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genetically constructed isogenic mutants transformed with serotype-specific 
capsule-associated DNA from all six serotypes [a±f], serotype b was demonstrated 
to be the most virulent, followed by serotype a, which is in turn more virulent than 
serotypes c±f (Zwahlen et al., 1989). 
1.7.2  H. influenzae Genome 
The H. influenzae Rd KW20 genome was the first complete genome sequence of a 
free-living organism which reported by Fleischmann et al., (1995). The complete 
nucleotide sequence of the chromosomal DNA is 1.83 Megabase (Mb), with a G+C 
content of 38% (Fleischmann et al., 1995). The number of predicted coding 
regions is 1,743 and the functional predictions were reported for 58% of the 
putative H. influenzae proteins (Fleischmann et al., 1995). The H. influenzae Rd 
KW20 metabolic genotype contains 488 metabolic reactions operating on 343 
metabolites (Fleischmann et al., 1995; Edwards & Palsson, 1999). 
1.7.3  H. influenzae Type b  
WHO reported that H. influenzae type b is responsible for more than 90% of 
infections among the six capsular types of (WHO, 2006). The peak incidence of 
disease is among those aged between 4 months and 18 months, however Hib 
disease is occasionally observed in infants aged less than 3 months (WHO, 2006). 
The highest frequency of invasive disease among unvaccinated children in 
developing countries happens between 6 and 7 months of age (Morris et al., 
2008). Before the era of the Hib conjugate vaccine, most cases of Hib-related 
morbidity and mortality were due to meningitis and pneumonia, but other severe 
invasive infections caused by Hib include epiglottitis, osteomyelitis, septic 
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arthritis, septicaemia, cellulitis, and pericarditis (William et al., 2005). For 
example, data collected from 357 Hib cases in Wales between 1988-1993 showed 
that meningitis and epiglottitis were the most common outcome of infection 
(51.2% and 16.8%, respectively), followed by pneumonia (9.5%), bone and joint 
infections (5.9%), bacteraemia (5.6%), cellulitis (6.7%) and miscellaneous (3.1%) 
(Collee et al., 1996). 
More recently, Peltola (2000) analysed the data from 3,931 patients from 21 
studies worldwide in the 1970s to 1990s and concluded that above 90% of 
invasive Hib infections manifested as six classical entities: meningitis; bacteremic 
pneumonia; epiglottitis; septicaemia; cellulitis; and osteoarticular infections (more 
often septic arthritis than osteomyelitis). Other clinical manifestations constituted 
only 3% of the total number, whereas multifocal cases were diagnosed in 6%. 
Notably, meningitis represented 52% of the entire Hib disease spectrum (Peltola, 
2000). 
1.8  Virulence Factors and Pathogenesis of H. influenzae 
H. influenzae possesses several virulence factors, which are related to 
transmission, adherence, colonization, and invasion. Some of these factors are 
found in all strains, whilst some are only found in sub-populations of strains 
(Vitovski et al., 2002). H. influenzae pathogenesis begins with colonization of the 
nasopharynx, which requires that the organism overcomes host clearance 
mechanisms (van Alphen & van Ham, 1994). This colonisation may be transitory 
or bacteria may remain for several months with no obvious deleterious effects to 
the host (asymptomatic carriage). Bacterial adherence to the respiratory 
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epithelium represents a mechanism to circumvent clearance, whereas invasion 
into host cells and the mucosa of the upper respiratory tract may allow evasion of 
immune function and subsequent entry into the blood. Hib was identified within 
epithelial cells several hours after inoculation of infant monkeys (Smith, 1987). 
Organisms may enter directly into the bloodstream from the nasopharynx via 
mucosal or sub-mucosal blood vessels or they may be transported to regional 
lymph nodes, where some may replicate, and result in bacteraemia (Rubin & 
Moxon, 1983). Subsequently, the bacteria spread in the bloodstream to distant 
sites in the body. Finally, meningitis-causing strains must cross the blood-brain 
barrier (BBB) in order to gain entry to the cerebrospinal fluid (CSF) and brain 
(Polin & Harris, 2001; Quagliarello & Scheld, 1992; Tunkel et al., 1992). Bacteria 
can traverse the BBB and consequently enter the brain transcellularly, 
paracellularly and/or in infected phagocytes (Kim, 2008).  
The BBB maintains the environment of the brain and spinal column by regulating 
the influx and efflux of molecules as well as protecting the central nervous system 
(CNS) from microorganisms and toxins that are circulating in the blood by 
separating the blood contained in the cerebral microvessels from the cerebrospinal 
fluid which surrounds the CNS (Rubin & Staddon, 1999; Leib & Tauber, 1999a). 
The BBB is formed by astrocytes and pericytes and brain microvascular 
endothelial cells (BMECs), which have tight junctions (Chaudhuri, 2000; 
Unkmeir et al., 2002). Studies have revealed that receptors for some meningeal 
pathogens such as H. influenzae are present on the choroid plexus cells, which 
supported bacterial entrance into the subarachnoid space and CSF at this site 
(Tunkel & Scheld, 1993). Once bacteria enter the CSF, they multiply and induce 
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the release of pro-inflammatory and toxic compounds, which lead to increased 
BBB permeability, induce transfer of neutrophils and protein into the 
subarachnoid space, as well as inducing an inflammatory response leading to 
many of the pathophysiologic consequences of bacterial meningitis, pleocytosis, 
encephalopathy, cerebral oedema, increased intracranial pressure, and altered 
cerebral blood flow (Kim, 2008; Molyneux et al., 2002). White blood cells are 
entrapped in fibrin, which cannot cross the villi, consequently producing 
arachnoid villus dysfunction; such dysfunction results in many of the signs and 
symptoms of Hib meningitis. Some of the major virulence factors that contribute 
to these processes are discussed below: 
1.8.1  Capsule 
The capsule is an essential virulence factor for the six encapsulated types (a, b, c, 
d, e and f) and its structure relates directly to the structure of the H. influenzae cap 
locus (17-kb). This consists of three regions; Regions 1 and 3 are similar while 
region 2 is different and is a type specific (Luong et al., 2004; Pittman, 1931). 
According to capsular polysaccharide structure: types a and b are composed of a 
neutral sugar, an alcohol (ribitol), and a phosphodiester bond; types c and f are 
composed of an N-acetylated amino sugar, another saccharide, and a 
phosphodiester bond; types d and e have a repeat unit of an N-acetylglucosamine 
and N-acetylmannosamine uronic acid (Figure 1.1) (Jin et al., 2007). The type b 
capsule is composed of a linear teichoic acid containing ribose, ribitol (a five-
carbon sugar alcohol), and phosphate linked by phosphodiester bonds and is 
named PRP (polyribosyl-ribitol-phosphate). The Hib capsule is unique in that it 
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contains two pentose monosaccharides rather than hexose sugars as subunit 
carbohydrates (Winn et al., 2006). 
 
 
Figure 1.1. Structures of H. influenzae capsular polysaccharide*. Reported from (Sutton 
et al., 1982) . 
Polysaccharide capsules are thought to protect the organism from desiccation, 
potentially facilitating transmission between hosts. Capsule polysaccharide 
also enhances survival in the blood by interfering with the binding of 
opsonising antibodies and complement to the bacterial surface (Marrs et al., 
2001). Thus, encapsulated H. influenzae can evade phagocytosis and 
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complement-mediated lysis in the non-immune host (Mahon & Manuselis, 
2000). 
As previously mentioned, the genes responsible for the biosynthesis and surface 
expression of the H. influenzae capsule are located in the cap locus, which 
contains three functionally distinct regions (Kroll et al., 1991). Region 1 contains 
the genes bexA, bexB, bexC, and bexD genes and encodes an ABC transporter 
system involved in the export of capsular polysaccharide to the bacterial surface 
(Kroll et al., 1990). Region 2 contains serotype-specific biosynthesis genes that 
appear to be unique to each of the six capsule types. The cap b region 2 contains 
the genes orf1 to orf4 which encode enzymes involved in the biosynthesis of 
ribose-ribitol-5-phosphate disaccharide subunit (Van Eldere et al., 1995). Region 
3 contains hcsA and hcsB, which have been shown to be involved in capsule 
transport across the outer membrane (Sukupolvi-Petty et al., 2006). 
In many H. influenzae strains the cap region contains two tandem copies of the 
cap locus, including one copy that is intact and a second copy that is complete 
except for a partial deletion of bexA (Kroll et al., 1988). In the remaining H. 
influenzae isolates, a single copy of the cap locus is present. The significance of 
this duplication is unclear, but gene dosage effects may result in higher capsule 
expression levels in strains containing the cap duplication (Kroll et al., 1988). 
1.8.2  Adhesins  
1.8.2.1  Fimbriae 
Fimbriae are filamentous organelles that extend from the bacterial surface and are 
found on encapsulated type b strains and on about 30-40% of non-typeable strains 
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(Gilsdorf et al., 1997). These organelles are peritrichous, hair-like helical 
structures approximately 5 nm in diameter and up to 450 nm in length (Stull, 
1984). Fimbriae are thought to mediate the initial bacterial attachment to human 
oropharyngeal epithelial cells, thus facilitating respiratory tract colonization 
(reviewed in (St Geme & Falkow, 1990). Spontaneous mutants that lacked surface 
fibrils were deficient in attachment to cultured human epithelial cells (Joseph & 
David, 1995). H. influenzae fimbriae are complex structures composed of 
molecules of the major subunit protein, HifA, and two minor tip proteins, HifD 
and HifE (McCrea et al., 1997). Like P pili and type 1 pili, H. influenzae pili are 
assembled via a chaperone/usher pathway (Bruant et al., 2002). HifA, HifD, and 
HifE bind to the HifB putative chaperone in the periplasm, so protecting them 
from degradation during export from the cell. These proteins are assembled at the 
bacterial surface through interactions with the HifC assembly platform protein. 
The genes encoding these proteins (hifA, hifD, and hifE) exist as a single-copy 
cluster along with hifC and hifB (Bruant et al., 2002). 
Mutants lacking HifA were shown to have a reduced ability to bind human mucin; 
furthermore, antibodies against HifA could block binding (Kubiet et al., 2000). 
HifE, which is found at the tip of the pilus, also has adhesive properties since 
mutations in hifE resulted in the production of fimbriae that had a reduced ability 
to cause hemagglutination and to adhere to epithelial cells (McCrea et al., 1994). 
In addition, antibodies against HifE hindered the binding of Hib to human 
erythrocytes (McCrea et al., 1998). A potential role for HifD remains unclear, but 
mutations in hifD resulted in strains expressing pili which were unable to 
agglutinate erythrocytes (McCrea et al., 1998). Moreover, it was reported that 
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purified Hib fimbriae interacted with two heparin-binding extracellular matrix 
proteins: human fibronectin and heparin-binding growth-associated molecule 
(Virkola et al., 2000).  
1.8.2.2  HMW1 and HMW2 
High-molecular-weight proteins HMW-1 (160 kDa) and HMW2 (155 kDa) are 
members of the auto-transporter family of proteins and are found in 70-80% of 
non-typeable H. influenzae but are rarely present in encapsulated strains (Winn et 
al., 2006). The HMW-1 and HMW-2 proteins are encoded by separate 
chromosomal loci, hmw1 and hmw2, respectively, each containing an hmwA gene, 
which encodes the structural protein, and two accessory genes, called hmwB and 
hmwC, encoding proteins involved in processing and surface localization of the 
HMW adhesins (Barenkamp & St Geme, 1994). These proteins were shown to 
have a role in adherence to human epithelial cells and are important colonization 
factors (St Geme & Falkow, 1993). St Geme & Falkow demonstrated that 
mutations in HMW-1 or HMW-2, or both in non-typeable H. influenzae led to a 
reduction in adherence to cultured human epithelial cells (St Geme & Falkow, 
1993). Furthermore, the HMW-1 and HMW-2 proteins exhibit different cellular 
binding specificities; HMW-1 binds to sialylated glycoproteins, whereas the 
receptor for HMW-2 remains unknown (St Geme, 1994). The amino acids 
sequences 555±914 of HMW-1 (1,536 amino acids) was defined to be the domain 
which is responsible for interacting with epithelial cell receptors while in HMW-2 
(1,477 amino acids) it was the region 553±916 (Dawid et al., 2001). Animals 
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immunized with purified HMW-1/HMW-2 were protected against otitis media 
(Barenkamp, 1996). 
1.8.2.3  Hia and Hsf  
Hia (H. influenzae adhesin) is a trimeric autotransporter protein expressed in non-
typeable H. influenzae strains and in some types a, e, and f strains (Rodriguez et 
al., 2003). Hia promotes adherence to respiratory epithelial cells via two 
homologous binding domains, named HiaBD1 and HiaBD2 (Yeo et al., 2004). 
Barenkamp & St Geme reported that a hia mutant showed reduced attachment to 
various human epithelial cell types (Barenkamp & St Geme, 1996). Interestingly, 
Hia is 81% identical to the Hsf protein (H. surface fibrils), an adhesin found in 
type b strains (St Geme et al., 1996). Hsf also plays an essential role in respiratory 
tract colonization (St Geme et al., 1996). Hsf strongly adheres to vitronectin and 
the active vitronectin binding domains of Hsf were suggested to be between 608±
1351 and 1536±2414 (Hallstrom et al., 2006). Furthermore, the Hia and Hsf 
proteins appear to recognize the same host cell receptor structure (St Geme et al., 
1996).  
1.8.2.4  Hap Adhesin 
The Hap (H. adherence and penetration) adhesin is ubiquitous among isolates of 
H. influenzae and is also a member of the autotransporter family of proteins. Hap 
is synthesized as a 155-kDa pre-protein encompassing a 110-kDa passenger 
domain, HapS, and a 45-N'Dȕ-barrel domain, Hapȕ(Hendrixson et al., 1997). The 
HapS passenger domain has been shown to promote adhesion to human respiratory 
cells as well as to extracellular matrix proteins such as fibronectin, laminin, and 
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collagen IV (Fink et al., 2002). HapS is also responsible for bacterial aggregation 
via Hap-Hap interactions, contributing to microcolony formation (Doran et al., 
2003). Immunization of mice with HapS led to reduction in nasopharyngeal 
colonization when mice were subsequently challenged with a non-typeable H. 
influenzae (Cutter et al., 2002). 
In addition to adhesive properties, HapS functions as a protease directing auto-
proteolytic cleavage of HapS from Hapȕ, resulting in release of the former from 
the cell surface (Fink et al., 2001). Hap protease activity can be blocked by human 
respiratory secretions which contain protease inhibitors, such as secretory 
leukocyte protease inhibitor (Hendrixson & St Geme, 1998). Inhibition results in 
retention of HapS on the bacterial surface, increased adherence to epithelial cells, 
increased adherence to extracellular matrix proteins, increased bacterial 
aggregation, and increased microcolony formation (Hendrixson & St Geme, 
1998). 
1.8.2.5  Opacity-associated Protein A (OapA)  
OapA is a 47-kDa adhesin found in all H. influenzae strains and it is responsible 
for an opaque colonial phenotype (Weiser et al., 1995; Prasadarao et al., 1999). 
Prasadarao et al. showed that OapA mediated attachment to Chang epithelial cells 
as binding was significantly reduced by mutating oapA (Prasadarao et al., 1999). 
Furthermore, both recombinant OapA and polyclonal anti-OapA antiserum 
blocked the binding of H. influenzae to Chang epithelial cells (Prasadarao et al., 
1999). 
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1.8.3  IgA Protease  
IgA1 protease is an extracellular autotransported enzyme that is capable of 
inactivating human immunoglobulin AI (Marrs et al., 2001). IgA1 protease was 
found to be produced by several species of pathogenic bacteria including H. 
influenzae, S. pneumoniae, N. gonorrhoeae and N. meningitidis (Mistry & 
Stockley, 2006). Neisseria gonorrhoeae IgA1 protease was shown to cleave an 
amino acid sequence of human lysosomal-associated membrane protein 1 
(LAMP-1) (Hauck & Meyer, 1997). IgA1 protease also has many effects on the 
immune system as Lorenzen et al have indicated, for example, it stimulates the 
release of cytokines such as tumour necrosis factor Į71)ĮLQWHUOHXNLQ-1ß (IL-
1ß), interleukin-6 (IL6), and interleukin-8 (IL8) (Lorenzen et al., 1999). The IgA1 
proteases are therefore thought to be an important virulence factor, which 
influence colonisation and infection by bacteria at the mucosal surfaces. IgA1 
protease is encoding by the gene iga, which is present in 97% of H. influenzae, 
however it is missing from non-pathogenic Haemophilus species (Fernaays et al., 
2006). Vitovski et al. found that IgA1 protease activity in strains isolated from 
sputum, blood, CSF, or normally sterile tissue of symptomatic individuals was 
considerably higher than in those isolated from throat swabs of asymptomatic 
carriers (Vitovski et al., 2002). However, the precise role of IgA1 protease in the 
pathogenesis of H. influenzae infection has not yet been elucidated. Recently a 
second IgA1 protease gene, igaB has been identified, which is present in around 
one-third of isolated strains (Fernaays et al., 2006). The contribution of this 
second IgA protease to pathogenesis has not yet been determined.  
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1.8.4  Lipooligosaccharide 
Lipooligosaccharide (LOS) of H. influenzae is an outer membrane-associated 
glyco-lipid composed of lipid A joined via 2-keto-3-deoxyoctulosonic acid to a 
core polysaccharide polymer and is analogous to the lipopolysaccharide of many 
Gram-negative bacteria (Swords et al., 2000). Innate responses to lipid A are 
mediated by Toll-like receptor 4 (TLR4) and are important for the containment of 
non-typeable H. influenzae (NTHi) infections in the airway and in the generation 
of the inflammatory response that is induced in chronic airway infections (Wang 
et al., 2002). The interaction between bacteria and host cells is affected by LOS 
structure, which varies considerably between strains and also among bacterial 
cells within a strain. LOS containing phosphorylcholine (ChoP) promotes 
adherence in the upper airway (Swords et al., 2000), and sialylated LOS promotes 
biofilm formation and persistence in the middle ear and lung (Swords et al., 2001). 
Furthermore, these additions have been shown to help the bacteria to survive in 
the nasopharynx and evade phagocytosis by mimicking molecular structures 
usually found in the host (Weiser et al., 1997). Moreover, NTHi invade host cells 
by binding to the platelet-activating factor (PAF) receptor via LOS glycoforms 
containing ChoP (Swords et al., 2001). Mutations affecting the oligosaccharide 
region of LOS or the incorporation of ChoP considerably reduce the adherence to 
and invasion of bronchial cells by NTHi (Swords et al., 2000). 
1.8.5  Outer Membrane Porins 
Outer membrane porins of Gram-negative bacteria are trimeric proteins which are 
mainly responsible for the molecular sieve properties of the outer membrane. 
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They act as a permeability barrier to the free diffusion of molecules across the cell 
envelope; they form water-filled channels, which allow the diffusion of 
hydrophilic molecules into the periplasm (Galdiero, 2007; Srikumar et al., 1992b; 
Vachon et al., 1985). Porins have both hydrophilic and hydrophobic features; the 
side in contact with the membrane is hydrophobic and the other side is 
hydrophilic so as to provide a hydrophilic lining to the pore. Loops are exposed to 
the aqueous environment on either side of the membrane will tend to be 
predominantly hydrophilic. In addition, they are composed of amphipathic 
membrane-spanning beta strands separating short periplasmic loops and longer 
and more variable extracellular loops (Srikumar et al., 1992b). Porins have 
characteristics of selective permeability to permit the uptake of nutrients into the 
cell. Solutes lower in molecular weight than the pore size such as sugars, amino 
acids, nucleosides, and small antibiotics diffuse readily through outer membrane, 
whereas substances such as proteins, detergents, and large antibiotics molecular 
do not readily gain access to the periplasm (Srikumar et al., 1997). The variety of 
porins and their exclusion limits differ from one bacterial genus to another 
(Srikumar et al., 1992); for example, the pore formed by the Hib OmpP2 porin 
has a molecular size exclusion limit of ca. 1,400 Da (Cope et al., 1990). 
Porin OmpP2 of Hib is one of the best-characterized porins in terms of its 
functional characteristics and is the most abundant outer membrane protein 
(OMP) in both non-typeable H. influenzae (NTHi) and Hib. Its molecular mass 
varies between 36 and 42 kDa, and it is present in all strains. OmpP2 contains 16 
anti-SDUDOOHOȕ-strands crossing the outer membrane, eight large loops, termed L1-
L8, of variable length on the external surface of the bacterial membrane, and 
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seven short periplasmic turns (Munson & Tolan, 1989; Srikumar et al., 1992b; 
Srikumar et al., 1997). Loops L1, L2, and L4 are important for monomer-
monomer interactions within the porin trimer. Pore size is determined by folding 
of the longest loop (L3) into the channel, leaving a gap in the wall between 
VWUDQGVȕDQGȕ (Figure 1.2); Loop L4 is the second longest loop after internal 
loop L3, it is oriented toward the central axis of the pore and deletions in this loop 
widen the pore entrance; loops L5, L6, and L7 are superficial; loop L8, which is 
the third longest loop, seems to fold back into the barrel interior and to contribute 
to the formation of the channel opening at the external side (Galdiero et al., 2003; 
Srikumar et al., 1997). Sequence comparisons of ompP2 genes indicate that all 
trans-membrane regions are relatively conserved among strains, whilst 
considerable heterogeneity exists in loop regions. It is likely that selective 
pressure imposed by the immune system is responsible for the heterogeneity of 
the extracellular loops (Bell et al., 1994). 
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Figure 1.2. Three-dimensional model of the OmpP2 monomer from Hib. A slice 
horizontally through the barrel; loops. (B) Overview of the molecule (Galdiero et al., 
2006).  
There is significant evidence that OmpP2 of H. influenzae plays an important role 
in the pathology of infection; studies have revealed that antibodies against the 
OmpP2 protein are bactericidal in both type b and non-typeable H. influenzae 
strains (Galdiero et al., 2001; Galdiero et al., 2003; Murphy & Bartos, 1988). 
Cope et al. confirmed that an ompP2 mutant lost the ability to producing 
bacteraemia in an infant rat model (Cope et al., 1990). Furthermore, antibodies 
against OmpP2 were shown to be protective in an infant rat model of bacteraemia 
and a OmpP2 mutant was unable to cause bacteraemia in infant rats (Chong et al., 
1993; Duim et al., 1996; Murphy & Bartos, 1988; Yi & Murphy, 1997). Porins 
also activate host inflammatory signalling cascades; it was demonstrated that 
whole OmpP2 from Hib and synthetic peptides corresponding to the surface 
exposed loops L5-L7 were able to activate cell phosphorylation and in particular 
the JNK and p38 mitogen-activated protein kinase (MAPK) pathways in U937 
cells (Galdiero et al., 2003),QFRQWUDVWSHSWLGHVFRUUHVSRQGLQJWRWKHȕ-barrel of 
OmpP2 were not able to activate this pathway (Galdiero et al., 2003). Moreover, 
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studies have suggested that OmpP2 and its loops are capable of activating signal 
transduction pathways such as MEK1-MEK2/MAP and JNK and the synthesis 
and secretion of inflammatory cytokines including IL-6 and TNF (Vitiello et al., 
2008).  
A more recent study by Vitiello et al., (2008) deduced that inoculation with loop 
L7 of OmpP2 from Hib induced significant patho-physiological changes in rats. 
Inoculation with L7 and whole OmpP2, but not a scrambled L7 peptide 
significantly induced E-selectin, a marker of endothelial injury, hyperglycemia 
and inflammatory cytokine production. In contrast, the coagulative/fibrinolytic 
cascade was impaired as shown by elevations of plasminogen activator inhibitor 
type I (PAI-1) levels (Vitiello et al., 2008). 
It was recently reported that H. influenzae binds laminin receptor (LamR) on 
human brain microvascular endothelial cells, suggesting that LamR binding is 
required for H. influenzae to invade the vascular endothelium of the blood brain 
barrier (Orihuela et al., 2009). LamR may also be important in infection since 
some pathogens use the 67-kDa laminin receptor (67LR) as cell-surface receptors 
WRHQWHUWKHLUKRVW¶VFHOOVDVSDUWRIWKHLUOLIHF\FOes (Anderson et al., 2000; Nelson 
et al., 2008; Tio et al., 2005; Chung et al., 2003). The LamR protein on the 
surface of microvascular endothelial cells was identified to be a common receptor 
for the meningeal pathogens N. meningitidis, H. influenzae and S. pneumoniae. 
Moreover, mutagenesis studies indicated that the corresponding bacterial LamR-
binding adhesins were pneumococcal CbpA, meningococcal PilQ and PorA, and 
OmpP2 of H. influenzae (Orihuela et al., 2009). Each of the bacterial meningeal 
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pathogens (pneumococcus, meningococcus, and H. influenzae) were shown to 
interact with LamR and the interaction was severely decreased in the presence of 
soluble LamR. Furthermore, adherence of the three pathogens to the rat brain 
endothelial cell line rBCEC6 cells was reduced by antibody against the LamR C-
terminus. Mutant H. influenzae which lack to OmpP2 (ǻompP2) showed 
dramatically less adherence to LamR. Moreover, when the expression of LamR 
was reduced by transfection of rBCEC6 cells with LamR siRNA, bacterial 
binding was significantly decreased compared with that of control transfected 
cells (Orihuela et al., 2009). LamR acts as receptor protein for alphaviruses, such 
as the Sindbis virus (Wang et al., 1992), the major dengue virus serotypes (Tio et 
al., 2005), Venezuelan Equine Encephalitis Virus (VEE) (Ludwig et al., 1996), 
and several serotypes of Adeno-Associated Virus (AVV) (Akache et al., 2006). 
LamR was identified as important receptor for developing bacterial meningitis 
caused by E. coli K1 (Kim et al., 2005). Furthermore, it was demonstrated that it 
is a receptor for both PrPc and PrPSc on the surface of mammalian cells (Nikles et 
al., 2008; Gauczynski et al., 2001).  
1.9  H. influenzae and the Immune Response 
The complement system is the first line of defence against pathogenic 
microorganisms, particularly against Gram-negative bacteria, and activation of the 
cascade leads to C3 deposition on the bacterial surface, phagocytosis and 
formation of the membrane attack complex (MAC) (Schneider et al., 2007; 
Hallstrom et al., 2008; Joiner, 1988). The complement system is organized into 
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three activation pathways; the alternative, the lectin and the classical pathway 
(Prescott et al., 2005). 
The ability of pathogens to survive in the human host and to circumvent the innate 
immune system including the complement system has role in their pathogenesis 
(Hallstrom & Riesbeck, 2010). Pathogenic microbes increase their serum 
resistance by interacting with complement components. For instance, H. 
influenzae, N. meningitidis and E. coli interfere with the classical complement 
activation pathway by binding to C4BP (Hallstrom & Riesbeck, 2010; Hallstrom 
et al., 2007). 
H. influenzae has developed several efficient strategies to circumvent complement 
attack such as the capsule, lipooligosaccharides, and several outer membrane 
proteins play role in bacterial survival by contribution in resistance against 
complement-mediated attacks and phagocytosis (Hallstrom & Riesbeck, 2010; 
Noel et al., 1996). Clearance of Hib from blood is associated with the deposition 
of C3 on these bacteria and is independent of the later complement components 
(C5-C9) (Crosson et al., 1976; Noel et al., 1988). 
It was shown that the interaction of Hib with factor H (FH) and factor H-like 
protein 1 (FHL-1), the inhibitors of the alternative pathway, increased its survival 
(Hallstrom et al., 2008). Similarly, the outer membrane protein Hib surface fibrils 
(Hsf) has been reported to bind vitronectin that prevents complement deposition 
and formation of the membrane attack complex (MAC) (Hallstrom et al., 2006). 
In addition, H. influenzae protein E (PE) interferes with complement-mediated 
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bacterial killing by capturing vitronectin (Singh et al., 2011; Hallstrom et al., 
2009). 
1.10  Laminin Receptor  
The 67-kDa laminin receptor (67LR) is a non-integrin cell surface receptor for the 
laminin (Ardini et al., 1998; Rao et al., 1983). The 67-kDa laminin receptor was 
first isolated and identified as a laminin-binding protein in 1983 (Malinoff & 
Wicha, 1983; Lesot et al., 1983; Rao et al., 1983; Terranova et al., 1983). 
Laminin is one of the components of the extracellular matrix molecule (ECM) and 
is the major glycoprotein of the basement membrane from all types of tissues 
(Nelson et al., 2008). In addition to its primary role as cell-matrix attachment, 
several biological activities have been demonstrated, such as nerve regeneration, 
tumour growth and metastasis, promoting cell growth and migration (Malinda & 
Kleinman, 1996).  
37/67-kDa laminin receptor (LamR) protein can be found to be expressed in a 
wide variety of mammalian cells (Ardini et al., 1998; Sobel, 1993; Garcia-
Hernandez et al., 1994; Nelson et al., 2008). It is established that three regions of 
the C-terminal domain of 67LR are involved in the interaction with the laminin 
and these include: TEDWS-containing C-terminal repeats, residues 205±229 and a 
heparan-sulfate-dependent laminin-binding region from 161±180 (peptide G) 
(Castronovo et al., 1991; Kazmin et al., 2000). Recently, the residues Phe32, 
Glu35, and Arg155 of the LamR were identified as a laminin binding site 
(Jamieson et al., 2011).  
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The exact structure of the 67LR is unclear; this receptor is believed to be formed 
from a 295-amino-acid 37-kDa precursor, while its observed molecular mass is 
approximately of 67-kDa on denaturing polyacrylamide gels. The corresponding 
gene has been identified and encodes a protein with a calculated molecular mass 
of approx. 37-kDa, a protein that is also observed in mammalian cells on SDS-
PAGE (Wewer et al., 1986; Wang et al., 1992) and is thought to be the precursor 
of the 67-kDa variant of the protein. The mechanism by which 37 laminin 
receptor precursor (LRP) gives rise to its mature form (cell-membrane-embedded 
67LR) has not been elucidated to date. LRP has been localized to the cytoplasmic, 
perinuclear and perichromosomal regions of the cell and also in the ribosomes of 
several tissues, such as heart, uterus, ovary, brain, liver, skeletal muscle and retina 
(Taylor et al., 2003; Bortoluzzi et al., 2001; Auth & Brawerman, 1992; Sato et al., 
1996; Kinoshita et al., 1998). One hypothesis could be that the protein undergoes 
some form of post-translational modification in order to become the mature 
protein (Nelson et al., 2008). Post-translational modification of the LRP including 
fatty acylation of the protein has been proposed to be a prerequisite of 67LR 
formation (Landowski et al., 1995; Akache et al., 2006; Scheiman et al., 2010). It 
has also been proposed that the 67LR is a heterodimer between LRP and galectin-
3 (Buto et al., 1998). However, it has been shown that both LRP and 67LR are 
present on the plasma membrane of a cell line N2a, which does not express 
galectin-3 (Gauczynski et al., 2001).  
67-kDa laminin receptors have been shown to play an important role in tumour 
invasion and metastasis of a variety of tumours (Menard et al., 1997; Pelosi et al., 
1997; Barsky et al., 1984). An increase in the expression of 67LR (compared with 
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the corresponding normal tissue) has been found in a variety of common cancers, 
such as breast, colon, cervical, gastric, lung, hepatocellular, pancreatic, thyroid, 
carcinomas, ovary and prostate (Castronovo, 1993; Martignone et al., 1993; 
Ménard et al., 1998; Sanjuan et al., 1996; al-Saleh et al., 1997; Ozaki et al., 1998; 
Fontanini et al., 1997; Pelosi et al., 1997; Montuori et al., 1999; Rao et al., 1989). 
1.11  Aims of the Project  
The general aim of the current study was to dissect the molecular interactions of 
H. influenzae outer membrane protein P2 and the human 37/67-kDa laminin 
receptor. More specfically, the initial aim was to define the LR-binding site(s) on 
OmpP2 by expressing specific regions of OmpP2 and investigating the ability of 
these recombinant proteins to bind to LamR. Having defined the extra-cellular 
loop 2 as the LamR-binding region (Chapter 3), a further aim was to produce and 
charaterise the LR-binding of an OmpP2 loop 2 deletion mutant of H. influenzae 
strain Rd KW20 (Chapter 4). Finally, the role of OmpP2 loop 2 in interactions 
with host cells was investigated using a combination of synthetic peptides, 
recombinant proteins and H. influenzae strains (Chapter 5).  
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CHAPTER TWO 
2.  MATERIAL AND METHODS  
2.1  Bacterial Strains, Growth Conditions, and Media 
Haemophilus influenzae Winslow Rd [KW20] (LGC/ American Type Culture 
Collection; ATCC), and its mutant derivatives, were grown at 37°C in either brain 
KHDUW LQIXVLRQ %+, 2[RLG VXSSOHPHQWHG ZLWK KHPLQ  ȝJ PO-1) and NAD 
 ȝJ PO-1) in liquid, agar media or chocolate horse blood agar (Oxoid). 
Neisseria meningitidis serogroup B, strain MC58 (B:15:P1.7.16b) (Tettelin et al., 
2000) and its mutant derivatives were cultured on Columbia agar with chocolate 
horse blood agar (Oxoid) at 37°C, in an atmosphere of air plus 5% CO2. When 
grown in suspension, meningococcal strains were grown in brain-heart infusion 
(BHI) broth (Oxoid) at 37°C with agitation. Broth cultures were aerated by 
agitation at 200 revolutions per min (rpm) in a shaking incubator. Agar or broth 
media were supplemented, where appropriate, with antibiotics. Antibiotics used 
(Sigma) were ampicillin (100 µg ml-1NDQDP\FLQȝJPO-1), streptomycin (50 
ȝJ PO-1 DQG VSHFWLQRP\FLQ  ȝJ PO-1). Escherichia coli JM109 strains 
(Promega) were routinely grown at 37°C in Lysogeny Broth (LB) (Bertani, 2004) 
or on LB agar (Fisher Scientific). These cells were used for the routine 
propagation of plasmids and for expression of 6 × histidine-tagged recombinant 
protein fragments. Where appropriate, blue/white selection of transformants in 
cloning experiments was achieved using IPTG (Roche) and X-gal at 0.5 mM and 
ȝJPO-1, respectively.  
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2.2  DNA Manipulation 
2.2.1   Chromosomal DNA Extraction 
Chromosomal DNA was isolated using the DNeasy Blood & Tissue kit (Qiagen) 
XVLQJWKHSURWRFROIRUEDFWHULDOFHOOVDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
Briefly, following overnight growth cells were harvested using a sterile loop and 
re-VXVSHQGHG LQ  ȝO RI $7/ EXIIHU DQG  ȝO RI 3URWHLQDVH . was added to 
disrupt the cells. The sample was then heated at 56°C until the complete lysis of 
cells was achieved. The lysate was applied to a DNeasy spin column (Qiagen). 
The bound DNA was washed twice using the buffers provided in the kit. The 
ERXQG'1$ZDVHOXWHGLQȝORIQXFOHDVH-free deionised water and stored at -
20°C. 
2.2.2  Extraction of Plasmid DNA  
Plasmid extraction was performed in accordance with the manufacturers' 
instructions using QIAprep Miniprep kit (Qiagen). Briefly, E. coli JM109, 
harboring the desired plasmid, was streaked onto LB agar plates supplemented, 
where appropriate, with antibiotics and incubated overnight at 37°C. Single 
colonies of cells were transferred to 5 ml of LB broth containing appropriate 
antibiotics and cultured overnight with shaking at 200 rpm. The following day, 
cells were harvested by centrifugation at 13,000 × g for 10 min and the pellet re-
suspended in 200 µl of re-suspension solution. Then, 200 Pl of the lysis buffer 
was added and mixed gently followed by adding neutralization solution and 
centrifuged at 13,000 × g for 10 min and the supernatant was added to a GenElute 
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tube and centrifuged for 1 min. After washing, the plasmid DNA was finally 
eluted in 100 Pl of nuclease-free deionised water and stored at -20°C. 
2.2.3  Restriction Endonuclease Digestion and Ligation of DNA 
To selectively cleave DNA at specific recognition nucleotide sequences, 
appropriate restriction endonuclease enzymes were purchased from New England 
%LRODE3URPHJDRU5RFKHDQGXVHGDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
followed by incubation with T4 DNA ligase (Promega). 
2.2.4  Dephosphorylation of DNA Fragments 
To prevent the re-circularization of linearized digested vector during ligation with 
a DNA insert, linearized vectors were dephosphorylated using alkaline 
phosphatase. Briefly, 50 units of Antarctic Phosphatase (New England Biolabs) 
was added to ȝJRIplasmid DNA and Antarctic Phosphatase reaction Buffer (10 
×) for 1 h at 37°C and heat inactivated for 5 min at 65°C. 
2.2.5  DNA Sequencing 
DNA fragments were sequenced on both strands using specific primers using 
fluorescent-labelled dye terminator reactions on a 3130xl Genetic Analyser 
(Applied Biosystems) at the Biopolymer Synthesis and Analysis Unit, School of 
Biomedical Sciences, University of Nottingham. DNAMAN version 3.14 
(Lynnon BioSoft) software was used to analyse DNA sequences.  
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2.3  Quantification of DNA and Protein 
The concentration of purified PCR products, plasmid, genomic DNA and 
recombinant purified proteins was quantified using a NanoDrop (ND-1000) 
spectrophotometer (Agilent Technologies) by measuring the absorbance at 260 
nm for DNA and 280nm for protein; the ratio of the readings at 260 nm and 280 
nm was used to determine the purity of the DNA. For more accurate 
determinations, proteins were quantified using a Pierce BCA protein assay kit 
(Thermo Scientific; kit 23225) or Bradford assay kit (Bio-Rad) in accordance with 
the manufacturer¶V instructions. 
2.4  Polymerase Chain Reaction (PCR) 
For all experiments, PCR reactions were performed iQ D  ȝO UHDFWLRQ PL[WXUH
using a C1000 model Thermal Cycler (BIO-RAD). The components, volumes and 
FRQFHQWUDWLRQVXVHGZHUHȝORISULPHULQDILQDOFRQFHQWUDWLRQȝ0-50 ng 
ȝO-1 ILQDOFRQFHQWUDWLRQRIDSODVPLGRUFKURPRVRPDO'1$LQOȝOof a 
ILQDO FRQFHQWUDWLRQ RI  ȝ0 G173V GHR[\ULERQXFOHRWLGH PL[ 10 mM each) 
(Roche); Expand High Fidelity Taq '1$SRO\PHUDVHȝO8ȝO-1) (Roche) 
or Taq DNA polymerase (Roche) and 2.5 µl of 10 × PCR buffer. The reaction 
PL[WXUH ZDV PDGH XS WR D ILQDO YROXPH RI  ȝO ZLWK QXFOHDVH IUHH GHLRQLVHG
water. The PCR amplification conditions were: initial template denaturation step 
of 3 min at 94°C, followed by 33 cycles consisting of 50s of annealing at 50-
56°C, extension at 68°C (for Expand High fidelity Taq polymerase) or 72°C (for 
Taq polymerase) for varying amouts of time according to the polymerase used 
(generally 1min/kb of expected product), and 30 s of denaturation at 94°C. The 
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final cycle consisted of 50s at 50°C for annealing and 10 min at 70°C for 
extension.  
2.5  Primer Design and Analysis 
All oligonucleotide sequences for PCR amplification of specific DNA sequences 
were designed using DNAMAN version 3.14 (Lynnon BioSoft). This software 
was also used for checking primer sequences for characteristics such as melting 
temperature and the presence of unique binding sites within templates. All primers 
used in this study were synthesized by Eurofins MWG GmbH (Germany) and 
listed in Table 2.1. 
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Table 2.1. DNA primers utilised in this study. 
Primer Oligonucleotide sequencea ¶-¶ Restriction 
site 
mP2_F CGCTAACATTTCATCAGTAATTCC -- 
mP2_R GACCAAACTAGCGTTGAAACC -- 
P2F3 GCCGCGGCCGCTAACATTTCATCAGTAATTCCATGAAC NotI 
P2R3_3 CGCGCGGCCGCAATTAAATGGCTGTGGTGGC NotI 
F1 CACGCTTTATAGTGATAGCC -- 
T7P TAATACGACTCACTATAGGG -- 
SP6 ATTTAGGTGACACTATAGT -- 
Fbg GGAAGATCTCACGCTTTATAGTGATAGCC BglII 
mP2bg GGAAGATCTGACCAAACTAGCGTTGAAACC BglII 
Omg_F GCGGATCCAAGTGCGGTCAAGCAAGGCGAATCGAAAGAT BamHI 
Omg_R GCGGATCCTCTAACAAATGATTAGAAGTAAACGC BamHI 
3ǻ,B) CGCAGATCTGGTGATATTACAAGCAAATATGCTTATG BglII 
3ǻ,B5 CGCAGATCTTTTTGTAACAAAACGAGTTTCTAAATAA BglII 
MegaR GCAAGTGTTTTTTTCATAATTTGTATTCC -- 
R2 CCAGAACTAGAAAGTTTTAC -- 
Mega 
primer 
539-bp fragment amplified from H. influenzae chromosomal DNA 
using MegaR/ R2 primers 
-- 
P2R8 GGCATTATCGTCGATGGTGTGCATATCA -- 
Kan_CTR GGTATGACATTGCCTTCTGCG -- 
P2R3_2 GCCGCGGCCGCACTTGGTTTACATATTGAAGGACCTTA NotI 
P2FR CGCGCGGCCGCGCGGTAAAAATTATGCGTGAA NotI 
3ǻ-8I_R CGCGTCGACGTAGTTAGTTCTACCATAAGCAATTTTTGC SalI 
P2F1 CGCGGATCCTATAACAACGAAGGGACTAACG BamHI 
P2R1 CGCGTCGACCAAATGATTAGAAGTAAACGC SalI 
3ǻ1-4I_F CGCGGATCCAACTACAAATATAACGAAGCTGACG BamHI 
3ǻ-4I_R GTCACTATTGTTGAGAACGCC -- 
3ǻ-8I_F GTGTCTCTAGATAGTGGCTATGC -- 
3ǻ/,B) CGCAGATCTGGTTCACGTTTCCACATTAAAGC BglII 
3ǻ/,B5 CGCAGATCTACTTTGTTCTGCGATAATGCTTAAAC BglII 
3ǻ/,B) CGCAGATCTGGTAATACCGTTGGCTATACTTTT BglII 
3ǻ/,B5 CGCAGATCTCGCACGACCAAGTTTTACTTCAC BglII 
3ǻ/,B) CGCAGATCTATAGGTGAAATCAATAATGGAATTCAAG BglII 
3ǻ/,B5 CGCAGATCTCTTTTGTGCTAATAAATAATTAGCGCC BglII 
P2CtHis_F ATGTATAACAACGAAGGGACTAAC -- 
P2CtHis_R GAAGTAAACGCGTAAACCTACAC -- 
P2FF CGCGCGGCCGCGGGGCGATCTGGCTTAATA NotI 
P2R3 GCCGCGGCCGCGTGATGTTTAACGACCAAACTAG NotI 
P2R5 GCCGCGGCCGCATTCCACAAAGGCGCAACTTTTG NotI 
Rbg GGAAGATCTCCAGAACTAGAAAGTTTTAC BglII 
ǻ3) CGCAGATCTGCGTTTACTTCTAATCATTTG BglII 
 
a Restriction site is underlined 
b H. influenzae DNA uptake sequences are shown in bold 
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2.6  PCR Purification 
After PCR and restriction digestion reactions, PCR products were purified using 
4,$TXLFN 3&5 SXULILFDWLRQ NLW 4LDJHQ DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instructions: 5 volume of binding buffer (PBT) was added to the 1 volume of PCR 
products and the mixture added to the column. This was then centrifuged for 1 
min and the flow-through discarded. Then, 750 µl of washing buffer (PE) was 
added and centrifuged for 1 min and flow-through discarded. After that 50 µl of 
nuclease free deionised water was added and incubated for 2 min at room 
temperature. Finally, DNA was eluted by centrifugation for 1 min. Purified DNA 
fragments then were quantified and stored at -20°C. 
2.7  Gel Electrophoresis and Gel Extraction 
DNA fragments were separated and visualized by horizontal gel electrophoresis 
W\SLFDOO\XVLQJȝORI WKHUHDFWLRQPL[WXUHVDW9LQD-1% w/v agarose 
gels. Before loading the DNA samples into the gel, 2 µl 6 × loading dye was 
added to each 10 µl DNA sample. Gels were run in 1 × Tris Acetate EDTA (TAE 
buffer, Sigma) buffer at 5 V/cm. Ethidium bromide (Sigma) was added to the gel 
at the concentration 10 mg ml-1 and DNA fragments were visualized using an 
ultraviolet trans-illuminator. Afterwards, the sizes of DNA bands in the agarose 
gel were estimated by comparison to the 2-log DNA molecular weight marker 
(New England Biolabs). Bands of interest were excised using a clean scalpel 
blade and extracted from the agarose gel using a QIAquick Gel Extraction kit 
4LDJHQDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV
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2.8  Bacterial Transformation  
2.8.1  Electro-transformation of H. influenzae 
Electro-transformation of H. influenzae was achieved according the method 
previously described by Mitchell et al., (1991) as follows: 
A) Preparation of electro-competent H. influenzae cells. Overnight growth was 
harvested from chocolate horse blood agar plates into 10 ml of supplemented BHI 
broth and centrifuged (4,000 × g for 4 min). The bacteria were then resuspended 
in 20 ml of ice-cold S&G buffer (272 mM sucrose, 15% glycerol) before being re-
centrifuged. This washing procedure was repeated three times before the bacterial 
cells were finally resuspended in 1 ml S&G buffer and left on ice until required. 
B) Electroporation of H. influenzae cells. Purified DNA (1-5 µg) of DNA was 
added to an electroporation cuvette (0.2 cm inter-electrode distance; Bio-Rad) 
along with 40 µl of competent H. influenzae cells and placed on ice for 10 min. 
This was then subjected to an electroporation in a Bio-Rad Gene Pulser at a 
YROWDJH RI  N9 DQG UHVLVWDQFH DQG FDSDFLWDQFH RI  ȍ DQG  ), 
respectively. The contents of the tube were then added to 2 ml of supplemented 
BHI broth and incubated at 37°C for 3 h. Aliquots were then plated out onto 
supplemented Brain Heart Infusion (BHIs) agar plates containing kanamycin (50 
µg ml-1) and incubated for up to 2 days at 37°C in air plus 5% CO2. 
2.8.2  Natural Transformation of H. influenzae 
Based on a previously described method for transformation of N. meningitidis 
(Hoda Abdel et al., 2001) H. influenzae strain Rd KW20 was naturally 
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transformed. Briefly, H. influenzae was grown to an optical density of 0.2 at 
600nm in supplemented Brain Heart Infusion (BHI) 2[RLG EURWK  ȝO RI
bacterial culture was added to a 15 ml tube containing BHI agar with NAD and 
hemin. After incubation for 6 h at 37°C in 5% CO2, 2 µg of the mutagenic 
fragment was added to the culture and incubation was continued for a further 16 
h. The cells were then harvested and plated onto BHI plates supplemented with 
NAD (10 µg ml-1), hemin (10 µg ml-1) and kanamycin (50 µg ml-1). Overnight 
colonies were observed and selected for analysis.  
2.8.3  Heat Shock Transformation of E. coli 
The desired plasmid DNA was transformed into competent E. coli JM109 
(Promega) using a heat shock approach DFFRUGLQJ WR WKH PDQXIDFWXUHUV¶
instructions as follows: 50 Pl of bacteria E. coli JM109 were thawed on ice for 10 
min then 100 ng (5Pl) of plasmid DNA was added to cells and mixed gently by 
stirring with a pipette tip. The mixture was incubated on ice for 10 min and the 
cells were heat shocked in a 42°C water bath for 45-50 seconds. Immediately after 
heat treatment, the cells were transferred onto ice for 2 min. 450 Pl of room 
temperature SOC medium (2% tryptone, 0.5% yeast extract, 10 mM sodium 
chloride, 10 mM magnesium chloride and 20 mM glucose) (Sigma) was added 
and the cell suspension was incubated at 37°C for 2 h with shaking at 250 rpm. 
Finally, 100 ȝOȝODQGȝO of the cell suspension was plated onto LB agar 
containing the appropriate antibiotic and incubated at 37°C overnight.  
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2.9  Expression of Recombinant Proteins 
Recombinant proteins were primarily expressed using E. coli JM109 (Promega) 
harboring the appropriate expression plasmid. E. coli BL21 (DE3) pLysS 
(Promega) contains the plasmid pET28LR was used for expression of 
recombinant laminin receptor precursor protein (rLRP). Briefly, 10 ml of LB 
medium containing the appropriate antibiotic was inoculated with 25 ml of an 
overnight bacterial culture. The cultures were incubated at 37°C with shaking. 
The optical density (OD) was monitored using a UV-160A spectrophotometer 
(Shimadzu) to mid log phase (OD600=0.6). Isopropyl-1-thio-ȕ-D-
galactopyranoside (IPTG) (Promega) was added to a final concentration of 1 mM. 
The culture tubes were then incubated at 37°C for 3-4 h with shaking. Aliquots of 
1 ml were removed from each culture pre-induction and also at hourly time points 
after induction, and cell were harvested by centrifugation at 13,000 × g. The cell 
pellets were resuspended in 1 × SDS-PAGE sample buffer (Appendix 1), 
according to the IRUPXODYROXPHLQȝO 2'î7KHVDPSOHVZHUHKHDWHG
to 95°C for 5 min and subsequently resolved by Sodium Dodecyl Sulfate-
Polyacrylamide Gel Electrophoresis (SDS-PAGE) (Laemmli, 1970).  
2.10  Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis 
(SDS-PAGE) and Immunoblot Analysis 
2.10.1  SDS-PAGE  
Purified recombinant proteins and the whole cell lysates were separated according 
to their electrophoretic mobility using 10-12% SDS-PAGE gels (Appendix 1) 
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(Sambrook & Maniatis, 1989). Proteins were dissolved in 1 × SDS-PAGE sample 
buffer (Appendix 1) and heated for 5 min at 95°C. An aliquot of 10 ȝORIVDPSOH
was loaded into a SDS-PAGE gel using Mini- Protean III equipment (BIO-RAD) 
at a constant 30mA per gel with a 200V voltage limit for approximately 50-60 
min using a Power PAC 300 (BIO-RAD). Protein l (Page RulerTM Plus Prestained 
Protein Ladder, Fermentas) was used as a protein marker. After separation, 
proteins were visualized using SimplyBlueTMSafeStainTM (Invitrogen) or 
PageBlueTM Protein Stain Solution (Fermentas) used according to the 
PDQXIDFWXUHU¶V LQVWUXFWLRQs. Gels were scanned using a GS-800 calibrated 
densitometer (BIO-RAD).  
2.10.2  Immunoblot Analysis 
After SDS-PAGE, proteins were transferred onto a nitrocellulose membrane 
(HybondTM ±ECLTM, Amersham Biosciences) in semi-dry blotting buffer 
(Appendix 1) at room temperature using a Trans-Blot SD semidry transfer cell 
(BIO-RAD) at a constant current of 13 mA for approximately 30 min. After 
transfer, the nitrocellulose membrane was incubated for 1 h in blocking solution 
[5% (w/v) skimmed milk powder in 20 ml PBS] (Oxoid, England) or 1% Bovine 
serum albumin (BSA) (Sigma). The membranes were then probed with the 
appropriate primary antibody diluted in blocking buffer and incubated overnight 
with shaking at 4°C. After washing in PBS containing 0.05% Tween-20 (PBST) 
(Sigma) three times, each for 15 min, the membranes were incubated for 1 h with 
an appropriate secondary antibody which had been diluted in blocking buffer. 
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Next, the membrane was washed with PBST and the membrane was then 
developed using the substrate BCIP/NBT (Perkin Elmer Life Science, USA). 
2.11  Protein Purification under Denaturing Conditions 
HispureTM cobalt resin (Thermo) was used to purify his-tagged proteins under 
denaturing conditions. A single colony of E. coli JM109 or E. coli BL21 (DE3) 
pLysS harboring the desired expression plasmid was inoculated into 10 ml LB 
containing appropriate antibiotic and grown at 37°C overnight. One litre of LB 
broth containing appropriate antibiotics was then inoculated with 10 ml of an 
overnight starter culture and grown to mid log phase (OD600 = 0.6), and induced 
by addition of IPTG to a final concentration of 1 mM. After a further 3h of 
induction the cells were harvested by centrifugation at 9,000 × g for 10 min at 4°C 
using an AllegraTM X-22R centrifuge (Beckman Coulter). Next, the culture pellet 
from 50 ml culture was resuspended in 5 ml of lysis buffer (8 M urea, 0.1 M 
NaH2PO4, 0.01 M Tris-Cl, pH 8.0). Following incubation at room temperature for 
30 min with shaking, the mixture was sonicated (15 s on, 10 s off pulses for 5 min 
on ice) using a SoniPrep Sonicator 150 (MSE). The lysate from disrupted cells 
was then centrifuged at 9,000 × g for 30 min at 4°C, the soluble phase 
(supernatant) was filtered using 0.45 µm filters and collected in polypropylene 
chromatography columns (Sigma) and 500 Pl of hispureTM cobalt resin (Thermo) 
was added. Then a low concentration (20 mM) imidazole solution (Qiagen) was 
added and the suspension was shaken at 50 rpm for 2 h. The sample was then 
loaded onto a gravity column (Evergreen) and the cleared lysate allowed to pass 
through using washing buffer (8 M urea; 0.1 M NaH2PO4; 0.01 M Tris.Cl; pH6.3). 
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Protein was eluted using elution buffer (8 M urea; 0.1 M NaH2PO4; 0.01 M 
Tris.Cl; pH4.5). Urea was removed by buffer exchange using PD-10 desalting 
columns (GE Health Care) or D-TubeTM Dialyzer Maxi, MWCO 12-14 kDa 
(Novagen). The protein eluates were stored at -20°C. 
2.12  Expression and Purification of Recombinant Proteins in a Cell-
free Protein Synthesis System 
Recombinant membrane proteins were expressed and purified using the 
0HPEUDQH0D[3URWHLQ([SUHVVLRQ.LW,QYLWURJHQ 
Recombinant proteins ZHUH V\QWKHVL]HG IROORZLQJ WKH PDQXIDFWXUHU¶V
recommendations. In brief, samples were prepared containing the following 
reagents: E. coli slyD± Extract, 20 µl; 2.5X IVPS Reaction Buffer (±amino acids), 
20 µl; 50 mM Amino Acids (±Met), 1.25 µl; 75 mM Methionine, 1 µl; 
0HPEUDQH0D[  µl; T7 Enzyme Mix, 1 µl; DNA Template (pMSA18 or 
pMSA19), not added to the negative control, 1 µg. Reactions were performed in a 
final volume of 50 µl in DNase/RNase-free water. Samples were incubated at 
37°C for 30 min then feed buffers (2 × IVPS Feed Buffer, 25 µl; 50 mM Amino 
Acids (±Met), 1.25 µl; 75 mM Methionine, 1 µl; 10 mM all-trans retinal, 0.5 µl, 
were added to a final volume of 100 µl and incubation continued up to 4 h and 
samples analysed. 
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2.12.1  Analysing Synthesised Recombinant Membrane Protein 
Sample 
Synthesised recombinant membrane proteins were analysed in accordance with 
the PDQXIDFWXUHU¶V instructions. Briefly, proteins were precipitated using acetone. 
5 µl of the samples mixed with 20 µl of acetone and centrifuged at 10,000 × g for 
5 min at room temperature. The supernatants were removed carefully and pellets 
were resuspended in 20 µl of sample loading buffer. 10 µl was loaded on a SDS-
PAGE gel and, after electrophoretic separation, transferred to nitrocellulose 
membranes. Membranes were probed with primary antibody diluted 1:5000, in 
blocking buffer [5% (wt/vol) milk, 1% (vol/vol) phosphate-buffered saline (PBS)] 
and incubated for overnight at 4°C. After washing in PBS with 0.1% Tween 20 
(PBST), membranes were incubated for 1 h with 1:30000-diluted (PBS-BSA) 
alkaline phosphatase conjugated secondary antibody (Sigma). After washing with 
PBST, blots were developed using BCIP/NBT-Blue liquid substrate (Sigma). 
2.13  Protein Purification Using Ion Exchange and Gel Filtration 
Ion exchange and then gel filtration were employed to purify proteins under non-
denatured conditions from H. influenzae strains. Bacteria cultured overnight on 20 
plates of chocolate agar were harvested in 1 × PBS, harvested cells were lysed 
overnight in 500 ml lysis buffer (50 mM Tris-HCl, 30 mM Zwittergent 3-12, pH 
8.5 and 1:500 DNase I) at 4°C, cell lysates then were centrifuged at 100,000 × g 
for 20 min (Aluminum rotor A-841, SORVALL ULTRASPEED). Supernatants 
were filtered through 0.22 µm filters. Membrane protein extracts were then 
applied to a Capto Q anion exchange column (GH Healthcare Life Science), with 
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flow rate 1 ml min-1 using an AKTA PrimePlus FPLC, pre-equilibrated with 
cooled wash buffer (50 mM Tris-HCl, 30 mM Zwittergent 3-12, pH 8.5). Proteins 
were eluted with a linear gradient of elution buffer 1 (50 mM Tris-HCl, 30 mM 
Zwittergent 3-12, 2M NaCl, pH 8.5). Protein fractions were applied to a gel 
ILOWUDWLRQ FROXPQ 6XSHUGH[   ml bed volume), flow rate 1 ml min-1, 
using elution buffer 2 [30 mM n-Octyl-ß-D-glucopyranoside (OG) (Calbiochem®) 
in PBS]. 
2.14  DIG-labeling of Proteins and Bacteria 
DIG-labeling was carried out using the Digoxigenin-3-0-succinyl-İ-aminocaproic 
acid-N-hydroxy-succinimide ester Protein labeling kit (DIG-NHS; Roche) in 
accordance to PDQXIDFWXUHU¶V LQVWUXFWLRQV %ULHIO\ IRU SURWHLQs the pH was 
adjusted to pH 9.0 by the addition of 2 M sodium carbonate, and DIG-NHS 
reagent added in a 1:10 molar ratio. Reactions were incubated at room 
temperature for 1 h, and then unbound DIG-NHS was removed using PD-10 
desalting columns (GE Healthcare). For bacteria, cells were harvested from an 
overnight plate, washed three times in PBS with 0.05% Tween 20 (PBST), 
resuspended in the sodium carbonate buffer (150 mM; 142 mM NaHCO3, 8 mM 
Na2SO3, pH 9.0) and the optical density adjusted (at 600 nm = 1.0) then labeled 
with 10 µg ml-1 DIG-NHS at room temperature for 30 min. Bacteria were then 
washed three times with PBST and resuspended in PBS containing 1% bovine 
serum albumin (BSA; Sigma).  
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2.15  rLRP Protein Labelling 
The Lightning-LinkTM Atto680 Conjugation Kit (Innova Biosciences) was used to 
label the rLRP SURWHLQDFFRUGLQJWRWKHPDQXIDFWXUHV¶LQVWUXFWLRQV ,QEULHIO
of LL Modifier reagent was added to each 10 µl of protein and mixed gently. 5 µg 
of Lightning-Link fluorescein was then mixed with every 1 µg protein sample 
(with added LL-Modifier) and resuspended gently for 3 h in the dark at room 
temperature. After incubating, 1 µl of LL-Quencher FD reagent was added for 
every 10 µl of protein and mixed gently for 30 min in the dark at room 
temperature and stored at 4°C.  
2.16  Synthetic peptides 
The synthetic OmpP2 peptides (loop 2 and its derivatives) utilised in this study 
were synthesized (high purity grade; peptide purity > 95%) by GenScript, USA 
and supplied as a lyophilized powder. Aliquots were prepared in PBS at a final 
concentration of 2 mg ml-1 and stored at -20°C. These are detailed in Table 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
53 
 
Table 2.2. Synthetic peptides used in this study 
Peptide  Peptide sequence  
OmpP2L2 CASENGSDNFC a 
L2-1 ASENGSDNF 
L2-2 AAENGSDNFb 
L2-3 ASANGSDNFb 
L2-4 ASEAGSDNFb 
L2-5 ASENASDNFb 
L2-6 ASENGADNFb 
L2-7 ASENGSANF b 
L2-8 ASENGSDAFb  
L2-9 ASENGSDNAb 
Scrambled L2  SNGFEDNSA 
PorA loop 4c CPIQNSKSAYTPAYYTKNTNNNLTLVPAVVGKPGSC a 
PorA loop 1c CVEGRNYQLQLTEAQAANGGASGQVKVTKVTKAKSRIRTKIC a 
aPeptide sequence includes terminal cysteine residues to facilitate disulfide bond 
formation. 
b The substituted amino acid is highlighted in red.  
cfrom previous study  
2.17  Enzyme-Linked Immunosorbent Assay (ELISA) 
Purified proteins were diluted in coating (carbonate) buffer (142 mM sodium 
bicarbonate, 8 mM sodium carbonate [pH 9.4]), concentrations were variable 
according to the experiment performed (typcially 1-5 Pg ml-1), before being added 
in 100 µl aliquots to plate wells (Nunc 96-well plates) for 4 h at room temperature 
or overnight at 4°C with shaking. Control wells were coated with PBS containing 
1% BSA (PBS-BSA) or recombinant PorA (positive control). Plates were washed 
three times in PBS containing 0.05% v/v Tween 20 (PBST) buffer and the wells 
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were blocked for 1 h at room temperature with 100Pl PBS-BSA. Wells were again 
washed six times with 3 min soaking intervals with PBST and 100Pl of binding 
protein (5 Pg ml-1) was added. Next, the plate was incubated at 4°C for 4 h then 
washed with PBST six times with 3 min soaking intervals. Rabbit polyclonal 
antibody (diluted 1:1000) in 1% BSA in PBS was added and plates were shaken 
overnight at 4°C. Wells were then washed with PBST six times with 3 min 
soaking intervals. Next, conjugated secondary antibody (Sigma; diluted 1:10,000 
in 1% BSA in PBS) was added and plates were shaken for 1 h at room 
WHPSHUDWXUH $IWHU ZDVKLQJ IRU VL[ WLPHV  O RI  ¶-azino-bis; 3-
ethylbenzthiazoline-6-sulphonic acid (ABTS; Chemicon international ES004) 
substrate or p-nitrophenyl phosphate (pNPP) substrate (Sigma) diluted in alkaline 
phosphatase buffer (Appendix 1) (1 mg ml-1ȝOSHUZHOOZHUHXVHGIRUFRORU
development and plate was incubated then read using an ELISA plate reader 
(BioTek EL800) at 405 nm. 
Alternatively, ELISAs were undertaken using DIG-labelled bacteria in the same 
principles described above. Wells were coated with protein (5 µg ml-1) and 
incubated for 1 h at room temperature. The plate was then washed three times 
with PBST and the wells then were blocked for 1 h at room temperature with 1% 
BSA in PBS followed with 4 washes with PBST. DIG-labeled H. influenzae were 
added (100 µl; optical density at 600 nm = 0.04) for 2 h at room temperature and 
plates were then washed four times. 100 µl of the anti-digoxigenin HRP conjugate 
antibody (Roche) (diluted 1:5000 made up in was added to each well and 
incubated for 1 h at room temperature. Wells were washed four times and ABTS 
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(Roche) substrate was added and plate was read for different time points with an 
ELISA reader (Biotek EL800) at an absorbance of 405 nm. 
2.18  Sub-cellular Fractionation of H. influenzae Cells 
Bacterial cell fractionation was undertaken based on a modification of a 
previously described method (Nossal & Heppel, 1966; Schnaitman, 1971). 
Briefly, H. influenzae cells were grown overnight at 37°C in supplemented BHI. 
Cells from 10 ml overnight cultures were harvested at 10,000 × g for 10 min, the 
pellet resuspended in 0.4 ml 10 mM Tris-HCl (pH 7.5) and the cells disrupted by 
sonication (5 min 10/5s cycles). The preparation was centrifuged at 16,000 × g for 
30 min and the supernatant (periplasmic proteins) was transferred to a fresh tube 
and stored at -20°C. The pellet was resuspended in 0.2 ml of 10 mM Tris-HCl (pH 
7.5), 10 mM MgCl2 then 0.2 ml 10 mM Tris-HCl (pH 7.5), 10 mM MgCl2 4% 
Triton X-100 was added and sonicated (2 min 10/5s cycles) and incubated at 37°C 
for 30 min. The mixture was centrifuged at 16,000 × g for 30 min. The 
supernatant (cytoplasmic membrane-enriched fraction) was transferred to a fresh 
tube and stored at -20°C. The remaining pellet was resuspended in 0.5 ml 10 mM 
Tris-HCl (pH 7.5), 10 mM MgCl2 and sonicated (2 min 10/5s cycles), then 0.5 ml 
10 mM Tris-HCl (pH 7.5), 10 mM MgCl2 2% Triton X-100 was added and the 
sample was incubated at 37°C for 30 min. Finally, the outer membrane protein-
enriched fraction was harvest by centrifugation at 16,000 × g for 30 min and 
resuspended in 0.2 ml 10 mM Tris-HCl (pH 7.5) and stored at -20°C.  
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2.19  Determining the in vitro Growth Rate of H. influenzae and Its 
Mutant Derivatives 
Bacterial cultures were incubated overnight at 37°C, with shaking at 200 rpm. The 
following day, the cultures were diluted in fresh BHI and were adjusted to a 
starting OD600 of 0.1 in the 15 ml of BHI. Next, the broth cultures were incubated 
at 37°C with shaking. The OD600 reading was taken at each 1.5 h interval for 16.5 
h and then at 24 h. The viable counts of broth cultures were determined by 
sampling during exponential growth over 24 h in triplicate. 
2.20  Flow Cytometry Analysis 
The ability of H. influenzae and mutants to bind to rLRP protein was determined 
by flow cytometry using an indirect fluorescence assay. H. influenzae strains were 
grown to mid-log phase (OD600 approximately 0.7). Then, they were washed three 
times with PBS and the concentration of bacterial cells in phosphate-buffered 
saline (PBS) was adjusted to 2 × 107 colony-forming units (CFU) ml-1 aliquots. 
After centrifugation at 5,000 × g for 7 min, 20 µg of fluorescein- conjugated rLRP 
was added in a total volume of 0.2 ml FACS buffer [0.1% BSA, 0.1% sodium 
azide and 2% fetal calf serum (FCS) in PBS] and untreated cells were used as a 
control. After being incubated of 3 h at room temperature in the dark, the samples 
were washed three times with FACS buffer (centrifugation at 5000 × g for 7 min). 
Finally, samples were re-suspended in 1 ml PBS containing 0.5% formaldehyde to 
fix the cells. The samples were analysed for fluorescence using a Coulter Altra 
Flow Cytometer. The cells were detected using forward and log-side scatter dot 
plots, and a gating region was set to exclude cell debris and aggregates of bacteria. 
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A total of 50,000 bacteria (events) were analysed for fluorescence signals using 
Weasel v2.7.4 software. 
2.21  Whole Cell lysate Pull-down Assay 
Bacterial strains were grown to mid-log phase (OD600 approximately 0.7). After 
washing twice with PBS, the bacterial pellet was resuspended to same OD in PBS 
and then mixed with soluble purified rLRP (20 µg). After incubation for 3 h at 
4°C with shaking, mixtures were washed three times in PBS. Harvested pellets 
were resuspended in SDS-PAGE loading buffer and run on the SDS-PAGE. 
Separated proteins transferred to nitrocellulose membrane (section 2.18), blocked 
for 1 h at room temperature with PBS containing 1% BSA (PBS-BSA). 
Nitrocellulose membranes were then incubated with anti-LR antibody diluted 
appropriately in blocking buffer (1:3000) overnight at 4°C. After being washed 
three times, each for 15 min in PBS containing 0.05% Tween-20 (PBST; Sigma), 
HRP-conjugated anti-rabbit IgG (Sigma) was added at the concentration of 
1:30,000 for 1 h at room temperature. Next, the membrane was washed with 
PBST for 1 h at room temperature and then was developed using BCIP/NBT-Blue 
liquid substrate (Sigma).The protein bands were quantitated on a Bio-Rad GS-800 
calibrated densitometer employing Quantity One 4.6.5 software.  
2.22  Adhesion Assay 
Adhesion and invasion assays were undertaken essentially based on the previously 
described method (Oldfield et al., 2007). In brief, confluent monolayers of human 
epithelial cell line 2 (HEp-2) cells (passage 55-60) and human brain 
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microvascolar endothelial cells (HBMECs) (passage 12-19) cells were obtained in 
24-well tissue culture plates (2cm2, Costar®, Corning Inc.), in growth media 
'0(0'XOEHFFR¶V02'(DJOH0HGLXP*LEFRIRU+(S-2 and endothelial cell 
medium (ECM) for HBMECs both were supplemented with 10% fetal calf serum 
(FCS) (Gibco), and 1% antibiotic-antimycotic solution (Sigma; penicillin and 
streptomycin) and 1% endothelial cell growth supplement (ECGS) was added to 
the ECM. After overnight incubation, the media was replaced with 1 ml of 
DMEM or ECM supplemented with 2% FCS (no antibiotics-antimycotic) and 
incubated overnight. One loopful of bacterial culture from an overnight plate was 
suspended in 20 ml of brain heart infusion broth (BHI) and incubated at 37°C for 
4 h with shaking. The OD600 reading of the bacterial cultures were taken, cultures 
were equilibrated using BHI, centrifuged at 4,000 × g for 5 min. Next, the pellets 
were thoroughly resuspended in pre-warmed DMEM or ECM supplemented with 
2% FCS (no antibiotic-antimycotic) and re-equilibrated in the same medium to 
similar OD600, adjusted to approximate 1 × 107 CFU ml-1 (confirmed 
retrospectively by plating out aliquots of serially diluted inoculums) and the cells 
infected with the bacteria in a total volume of 0.5 ml medium. Following the 
incubation period, 3 h at 37°C 5% CO2, monolayers were rinsed three times with 
1 ml 1 × PBS to remove non-adherent bacteria and then disrupted and 
homogenised in 1 ml of 0.1% Saponin in PBS. 10 µl volumes of the serial 10-fold 
dilutions in PBS were plated out on a chocolate agar plates and incubated at 37°C 
overnight in 5% CO2. The viable count plates yielded the number of adherent 
bacteria per monolayer (CFU/well per strain). 
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2.23  Invasion Assay 
To determine the number of bacteria entering the cells of HBMEC and HEp-2 
monolayers, invasion assays were performed identically to adhesion assay except 
that after the initial 3-h incubation, monolayers were rinsed three times with PBS 
and DMEM or ECM media containing 2% FCS (no antibiotics-antimycotic) and 
gentamicin (100 µg ml-1) was added. The susceptibility of H. influenzae strain to 
JHQWDPLFLQDWȝJPO-1 was confirmed prior to testing. To assess cell invasion, 
tissue culture plates were further incubated for 2 h, rinsed twice with PBS, and 
then treated with 0.1% saponin in PBS. Well contents were agitated and colony-
forming units determined E\SODWLQJȝOVSRWVIURPDSSURSULDWHGLOXWLRQVRIWKH
lysates on agar to quantify the number of internalized bacteria per monolayer. 
2.24  Micro-beads Adhesion Assay 
PolyLink protein coupling kit (Polysciences, Inc.) was used for coupling the 
microspheres (beads) with the desired proteins according to the manufacturerV¶
instructions. In brief, all buffers were pre-warmed to room temperature. 0.5 ml of 
microparticles was centrifuged for 10 min at 8,000 × g and the pellet was then re-
suspended in 0.4 ml PolyLink coupling buffer, samples were centrifuged for 10 
min at 8,000 × g and the pellet resuspend in 0.17 ml of PolyLink coupling buffer. 
200 mg ml-1 EDCA solution was prepared by dissolving 10 mg DCA in 50 µl 
PolyLink coupling buffer and used immediately. After adding 20 µl of the EDCA 
to the microparticles suspension, it was gently mixed, then 300-350 µg of protein 
was added and incubated at room temperature for 5 h. After centrifugation for 10 
min at 8,000 × g, pellet was resuspend in 0.4 ml of wash/storage buffer (10 mM 
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Tris, pH 8.0, 0.05% bovine serum albumin, 0.05% Proclin® 300) and then 
centrifugation was repeated again and the pellet was resuspended in 0.4 ml of 
wash buffer and stored at 4°C. 
HBMECs (passage 12-19) were grown on ECM medium supplemented with 1% 
ECGS, 10% FCS and 1% antibiotic-antimycotic solution (A&A) (penicillin [1 
U.ml-1], streptomycin [1 g.ml-1]). After overnight incubation at 37°C in 5% CO2 
on human fibronectin cellware 75cm2 flask (BD BioCoatTM), confluent cells were 
harvested, resuspended in ECM medium (1% ECGS, 1% A&A, 5% FCS) and 
transferred into 12-well plates (1 ml/well) containing sterile coverslips. Cells were 
then incubated overnight at 37°C with 5% CO2 followed by the additiona of fresh 
media (1% ECGS, 1% A&A, 5% FCS) containing the desired recombinant 
proteins and synthetic loops coupled to micro-beads (5 µl). Cells were incubated 
at 4°C for 1 h, rinsed once with PBS before fixing with 4% PFA/PBS (500 µl per 
well) for 10 min at room temperature. Following fixation, cells were washed three 
times with 1% PBS, blocked with 4% BSA in PBS overnight at 4°C. Cells were 
incubated for 1 h with 1:150-diluted (4% BSA in PBS) IHLR against anti-37LR 
or with 1:100-diluted (4% BSA in PBS) Mluc5 IgM mouse against 67LR. After 
being washed three times with PBS, cells were incubated for 1 h with 1:500-
diluted (4% BSA in PBS) with anti-rabbit Alexa 488 (against anti 37LR), anti-
mouse IgM 647 1:1000 (against Mluc5 IgM), and also Hoechst 33258 1:1000 
(against double-stranded DNA). Following incubation, cells were rinsed three 
times with PBS and once with dH2O and coverslips were mounted with Prolong 
Gold anti-fade (Invitrogen) and images acquired on a Zeiss LSM 700 
 
 
 
 
61 
 
AxioObserver confocal microscope using a Plan-Apochromat 63 × /1.4 Oil DIC 
M27 objective. In addition, slides were read using a compound light microscope 
at 400 × magnification, starting from a spot and moving in a zigzag pattern; 
micro-beads were counted from a minimum of 15 randomly chosen fields per 
slide, excluding those in which the monolayer was not confluent.  
2.25  RhoA-GTP Assay 
2.25.1  Growth and Treatment of HBMECs Cell Line 
The G-LISATM RhoA activation assay biochem kitTM (Cytoskeleton) was used 
DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV %ULHIO\ +%0(&s (passage 15-19) 
were cultured in ECM medium supplemented with 10 % FCS, 1% Antibiotic-
Antimycotic (A&A) and 1% ECGS overnight at 37°C, 5% CO2 overnight in 
human fibronectin cellware 75cm2 flasks (BD BioCoatTM). Confluent cells were 
split into 6-well plates and incubated overnight at 37°C in ECM containing 10% 
FCS, 1% A&A and 1% ECGS. Next, 50-60% confluent cells were rinsed once 
with pre-warmed serum free medium (ECM) and then re-incubated with fresh 
ECM medium containing 0.5% FCS, 1% A&A and 1% ECGS for 24 h at 37°C, 
5% CO2. To obtain serum-starved cultures, media was changed to fresh serum-
free ECM medium and cells were incubated for 16-24 h at 37°C, 5% CO2. Cells 
were treated for 30 min at 37°C 5% CO2 with 5 µM protein. The medium was 
then aspirated and cells were washed with ice cold PBS and lysed using cell lysis 
buffer (70 µl). Cell lysates were harvested with a cell scraper, transferred into 
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sample tubes on ice, centrifuged at 10,000 × g, at 4°C for 2 min, 20 µl was saved 
for protein quantitation. Samples were stored at -70°C until use.  
2.25.2  Protein Concentration Equivalence 
For accurate comparison between samples in the Rho activation assay, an equal 
protein concentration in all samples was desired. 10 µl aliquots of cell extracts 
were pipetted into a 96-well plate followed by the addition of 300 µl of protein 
assay reagent, the plate was then read at 600 nm and the absorbance was 
multiplied by 3.75 to obtain the protein concentration in mg ml-1.  
2.25.3  G-LISATM Assay 
Buffer blank sample was prepared (80 µl of lysis buffer diluted with 80 µl of ice 
cold binding buffer). Positive control sample was prepared by diluting 18 µl of 
Rho control protein with 72 µl of cell lysis buffer and 90 µl of binding buffer. The 
powder in the Rho plate was dissolved in 100 µl ice cold water and solution 
removed from wells and the plate was put back on ice. Then, 1.6 mg ml-1 of 
samples were prepared (0.4 -2 mg ml-1 was recommended) in ice-cold lysis buffer 
and equal amount of ice-cold binding buffer was then added. Immediately 50 µl of 
equalized cell lysate for each sample was added to triplicate wells and incubated 
at 4°C for 30 min. Wells were washed with 200 µl of wash buffer at room 
temperature and then 200 µl of room temperature antigen presenting buffer was 
added and incubated for 2 min at room temperature. Wells were washed three 
times with 200 µl of room temperature washing buffer and 50 µl of diluted anti-
RhoA primary antibody (1/250 in antibody dilution buffer) was added, incubated 
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for 45 min at room temperature followed by washing using washing buffer and 
then 50 µl of diluted secondary antibody (1/62.5 in antibody dilution buffer) was 
added, incubated for 45 min at room temperature. After washing with 200 µl 
washing buffer, 50 µl of HRP detection reagent (prepared by mixing same equal 
of par A and B) was added and incubated at 37°C. The signal was read by 
measuring absorbance at 490 nm using a microplate spectrophotometer. All 
incubations were performed on a 150 × g shaker. 
2.26  Statistical Analysis 
Statistical significance of the experimental results was determined by unpaired 
two-tailed Student's t-test using the Excel 2007 or Minitab 15 software program 
(Minitab). All experiments were performed using three technical replicates and 
unless otherwise stated and were repeated at least three times. Data were 
expressed as the mean ± standard error (SE). Differences were considered 
statistically significant at probability p value < 0.1; highly significant at p < 0.05 
and very highly significant at p < 0.01.  
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CHAPTER THREE: Localisation of the LamR-Binding 
Domain(s) of H. influenzae OmpP2 Determined Using 
Purified Recombinant OmpP2 Derivatives 
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CHAPTER THREE 
3. LOCALISATION OF THE LamR-BINDING DOMAIN(S) OF H. 
INFLUENZAE OMPP2 DETERMINED USING PURIFIED 
RECOMBINANT OMPP2 DERIVATIVES 
3.1  Introduction  
There is evidence that OmpP2 of H. influenzae plays an important role in the 
pathology of infection (Murphy & Bartos, 1988; Chong et al., 1993; Duim et al., 
1996; Yi & Murphy, 1997). Porins can activate host inflammatory signalling 
cascades and it was demonstrated that whole OmpP2 from H. influenzae type b 
(Hib) and synthetic peptides corresponding to the surface exposed loops L5-L7 
were able to activate cell phosphorylation and in particular the JNK and p38 
mitogen-activated protein kinase (MAPK) pathways in human monocytic U937 
cells (Galdiero et al., 2003),QFRQWUDVWSHSWLGHVFRUUHVSRQGLQJWRWKHȕ-barrel of 
OmpP2 were not able to activate this pathway (Galdiero et al., 2003). In a more 
recent study, using two-dimensional electrophoresis and mass spectrometry 
proteomic approaches, OmpP2 from Hib and, specifically, its surface exposed 
loop L7 was shown to induce post-transcriptional alterations in U937 cells 
(Severino et al., 2009). The study provided a list of candidate proteins with 
potential relevance to the host immune and inflammatory response. Most of the 
differentially expressed proteins are involved in metabolic processes, remodelling 
of cytoskeleton, stress response and signal transduction pathways (Severino et al., 
2009). 
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In an investigation of Hib OmpP2 and its loop 7- induced effects on human 
astrocytes (U87-MG cells), it was demonstrated that MEK1-MEK2/mitogen-
activated protein kinase phosphorylation was induced and also the production of 
cellular adhesion molecule and interleukin-6 (IL-6) was up-regulated. In addition, 
the expression of adhesion molecules ICAM-1, VCAM-1 and E-selectin was 
considerably induced by treatment with either Hib OmpP2 or loop 7 (Vitiello et 
al., 2011). 
To cause bacterial meningitis, H. influenzae must cross the blood±brain barrier 
(BBB) to gain entry to the CNS where it can proliferate. It was recently reported 
that H. influenzae binds 37/67-kDa laminin receptor (LamR) on human brain 
microvascular endothelial cells, suggesting that LamR binding is required for H. 
influenzae to invade the vascular endothelium of the blood-brain barrier (Orihuela 
et al., 2009). The LamR protein on the surface of microvascular endothelial cells 
was identified to be a common receptor for the meningeal pathogens Neisseria 
meningitidis, H. influenzae and Streptococcus pneumoniae. Moreover, 
mutagenesis studies indicated that the corresponding bacterial 37/67-kDa laminin 
receptor (LamR)-binding adhesins were pneumococcal CbpA, meningococcal 
PilQ and PorA, and OmpP2 of H. influenzae (Orihuela et al., 2009). In ELISA 
experiments, H. influenzae was shown to bind recombinant laminin receptor 
precursor (rLRP) and the interaction was significantly reduced in the presence of 
soluble rLRP. Furthermore, H. influenzae mutants lacking OmpP2 showed 
dramatically less adherence to rLRP compared to the parental wild-type strain 
(Orihuela et al., 2009). Further confirmation of OmpP2-mediated rLRP binding 
by H. influenzae was demonstrated by visualizing binding of Cy5-labelled rLRP 
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to the wild-type but not the ¨ompP2 derivative, and by the reduction of LamR 
expression in brain endothelial cells using siRNA; wild-type H. influenzae 
binding was significantly reduced compared with binding to control cells. In 
contrast, the binding of the ¨ompP2 mutant was not affected by LamR siRNA 
(Orihuela et al., 2009).  
The aim of the work described in this chapter was to identify the region(s) of H. 
influenzae OmpP2 involved in the interaction with LamR. This was achieved by 
expressing and purifying recombinant OmpP2 derivatives lacking specific regions 
or extracellular loops and then investigating their rLRP-binding activities using 
ELISA.  
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3.2  Results 
3.2.1  Binding of Whole Recombinant OmpP2 of H. influenzae to 
Laminin Receptor 
As an initial step towards determining the region(s) of OmpP2 responsible for the 
interaction with LamR, ELISAs were performed to confirm the previously 
published results showing that recombinant OmpP2 could bind to recombinant 
LRP (Orihuela et al., 2009). For these experiments, recombinant PorA, OmpP2 
and LRP were purified as previously described (Orihuela et al., 2009). PorA from 
N. meningitidis was used as a comparative positive control. The data obtained 
showed that both proteins, OmpP2 and PorA, bound to rLRP at similar levels and 
that the binding was significantly (p < 0.01) higher than binding to the negative 
control (Figure 3.1). This finding confirms the previously described finding that 
PorA and OmpP2 bind rLRP (Orihuela et al., 2009).  
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Figure 3.1. Interaction of rLRP with OmpP2 of H. influenzae and PorA of N. 
meningitidis. ELISA wells were coated with recombinant OmpP2 or PorA. After 
blocking, rLRP was added followed by rabbit anti-LR and then anti-rabbit IgG-HRP 
antibodies. Specific binding of LRP to OmpP2 and PorA-coated ELISA plates was 
determined by subtracting the absorbance in BSA-coated wells from that in OmpP2 and 
PorA-coated wells. Data shown are the means of at least three independent experiments, 
with each sample tested in triplicate. Error bars indicate standard error (SE). 
3.2.2 Construction Plasmids of expression OmpP2 Derivatives, OmpP2¨L1-
4 and OmpP2¨L5-8 
After confirmation of the binding of OmpP2 to rLRP, the next step was to identify 
the region of OmpP2 that was responsible for the binding activity. Therefore, two 
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fragments; one corresponding to the N-terminal portion of OmpP2 (spanning the 
ILUVWIRXUSUHGLFWHGVXUIDFHH[SRVHGORRSVDQGQDPHG2PS3¨/-8) and a second 
corresponding to the C-terminal portion (spanning loops 5-8 and named 
2PS3¨/-4) were expressed, purified and tested for rLRP binding. Plasmids 
encoding these OmpP2 derivatives were constructed by inverse PCR deletion of 
regions of ompP2 from a previously constructed plasmid pNJO74 (made by Dr. N. 
J. Oldfield). Briefly, pNJO74 was constructed by amplifying ompP2 of H. 
influenzae strain Rd KW20, using primers P2F1 and P2R1 (Table 2.1; Figure 3.2; 
Figure 3.3). The product was digested with BamHI and SalI, and cloned into 
BamHI- and SalI-digested pQE30 to yield pNJO74. The amplified region of 
ompP2 corresponded to amino acids 24-359 of OmpP2, and since the N-terminal 
signal peptide cleavage site is predicted to be between amino acids 20 and 21, 
pNJO74 encodes the full length mature OmpP2 minus three N-terminal amino 
acids and in their place has amino acids MRGSHHHHHHGS (encoded by 
pQE30).  
7R REWDLQ 2PS3¨/- DQG 2PS3¨/-8, two sets of primers (3¨1- 4I_F/ 
3¨1- 4I_R and 3¨5-8I_F/ 3¨5-8I_R) were designed based on pNJO74 (Table 
2.1, Figure 3.2). The resulting PCR products obtained using pNJO74 as template 
DNA were digested and self-ligated to form pMSA1 and pMSA2 (Figures 3.3 and 
3.4). 
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Figure 3.2. Diagram showing the ompP2 nucleotide and OmpP2 protein sequence, and 
the annealing sites of primers used in this study. Loops 1-8 are also highlighted in red. 
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Figure 3.3. A schematic representation of the construction of pMSA1 (encoding OmpP2 
lacking loops 1-4). $ ,3&5 IURP S1-2 XVLQJ 3¨- ,B) 3¨-4I_R primers. B: 
IPCR product obtained. C: BamHI-digested IPCR product. D: self-ligated BamHI-
digested IPCR product to form pMSA1. 
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Figure 3.4. A schematic representation of the construction of pMSA2 (encoding OmpP2 
lacking loops 5-8). $ ,3&5 IURP S1-2 XVLQJ 3¨-,B) 3¨-8I_R primers. B: 
IPCR product obtained. C: BamHI-digested IPCR product. D: self-ligated BamHI-
digested IPCR product to form pMSA2. 
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7KHILUVWVHWRISULPHUVZDV3¨-4I_F (forward primer, to anneal to nucleotides 
670-694 of ompP2 DQG SULPHU 3¨-4I_R (reverse primer, to anneal to 
nucleotides 418-438 of ompP2). These primers, used with pNJO74 as template, 
yielded a fragment of 4,285 bases (Figure 3.6). The second set of primers was 
3¨-,B) DQG 3¨-8I_R, which were designed to anneal to nucleotides 763-
785 and 646-675 of ompP2, respectively. These two primers yielded a fragment of 
4,413 bases when used with pNJO74 as template (Figure 3.5). 
 
Figure 3.5. Inverse PCR products obtained from the pNJO74 template plasmid 
(comprising pQE30 with ompP2). Lane 2, the DPSOLILHG IUDJPHQW ZLWK SULPHUV 3¨-
,B) DQG 3¨-,B5 ODQH  DPSOLILHG IUDJPHQW ZLWK SULPHUV 3¨-,B) DQG 3¨-
4I_R. Molecular mass markers are shown in lane 1. 
Amplified fragments were purified, digested with BamHI or SalI as appropriate, 
then self-ligated and finally transformed into Escherichia coli JM109 competent 
cells. Transformant colonies were selected and screened by BamHI/SalI restriction 
digestion of the purified plasmids (Figure 3.6). One clone from each 
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transformation was chosen for further confirmation by DNA sequencing, and then 
designated pMSA1 or pMSA2.  
 
Figure 3.6. Agarose gel electrophoresis showing BamHI/SalI restriction fragments of 
pNJO74, pMSA1 and pMSA2. Lane 2 is pNJO74 (3.5 kb and 1.017 kb bands are 
apparent); lane 3 is pMSA2 (3.5 kb and 0.605 kb); lane 4 is pMSA1 (3.5 kb and 0.417 
kb). Molecular mass markers are shown in lane 1. 
3.2.3  Expression of OmpP2 Truncated Derivatives 2PS3¨L1-4 
and 2PS3¨L5-8  
pMSA1 and pMSA2 were successfully constructed and used to transform E. coli 
JM109 (section 3.2). pMSA1 encoded the vector-derived sequence 
MRGSHHHHHHGS, followed by H. influenzae OmpP2 N24-F359. In contrast, 
pMSA2 encoded the vector-derived sequence MRGSHHHHHHGS, followed by 
OmpP2 Y24-Y225, followed by the vector-derived sequence VDLQPSLI. 
Expression of the recombinant proteins was performed using exponential-phase E. 
coli JM109 harbouring either pMSA1 or pMSA2 and induced with IPTG for 3 h. 
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Pre-induced and induced samples were solubilized with SDS sample buffer and 
run on 10% SDS-polyacrylamide gels. Bands of ca. 17 kDa and ca. 28 kDa were 
observed in induced samples of cells harbouring plasmids encoding 2PS3¨L1-4 
DQG2PS3¨L5-8 respectively (Figure 3.7A). Histidine-tagged proteins were then 
detected by immunoblotting using anti-Penta-His antibodies (Figure 3. 7B). 
 
Figure 3.7. SDS-PAGE (A) and immunoblot using penta-his antibodies (B) showing 
2PS3 2PS3¨/- DQG 2PS3¨/-4 expression. In both panels: Lane 1, protein 
marker; 2, non-induced E. coli JM109 (pNJO74); 3, induced E. coli JM109 (pNJO74) 
(OmpP2); 4, non-induced E. coli JM109 (pMSA2); 5, induced E. coli JM109 (pMSA2) 
2PS3¨L5-8); 6, non-induced E. coli JM109 (pMSA1); 7, induced E. coli JM109 
(pMSA1) 2PS3¨L1-4).  
3.2.4  Protein Purification by Affinity Chromatography 
HisPur cobalt resin was used for recombinant protein purification. Due to the 
insoluble nature of OmpP2, protein purification was performed under denaturing 
conditions using affinity chromatography as described in section (2.11). To 
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confirm the purity and identity of the purified proteins, they were analysed by 
SDS-PAGE and immunoblotting. Recombinant protein bands with apparent 
molecular weight of ca. 17-kDa and 28-N'DFRUUHVSRQGLQJ WR WKH2PS3¨L1-4 
DQG 2PS3¨L5-8, respectively, were observed by SDS-PAGE (Figure 3.8A). 
Immunoblot analysis also detected the tagged recombinant protein, and single 
bands corresponding to the expected protein size obtained (Figure 3.8B).  
 
 
Figure 3.8. 10% SDS-polyacrylamide gel (A) and immunoblot analysis using anti-penta 
his antibodies (B) demonstrating affinity purification of OmpP2, 2PS3¨/-8 and 
2PS3¨/-4. E. coli JM109 harbouring pNOJ74, pMSA1 or pMSA2 were grown to 
exponential phase and induced with IPTG. After induction, cells were harvested by 
centrifugation and recombinant protein purified using a Qiagen Ni-NTA spin kit under 
denaturing conditions. In both panels: Lane 1, protein marker; lane 2, OmpP2; lane 3, 
2PS3/¨-ODQH2PS3¨/-4.  
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3.2.5  Binding of RHFRPELQDQW2PS3¨L1-DQG2PS3¨L5-8 to 
Laminin Receptor 
The purified truncated OmpP2 proteins were tested for rLRP-binding by ELISA. 
In these assays, wells were coated with 5 ȝJ ml-1 OmpP2 or truncated OmpP2, 
blocked and later challenged with rLRP (5 ȝJ ml-1). After rigorous washing, anti-
LR was added to detect the interaction between the bacterial proteins and rLRP. 
PorA was used as a positive control for rLR-binding. Each sample was tested at 
least in triplicate and each test was repeated at least three times. The data obtained 
showed that the binding of rLRP to 2PS3¨/-4 was significantly lower (p < 
0.01) than binding to whole OmpP2. In contrast, rLRP-binding to PorA or 
2PS3¨L5-8 was not significantly reduced compare to whole OmpP2 (Figure 
3.9). 
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Figure 3.9. Binding of rLRP to OmpP2 and its derivatives. 2PS3 2PS3¨L1-4, 
2PS3¨L5-8 and PorA (as a positive control) were used as the solid-phase ligands. After 
blocking, rLRP was added followed by rabbit anti-LR and then anti-rabbit IgG-HRP 
antibodies. The absorbance in BSA-coated wells was subtracted from that in OmpP2 and 
PorA-coated wells. Data shown are the means of at least three independent experiments, 
with each sample tested in triplicate. *p < 0.01 compared with whole OmpP2. Error bars 
indicate SE.  
3.2.6  Construction Plasmids of expression OmpP2 Derivatives: 
2PS3¨/ 2PS3¨/2, 2PS3¨/3 and 2PS3¨/ 
The data shown in Figure 3.9 suggested that the rLRP-binding domain of OmpP2 
was localised to the N-terminal portion of the protein. Therefore, further studies 
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were undertaken to identify the rLRP binding site present in this region. 
Specifically, plasmids encoding deletions in each of the first four extracellular 
loops of OmpP2 were constructed, since it was hypothesized that rLRP-binding 
was likely to be localised to one of the extra-cellular loops. All plasmids encoding 
OmpP2 loop deletions were derived from the pNOJ74 using inverse PCR 
methodology. Primers were designed based on the nucleotide sequence of ompP2 
from H. influenzae. BglII restriction sites were incorporated into both forward and 
reverse primers to facilitate self-ligation of amplified products.  
After amplification, all PCR products were visualised on an agarose gel (Figure 
3.10). PCR products then were digested using BglII and self-ligated to yield 
plasmids pMSA3 (encoding OmpP2 lacking loop 1), pMSA4 (encoding OmpP2 
lacking loop 2), pMSA5 (encoding OmpP2 lacking loop 3) and pMSA6 (encoding 
OmpP2 lacking loop 4). Constructs were confirmed using restriction digest and 
DNA sequencing (data not shown).  
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Figure 3.10. Agarose gel analysis showing the inverse PCR amplicons generated from 
pNJO74. $ /DQH  3¨/,B) ZLWK 3¨/,B5 SURGXFW ORRS  GHOHWLRQ /DQH 
3¨/,B) ZLWK 3¨/,B5 SURGXFW ORRS  GHOHWLRQ % /DQH  3¨/,B) ZLWK
3¨/,B5SURGXFWORRSGHOHWLRQ/DQH3¨/,B)ZLWK3¨/,B5SURGXFWORRS
deletion). In both panels, molecular mass markers are shown in lane 1. 
3.2.7  Expression and Purification of 2PS3¨/, 2PS3¨/2, 
2PS3¨/3 DQG2PS3¨/4 Recombinant Proteins  
Plasmids pMSA3, pMSA4, pMSA5 and pMSA6 were transformed into E. coli 
JM109 and the transformants used to express recombinant OmpP2 derivatives 
lacking defined loops as described in section (3.2.6). Whole cell lysates from pre- 
and post-induced samples were solubilised in SDS sample buffer and run on 10% 
SDS-polyacrylamide gels. N-terminally 6 × His-tagged recombinant proteins were 
VHHQ LQ LQGXFHG VDPSOHV RI FHOOV KDUERXULQJ SODVPLGV HQFRGLQJ 2PS3¨/
2PS3¨/ 2PS3¨/ DQG 2PS3¨/ UHVSHFWLYHO\ (Figure 3.11A). 
Immunoblotting using anti-penta His antibodies confirmed that these proteins 
were histidine-tagged (Figure 3.11B). Faint immuno-reactive bands were also 
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observed in un-induced samples. This was probably due to leaky expression of the 
gene even without induction. 
 
Figure 3.11. SDS-PAGE (A) and immunoblotting analysis using anti-penta His antibodies 
% VKRZLQJ 2PS3 2PS3¨/ DQG 2PS3¨/ 2PS3¨/ DQG 2PS3¨/
expression in pre- and post- induced E. coli JM109 strains. Lane 1, protein marker. 
Lanes: 2, 4, 7, 8 and 10 cell are lysates of E. coli JM109 harbouring pNJO74, pMSA3, 
pMSA4, pMSA5 or pMSA6 respectively before induction. Lanes 3, 5, 6, 9 and 11 are 
corresponding cell lysates of E. coli JM109 harbouring pNJO74 (OmpP2), pMSA3 
2PS3ǻ/ S06$ 2PS3ǻ/ S06$ 2PS3ǻ/ RU S06$ 2PS3ǻ/
respectively, after induction with IPTG. Immunoblot analysis shows that recombinant 
proteins are recognized by anti-penta histidine antibody.  
  
 
83 
 
Recombinant proteins were then purified under denaturing conditions and the urea 
removed using desalting columns or D-TubeTM Dialyzers. Purified proteins were 
analysed by SDS-PAGE and immunoblotting with anti-penta histidine or anti-
OmpP2 antibodies. SDS-PAGE analysis showed single bands corresponding to 
2PS3¨/ 2PS3¨/ 2PS3¨/ DQG 2PS3¨/, respectively (Figure 
3.12A). Immunoblot analysis confirmed that the purified proteins were histidine-
tagged (Figure 3.12B). In addition, the purified recombinant proteins were 
identified by anti OmpP2 antibody (Figure 3.12C). 
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Figure 3.12. SDS-PAGE analysis (A), immunoblotting with anti-penta his (B) or anti-
OmpP2 (C) confirming the purity and identity of the purified OmpP2 derivatives lacking 
specific loops. In all panels: lane 1, protein marker; ODQH2PS3ODQH2PS3ǻ/-
8; lane 4, 2PS3¨/- ODQH  2PS3¨/ ODQH  2PS3¨/ ODQH  2PS3¨/
ODQH2PS3¨/ 
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3.2.8  Binding of rLRP to Recombinant 2PS3¨/2PS3¨/
2PS3¨/DQG2PS3¨/ Using ELISA 
The four purified truncated OmpP2 proteins were then tested for rLRP-binding by 
(/,6$ ,Q WKHVH DVVD\V ZHOOV ZHUH FRDWHG ZLWK  ȝJ PO-1 OmpP2 or truncated 
OmpP2, blocked and later challenged with rLRP  ȝJ PO-1). After rigorous 
washing, anti-LR was added to detect the interaction between the bacterial 
proteins and rLRP. PorA was used as a positive control for rLRP-binding. Each 
sample was tested at least in triplicate and each test was repeated at least three 
times. The data obtained showed that the binding of rLRP WR 2PS3¨/2 was 
significantly lower (p < 0.01) than binding to whole OmpP2. In contrast, LRP-
binding to 2PS3¨/1, 2PS3¨/3 or 2PS3¨/4 was not significantly reduced 
compare to whole OmpP2 (Figure 3.13). This data suggested that loop 2 is 
important for the interaction of OmpP2 with rLRP.  
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Figure 3.13 %LQGLQJ RI U/53 WR 2PS3 DQG LWV 2PS3¨/ 2PS3¨/ 2PS3¨/
DQG2PS3¨/GHULYDWLYHV OmpP2, 2PS3¨/ODEHOHG3¨/2PS3¨/(labeled 
3¨/2PS3¨/ODEHOHG3¨/2PS3¨/ODEHOHG3¨/ were used to coat the 
wells of an ELISA plate at a concentration of 5 µg ml-1. PorA and BSA-coated wells were 
included as comparative positive and negative controls respectively. After blocking, rLRP 
was added followed by rabbit anti-LR and then anti-rabbit IgG-HRP antibodies. The 
absorbance in BSA-coated wells was subtracted from that in OmpP2 and PorA-coated 
wells. Data shown are the means of at least three independent experiments, with each 
sample tested in triplicate. *p < 0.01 compared with whole OmpP2. Error bars indicate 
SE.  
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3.2.9  Construction of Plasmids for Expressing Native OmpP2 and 
2PS3¨/Using a Cell-free Protein Synthesis Methodology 
The data shown in Figure 3.13 suggested that loop 2 was important for the 
interaction of OmpP2 with rLRP. However, the recombinant proteins used in this 
analysis were purified under denaturing conditions. This could dramatically affect 
protein structure and thus their biology activity (i.e. LRP-binding properties). 
Therefore, the aim was to purify OmpP2 and 2PS3¨/ XQGHU QRQ-denatured 
conditions. If successfully purified these proteins could be tested for LRP-binding, 
so provide additional confirmation that loop 2 was required for optimal OmpP2 
LRP-ELQGLQJ7KH0HPEUDQH0D[3URWHLQ([SUHVVLRQ.LW,QYLWURJHQ) was used 
for this purpose. 7KH 0HPEUDQH0D[ 5HDJHQW SURYLGHV SURSHU IROGLQJ DQG
stability of the membrane protein becuase the expressed membrane protein is 
embedded in the lipid bilayer which prevents aggregation of the protein. 
According to the manufactXUHU¶V LQVWUXFWLRQV WKH'1$ WHPSODWHPXVW FRQWDLQ D
T7 promoter and the gene of interest must contain an ATG initiation codon. 
Hence, ompP2 fragments were cloned into the pEXP5-CT/TOPO vector which 
contains these elements. Primers P2CtHis_F and P2CtHis_ R (Table 2.1) were 
used to amplify ompP2 and RPS3¨/ from plasmids pNJO74 and pMSA4 
respectively to yield 1.011 kb (ompP2) and 0.99 kb (RPS3¨/) amplicons 
(Figure 3.14A). These products were then cloned into pEXP5-CT/TOPO to yield 
pMSA18 and pMSA19 respectively. Constructs were confirmed by PCR (Figure 
3.14B), restriction digestion and DNA sequencing (data not shown).  
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Figure 3.14. Generation of pMSA18 and pMSA19 constructs for cell-free protein 
expression. Agarose gel analysis of PCR products of (A) amplified fragment from 
templates pNJO74 (lane 2, ca. 1.011 kb) and pMSA4 (lane 3, ca. 0.99 kb) using 
P2CtHis_F and P2CtHis_R primers, (B) PCR-amplified fragments from pMSA18 (lane 2, 
ca. 1.092 kb) and pMSA19 (lane 3, ca. 1.071 kb) using T7_F and P2CtHis_R primers. In 
both panels, DNA markers are shown in lane 1.  
3.2.10  ([SUHVVLRQRI2PS3DQG2PS3¨/Proteins Using the 
0HPEUDQH0D[3URWHLQ([SUHVVLRQ.LW 
The MembraneMaxTM protein expression kit is designed for in vitro expression of 
soluble membrane proteins from template DNA. For proper expression in the 
MembraneMaxTM system, it is recommended that the template must contain the 
T7 promoter and the gene of interest must contain an ATG initiation codon. 
Therefore, the pEXP5-CT/TOPOR vector, which is ideally suited for use with 
0HPEUDQH0D[3URWHLQ([SUHVVLRQ.LWVZDVXVHG 
*HQHV HQFRGLQJ 2PS3 DQG 2PS3¨/ ZHUH UHFRPELQHG S(;3-CT/TOPO 
SODVPLG ,QYLWURJHQ IROORZLQJ WKHPDQXIDFWXUHU¶VGLUHFWLRQV ,QEULHI WKHJHQHV
ompP2 and RPS3¨/ were PCR-amplified from plasmid pNJO74 and pMSA4 
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respectively using primers P2CtHis_F and P2CtHis_R (Table 2.1) and 
recombined into pEXP5-CT/TOPO to yield pMSA18 (encoding OmpP2) and 
pMSA19 HQFRGLQJ 2PS3ǻ/ UHVSHFWLYHO\ ZKLFK ZHUH XVHG WR WUDQVIRUP E. 
coli JM109. These primers amplify the whole gene of ompP2 or RPS3¨/, 
incorporating the start codons and devoid of the stop codon of the genes. 
The 0HPEUDQH0D[ protein expression kit includes all the components and 
reagents needed for the production and solubilisation of desired recombinant 
membrane proteins. The membrane protein of interest is synthesized into an 
environment that mimics its cellular surroundings with consistent soluble 
structure and less aggregates or clumping.  
pMSA18 and pMSA19 were purified from E. coli JM109 and used for protein 
expression using the MembraneMaxTM protein expression kit according to the 
manufactureU¶V instructions. Following the expression reaction, samples were 
analysed by SDS-PAGE (Figure 3.15A) and immunoblotting using anti-penta-his 
(Figure 3.15B) and anti-OmpP2 antibodies (Figure 3.15C). This analysis showed 
that expression of both proteins was successful using this approach. However, the 
yield of the protein was comparably low, and further purification steps would be 
required to remove the cell lysate of the E. coli slyD- extract which was used in 
the reaction. To purify the DPRXQW RI 2PS3 DQG 2PS3¨/ QHHGHG IRU the 
further investigation of LRP-binding, many expression kits would be required and 
the cost prohibitive. Hence, the purification of OmpP2 and 2PS3¨/using this 
strategy was not pursued further. 
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Figure 3.15 ([SUHVVLRQ DQG SXULILFDWLRQ RI 2PS3 DQG 2PS3¨/ XVLQJ D FHOO-free 
protein purification system. SDS-PAGE (A) and immunoblot analysis (B; SUREHGZLWKĮ-
His antibody, C; SUREHGZLWKĮ-OmpP2 antibody) of expressed proteins obtained using 
WKH0HPEUDQH0D[3URWHLQ([SUHVVLRQ.LWLane 2, 2PS3ODQH2PS3¨/ODQH
4, negative control, contains all additives except DNA template (pMSA18 or pMSA19). 
Broad range protein markers (6-175 kDa) are shown in all panels in lane 1.  
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3.3  Discussion  
Invasive disease caused by Hib can affect many organ systems. The most 
common types of invasive disease are meningitis, epiglottitis, pneumonia, arthritis, 
and cellulitis. Meningitis is infection of the membranes covering the brain and is 
the most common clinical manifestation of invasive Hib disease. To cause 
meningitis, the bacteria have to cross the blood±brain barrier (BBB), but the 
precise mechanisms by which bacterial meningeal pathogens such as N. 
meningitidis, S. pneumoniae, and H. influenzae cross the BBB and gain access to 
the CNS and brain is not fully understood (Kim, 2006).  
Recent work has shown that CbpA of S. pneumoniae, PorA and PilQ of N. 
meningitidis and OmpP2 of H. influenzae are LamR-binding ligands and enable 
these bacterial pathogens to bind to rodent and human brain microvascular 
endothelial cells of the BBB (Orihuela et al., 2009). 
OmpP2 is the most abundant protein in the outer membrane of H. influenzae and, 
besides its basic function as a porin, it has many activities associated with host 
cell interactions. For instance, Anderson et al found that mutation of ompP2 
caused reduced uptake of nicotinamide adenine dinucleotide (NAD) and 
nicotinamide mononucleotides (NMN) (Andersen et al., 2003). Additionally, 
changes in the OmpP2 sequence led to differences in antibiotic sensitivity 
(Regelink et al., 1999). Antibodies against OmpP2 were shown to be protective in 
the infant rat model of bacteremia (Chong et al., 1993; Duim et al., 1996). 
In this chapter, the interaction between purified OmpP2 and rLRP was 
investigated using ELISA with the aim of defining the regions of OmpP2 required 
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for optimal rLRP binding. Initially, two truncated fragment of OmpP2 were 
expressed and purified. The first fragment corresponded to the N-terminal half of 
OmpP2 and including the first four extracellular loops of the molecule. The 
second part corresponded to the C-terminal half of OmpP2 including the last four 
extracellular loops of the protein. ELISA analysis suggested that the region of 
OmpP2 that interacts with rLRP was contained in the N-terminal part of OmpP2. 
In order to investigate which of the four extracellular loops contained in this 
fragment was important in the interaction of OmpP2 with rLRP, four plasmids 
were constructed in which the coding regions of these loops were individually 
removed from OmpP2. The truncated proteins encoded by these plasmids were 
then expressed and purified and the ability of the proteins to interact with rLRP 
was investigated. The data suggested that OmpP2 lacking loop 2 significantly 
reduces its binding to rLRP in comparison to the whole protein.  
The work described in this chapter utilised OmpP2 derivatives purified under 
denaturing conditions. Attempts were also made to purify them under native 
conditions, so that the purified protein would more closely mimic the membrane-
embedded OmpP2 protein produced by H. influenzae. This was performed using 
the 0HPEUDQH0D[ 3URWHLQ ([SUHVVLRQ .LW SDS-PAGE analysis and 
immunoblotting confirmed expression of the recombinant proteins. However, the 
yield of expressed protein obtained from each reaction was low, and given the 
cost of the expression kit, it was not considered a viable option for purifying the 
amount of OmpP2 derivatives needed for further analysis of LR-binding.  
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The interaction between OmpP2 of H. influenzae and LamR has been shown to be 
important in the pathogenesis of this organism. To test the hypothesis that loop 2 
of OmpP2 is important for the interaction of H. influenzae and LamR (rather than 
just OmpP2 alone), a specific mutant was then generated in H. influenzae in 
which this loop was deleted. This mutant was then be tested in assays for LamR-
binding and additional models of virulence. This work is detailed in subsequent 
chapters of this thesis.  
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CHAPTER FOUR: Mutagenesis of ompP2 and 
omp3¨/ of H. influenzae 
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CHAPTER FOUR 
4. MUTAGENESIS OF OMPP2 AND 2033¨/ OF H. 
INFLUENZAE 
4.1  Introduction 
Initial investigations into the specific regions of OmpP2 mediating interactions 
with recombinant laminin receptor precursor protein (rLRP) were described in the 
previous chapter. Two fragments of OmpP2 were expressed in Escherichia coli: 
one corresponded to the N-terminal portion of OmpP2, and included loops 1-4 
2PS3ǻ/-8); the second corresponded to the C-terminal portion, and included 
loops 5- 2PS3ǻ/-4). ELISA experiments using purified rLRP showed that 
the region of OmpP2 which interacts with recombinant laminin receptor protein 
was contained in the first four loops of OmpP2. In contrast, the last four loops 
were unable to bind rLRP. Furthermore, deletion of loop 2 from full length 
recombinant OmpP2 expressed in E. coli significantly reduced its interaction with 
rLRP. These results suggest that loop 2 is important for the ability of OmpP2 to 
bind to rLRP, and thus, it is likely that loop 2 plays an important role in the 
pathogenesis of Haemophilus influenzae. A study carried out by Orihuela and 
colleagues suggested that the initiating step of invasion of the vascular 
endothelium of the blood-brain barrier by meningeal pathogens (including 
Neisseria meningitidis, H. influenzae and Streptococcus pneumoniae) is the 
interaction of outer membrane proteins of these microorganisms with the 37/67-
kDa laminin receptor (LamR) on the surface of human brain microvascular 
endothelial cells (HBMECs) (Orihuela et al., 2009). LamR was identified to be a 
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common receptor for all three species of meningeal pathogens (Orihuela et al., 
2009). Moreover, mutagenesis studies indicated that the bacterial LamR-binding 
adhesins were pneumococcal CbpA, meningococcal PilQ and PorA, and OmpP2 
of H. influenzae (Orihuela et al., 2009). It had already been shown that LamR acts 
as a receptor for a number of neurotrophic viruses, such as Sindbis virus and 
Dengue virus (Wang et al., 1992), thus LamR may act as a common determinant 
in mediating the entry of viral and bacterial pathogens to the immunologically-
privileged CNS. 
To further characterize the role of OmpP2 loop 2 of H. influenzae in its interaction 
to LamR, ompP2 and oPS3ǻ/ null mutants were generated. The mutants will 
be utilized in subsequent characterization experiments to facilitate a study of the 
potential role of OmpP2 and its second loop in the pathogenesis of H. influenzae. 
In addition to mutating ompP2 (H. influenzae ¨ompP2) and its loop 2-encoding 
region (H. influenzae RPS3¨/), the H. influenzae ompP2::kanR mutant was 
created, in which the kanamycin resistance cassette was inserted into the wild type 
H. influenzae, and was used as negative controls in experiments. Moreover, the 
surface location of the mutated OmpP2 protein was investigated using cell 
fractionation by a modification of the method of Nossal and Heppel (Nossal & 
Heppel, 1966). In this study interaction of H. influenzae and its derivative mutants 
to rLRP was investigated using a combination of molecular and immunological 
techniques, including ELISA, whole cell lysate pull-down assays, and flow 
F\WRPHWU\ ,QDGGLWLRQWKHSURWHLQV2PS3DQG2PS3¨/ZHUHSXULILHGXQGHU
non-denatured conditions using ion exchange and gel filtration. Purified proteins 
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then tested to their binding with rLRP by enzyme-linked immunosorbant assay 
(ELISA).  
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4.2  Results 
4.2.1  Generating a Mutant Lacking the Region of Loop 2 Gene 
Encoding OmpP2 Lack the loop 2 Peptides 
Previous results indicated that the second loop of recombinant OmpP2 is 
important for OmpP2 interaction with rLRP. Therefore, the next aim was to 
construct a H. influenzae strain expressing OmpP2 with loop 2 deleted. This strain 
could then be tested for LamR-binding. In order to create a loop 2 knock-out 
mutant in H. influenzae strain Rd KW20, a region of DNA containing ca. 1-kb 
upstream and ca. 1-kb downstream of the ompP2 gene sequence was successfully 
amplified by PCR from genomic DNA of H. influenzae Rd, Amplification was 
done by PCR using primers mP2_F and mP2_R (Table 2.1). The fragment 
containing ompP2 plus flanking regions was amplified, A-tailed to facilitate T-
cloning and then purified (Figures 4.1 and 4.2A). 
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Figure 4.1. Topology of the OmpP2 protein in the H. influenzae cell envelope, based on 
the model of Galdiero et al. (2006). The highlighted sequences represent the separately 
deleted loops in this work. 
The amplified fragment was then ligated into pGEM-T Easy (Promega) and used 
to transform E. coli JM109. The resulting colonies were screened for the presence 
of the desired insert by PCR using T7P and SP6 vector-specific primers. 
However, no product bands corresponding the expected size were generated 
despite repeating this experiment several times using a range of different 
conditions. Similar results were obtained when another set of primers: p2F3 and 
P2R3_3 (Table 2.1) was employed in conjunction with the alternative cloning 
vector.  
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It was hypothesized that the amplified region may be deleterious to E. coli. In 
particular, the gene upstream of ompP2 (rnh), which encodes for ribonuclease H 
(an enzyme involved in DNA replication, recombination and repair) might also be 
harmful to E. coli. Therefore, new primers were designed: F1 and mP2_R (Table 
2.1), which are predicted to yield a 2.72-kb amplicon (containing ca. 0.52-kb 
upstream and ca. 1.1-kb downstream of the ompP2 gene sequence). A PCR 
product of the expected size was obtained using H. influenzae Rd KW20 
chromosomal DNA as template (Figure 4.2B), purified, A-tailed, cloned into 
pGEM-T Easy and used to transform E. coli JM109. Transformants containing the 
desired insert were identified by blue white screening and confirmed by PCR and 
restriction digestion analysis. PCR analysis employed the plasmid pGEM-T Easy 
vector-specific primers T7P and SP6 to yield ca. 2.9-kb band (Figure 4.2C). 
Furthermore, restriction digestion using EcoRI produced the expected three bands 
of ca.3 kb, ca. 1.6 kb and ca.1.13kb (Figure 4.2D). 
  
 
 
101 
 
 
Figure 4.2. Agarose gel analysis showing (A) the PCR product amplified from H. 
influenzae using mP2_F and mP2_R primers (3.199-kb). Lanes: 1, 2-kb DNA marker; 2, 
3 PCR product before and after gel purification, (B) the F1 and mP2_R PCR products 
lane 2. Lane 3 is A-tailed, purified F1 and mP2_R product (ca. 2.7-kb), (C) T7P and SP6 
PCR products generated from E. coli JM109 transformants containing the F1 and mP2_R 
insert (expected size 2.9-kb), (D) pMSA8 restriction digestion fragments. Lane: 2-4 
pMSA8 extracted plasmids digested with EcoRI. 2-kb DNA marker is shown in lane 1 in 
all panels. 
PCR analysis and restriction digestion results demonstrated that only one of the 
tested colonies harboured the expected plasmid with the ca. 2.7-kb fragment 
generated by the F1 and mP2_R primers. Both approaches confirmed the 
successful ligation of the desired insert to pGEM-T Easy and this plasmid was 
designated pMSA8. 
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Following on from this characterization, the inserts from pMSA8 were sequenced 
to ensure they contained no errors. This analysis showed that the plasmid lacked a 
single adenine nucleotide in the ompP2 coding region compared to the genome 
sequence (Figure 4.3). 
 
Figure 4.3. DNA sequencing data showing the missing adenine nucleotide in the ompP2 
coding region compared to the H. influenzae type b genome. The alignment was 
generated using DNAMAN software and the wild type H. influenzae genome and the 
sequenced fragment of pMSA8 (carrying ompP2 plus flanking regions). The start codon 
of ompP2 is highlighted in white and the A nucleotide is shown in green which is missing 
in pMSA8. 
4.2.2  Constructing Amplicon to Facilitate Deletion of OmpP2 Loop 
Using the Missing Nucleotide Construct (pMSA8)  
Since the previously constructed plasmid pMSA8, which contained ompP2 plus 
flanking regions, was missing a single adenine within the open reading frame 
(ORF) of ompP2, the protein OmpP2 would not be expected to be expressed in 
the transformant cells. Consequently, it was hypothesized that this construct could 
be manipulated and cloned in E. coli by avoiding the suspected problems with 
toxicity resulting from the introduction of the intact ompP2 gene. A construct 
based on this plasmid was generated by amplifying using primers F1 and mP2_R 
to yield a ca. 2.7 kb amplicon (ompP2 plus 0.5 kb upstream and 1.1 kb 
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downstream) and used to facilitate further constructions needed for deletion of the 
loop 2-encoding region of ompP2 (Figures 4.4 and 4.5). 
 
Figure 4.4. Schematic diagram representing steps used to generate designing mutagenic 
constructs using pMSA8 as a template. (A) pMSA8 plasmid comprising 3-kb pGEM-T 
easy, ompP2 plus ca. 0.52-kb upstream flanking region and 1.113 kb downstream region. 
(B) plasmid derived from pMSA8 containing 3-kb pGEM-T easy, ca. 1.5-kb kanamycin 
resistance cassette and the ompP2 plus 0.52-kb upstream and 1.113-kb downstream 
flanking regions (pMSA10). (C) plasmid pMSA12 derived from pMSA10 comprising 3-
kb pGEM-T easy, 1.5-kb kanamycin resistance cassette and the RPS3¨/ plus 0.52-kb 
upstream and 1.113-kb downstream flanking regions. 
pMSA8 was subjected to Inverse PCR (IPCR) using Omg_F and Omg_R primers 
(Figure 4.5A) incorporating BamHI restriction sites in both sides of the product. A 
copy of the H. influenzae '1$XSWDNHVHTXHQFH¶$$*7*&**7&$¶ZKLFK
is required for efficient DNA uptake and natural transformation of H. influenzae 
(Danner et al., 1982; Smith et al., 1995), was incorporated into the forward primer 
Omg_F and hence the amplified fragment. The PCR product was purified, 
  
 
 
104 
 
dephosphorylated and ligated with the 1.5-kb BamHI-digested Kanamycin 
resistance cassette isolated from the vector pJMK30. Following transformation of 
E. coli JM109, putative transformant colonies were selected on kanamycin plates 
and analysed by PCR using the plasmid pGEM-T Easy vector-specific primers 
T7P and SP6 to yield an expected band of ca. 4.1-kb band (Figure 4.5B). 
 
Figure 4.5. Construction of intermediate plasmid pMSA10. Agarose gel analysis of (A) 
BamHI-digested purified PCR products. Product obtained from pMSA8 using Omg_F 
and Omg_R primers to yield a 5.7-kb product (pMSA8). (B) PCR products obtained from 
transformed cells with pMSA10 using primers T7P and SP6. Lanes 2-9: PCR products 
from seven colonies expected to harbour pMSA10 (expected size ca. 4.1-kb in total; ca. 
2.6-kb plus ca. 1.5-kb). In both panels 2-kb DNA marker is shown in lane 1. 
A transformant harbouring the expected product was selected, sequenced and 
named pMSA10. pMSA10 was subsequently used as a template for inverse PCR 
XWLOL]LQJSULPHUV3ǻ,B)DQG3ǻ,B57DEOH)LJXUH$GLJHVWLRQZLWK
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BglII and self-ligation resulting in a construct lacking the DNA encoding loop 2, 
which was designated pMSA12. The plasmid was confirmed by restriction 
digestion using NotI and BglII (Figure 4.6B). Sequence analysis of both pMSA10 
and pMSA12 confirmed that they contain no errors except the expected missing 
adenine nucleotide which was missing from the parent plasmid pMSA8. This 
GHOHWLRQ ZDV ORFDWHG DW WKH ¶ HQG RI ompP2 and recombining this into the H. 
influenzae chromosome would yield an OmpP2-deficient strain, rather than one 
expressing OmpP2, but with loop 2 missing.  
 
Figure 4.6. Constructing of mutagenic plasmid pMSA12. Agarose gel analysis of (A) 
,3&5SURGXFWVGHULYHGIURPS06$XWLOL]LQJ3ǻ,B)DQG3ǻ,B5SULPHUV WR\LHOG
7.2-kb product followed by restriction digestion with BglII. (B) digested pMSA12 
plasmids extracted from three E. coli JM109. Lanes 2-6 are double digestions using NotI 
and BglII of the five putative positive transformants with pMSA12. Positive result of the 
digestion yield 3 expected bands of 3, 3.4 and 0.81-kb as it is shown in lanes 2 and 6. 
Lane 1 is 2-kb DNA marker in both panels. 
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4.2.3  Correction of the Mutation in the ompP2 Gene Cloned in 
pMSA12 
Before plasmid pMSA12 could be used to mutate H. influenzae Rd KW20 it was 
necessary to correct the sequence. Site-directed mutagenesis was applied to 
correct the plasmid pMSA8 by inserting an adenine nucleotide in the construct 
(Figure 4.7). A fragment of DNA consisting of the 539 bp upstream region of the 
ompP2 gene (including 7 consecutive adenine residues in ompP2) was amplified 
using MegaR and F1 primers from H. influenzae Rd KW20 chromosomal DNA 
(Table 2.1). This fragment was used in subsequent rounds of PCR as a forward 
mega primer in conjunction with the mP2_R reverse primers and pMSA12 as a 
template. The 2.7 kb product of this amplification included ompP2 minus loop 2 
region and flanking regions, and incorporated the kanamycin resistant cassette. 
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Figure 4.7. Schematic diagrams showing the steps of site-directed mutagenesis to add an 
adenine nucleotide to the pMSA12. A, a mega primer was amplified using the F1 and 
MegaR primers. B, the generated mega primer with mP2_R was used to amplify the 
corrected region indicated using pMSA12 as a template. C, the 4.1 kb product amplified 
from pMSA12, was used to transform H. influenzae.  
The 0.539-kb mega primer fragment was amplified from H. influenzae using 
MegaR and R2 primers. The mega primer consists of part of the upstream region 
of ompP2, the ribonuclease H DNA metabolism gene (rnh), plus 7 nucleotides of 
ompP2 totaling 539 bp (Figure 4.8). The amplicon (mega primer; 539 bp) was 
utilised in the PCR as a forward primer with the mP2_R reverse to yield 4.1 kb 
fragments from the plasmid pMSA12 (Figure 4.8B).  
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Figure 4.8. Generation of the mutagenic PCR amplicon for deletion of the loop 2-
encoding region of ompP2. pMSA12 was used as a template to amplify the 539-bp mega 
primer using MegR and F1 primers (lane 1, A). (B) The 4.1 kb mutagenic PCR product 
was amplified using the mega primer and the mP2R (lane 2), lane 1 contains the 2 kb 
DNA marker. 
4.2.4  Mutagenesis of ompP2 in H. influenzae Rd KW20 
H. influenzae cells were mutagenised using the PCR amplicon described above. 
Attempts to transform the cells by electro-transformation did not yield the desired 
mutants. Naturally transformed H. influenzae cells were grown on the selective 
media containing kanamycin and putative colonies were screened by PCR. Primers 
flanking the region of interest amplified a fragment that was ca. 1.5-kb larger than 
the wild type H. influenzae (ca. 2.2 kb for the wild type and ca. 3.7 kb in mutated 
cells), which corresponded to the size of the kanamycin resistance cassette (Figure 
4.9). 
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Figure 4.9. PCR analysis of electro and naturally-transformed H. influenzae. (A) 
Schematic diagram showing the positions of the primers relative to the region of interest. 
Chromosomal DNA of the (B) electro and (C) naturally-transformed H. influenzae 
colonies amplified with primers F1 and P2R8. Lane B, 2 represents the wild type H. 
influenzae; Lane B, 3 shows a band amplified from one of the putative mutant H. 
influenzae colonies; Lane C, 2 shows the amplified fragment from wild type H. 
influenzae; Lanes C, 3-5 are the amplified fragments from loop 2-mutated H. influenzae 
colonies. Molecular marker size in kb is shown in the lane 1. 
For further confirmation of the mutagenesis primers mP2F and mP2R (both 
external to the mutagenic amplicon) were employed (Figure 4.10B). Amplicons of 
4.1-kb for the mutated colonies and 3.2-kb for the wild type bacteria were 
obtained, confirming the insertion of the kanamycin resistance cassette. To 
determine the orientation of the kanamycin gene a PCR screen using the primers 
mP2F and Kan_CTR (C-terminal primer of the kanamycin cassette) was 
employed (Figure 4.10C). This showed that the kanamycin resistance cassette was 
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inserted in the reverse orientation on a chromosome with respect to the orientation 
of ompP2 (Figure 4.10A). 
 
Figure 4.10. PCR analysis of mutated H. influenzae using mP2F and mP2R primers or 
mP2_F and Kan_CTR primers. (A) Schematic diagram showing the PCR reaction. 
Agarose gel electrophoresis analysis demonstrating PCR-amplified fragments with 
natural-transformed H. influenzae DNA, (B) mP2F and mP2R primers were used. Lane 6 
is wild type. Lanes 2 to 5 are the mutated H. influenzae colonies. (C) mP2F and 
Kan_CTR primers were used. Lanes 2 to 5 are the PCR-fragments amplified from the 
loop 2 mutated H. influenzae colonies. Molecular marker size in kb is shown in the lane 1 
of panels A and B.  
To confirm the deletion of the loop 2-encoding region in the mutated cells the 
2.267 kb amplicon amplified using primers mP2F and Kan_CTR was digested 
using BglII (a BglII site was incorporated after deletion the loop 2). Two 
fragments of ca. 1.26 and 1.0 kb were obtained (Figure 4.11) confirming that the 
loop 2-encoding region had been deleted in the mutated H. influenzae. The 
fragment amplified using primers mP2_F and Kan_CTR using DNA from the 
putatively mutated colony DNA was sequenced and shown to carry the intended 
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sequence which includes ompP2 minus the second loop encoding region and the 
kanamycin resistance cassette.  
 
Figure 4.11. Agarose gel analysis showing the digested amplicon from the mutated H. 
influenzae DNA. Lanes: 1, 2kb DNA marker; 2, 2.267 kb fragment amplified using 
mP2_F and Kan-CTR; 3, digested amplicon with BglII, which yielded 2 bands 
corresponding to 1.26 and 1.0 kb. 
4.2.5  OmpP2 Expression in the Wild type H. influenzae and Loop 2-
Deleted Mutant  
Expression of the OmpP2 protein in the loop 2-deleted H. influenzae (RPS3ǻ/) 
was analysed by SDS-PAGE. Overnight cultures of wild type, RPS3ǻ/and the 
ompP2 deletion mutant grown in BHI broth overnight at 37°C and whole cell 
lysates analysed by SDS-PAGE. Bands corresponding to OmpP2 were observed 
in wild type and RPS3ǻ/ H. influenzae, but not in the negative control ǻRPS3 
H. influenzae (Figure 4.12A). Lysates were also analysed by immunobolotting 
and probed with anti-OmpP2 antibody. Bands corresponding to OmpP2 were only 
VHHQLQWKHZLOGW\SHDQG2PS3ǻ/H[WUDFWV)LJXUH% 
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Figure 4.12. Expression of mutated OmpP2. (A) SDS-PAGE analysis of whole cell 
lysates from the mutated H. influenzae. Lane 1, Broad range protein marker (6-175 kDa); 
lane 2, Wild-type H. influenzae; lane 3, OmpP2ǻ/ PXWDQW ODQH  ǻOmpP2 mutant; 
lane 5, purified recombinant OmpP2. Arrows in panel A indicate the position of the 
OmpP2 protein. (B) Immunoblot of lysates as described for panel A and probed with anti-
2PS3DQWLERG\$EDQGFRUUHVSRQGLQJWR2PS3LVVHHQLQZLOGW\SHDQG2PS3ǻ/
lysates, and purified OmpP2 only.  
To determine whether the mutant and wild type OmpP2 proteins were expressed 
at similar levels, samples of whole cell lysates were taken at various times (7, 10.5 
and 15 h of the growth; log and stationary phase) and analysed by SDS-PAGE 
(Figure 4.13). Expression of the OmpP2 derivative lacking loop 2 (Ala91-Phe99) 
was lower by comparison with expression of the wild type protein at each time 
point.  
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Figure 4.13. SDS- PAGE showing expressed OmpP2 in H. influenzae. (A) lanes 2-4 the 7 
KFHOOVFXOWXUHRIZLOG W\SH2PS3ǻ/PXWDQWDQGǻ2PS3PXWDQW UHVSHFWLYHO\-7, 
WKH  K FHOOV FXOWXUH RI ZLOG W\SH 2PS3ǻ/ PXWDQW DQG ǻ2PS3 PXWDQW
respectively; (B) lanes 2- WKHKFHOOVFXOWXUHRIZLOG W\SH2PS3ǻ/PXWDQt and 
ǻ2PS3PXWDQWUHVSHFWLYHO\$DQG%SXULILHGUHFRPELQDQW2PS3IURPE. coli 
JM109. A 36- N'D EDQG FRUUHVSRQGLQJ WR 2PS3 LV VHHQ LQ ZLOG W\SH 2PS3ǻ/
lysates and purified OmpP2 only. The arrows indicate the position of the OmpP2 protein. 
Lane 1 in panel A and B, protein marker. 
4.2.6  Construction of Mutants with Similar Levels of Protein 
Expression  
2PS3¨/PXWDQWZDVLQWURGXFHGLQWKHH. influenzae. However, the amount of 
WKHH[SUHVVHG2PS3¨/SURWHLQZDVORZer compared to the expression levels of 
OmpP2 in the wild type. This might be due to the fact that the orientation of the 
kanamycin resistance gene in the chromosome was in the opposite orientation of 
the ompP2. For this reason, the kanamycin resistance cassette was replaced with 
the Omega cassette, which encodes resistance to spectinomycin and streptomycin 
and is transcriptionally isolated as the resistance gene is flanked by transcription 
termination signals. Two plasmids pMSA13 and pMSA14 were derived from the 
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two previously designed plasmids pMSA10 and pMSA12 respectively. Plasmids 
pMSA10 and pMSA12 digested with BamHI to eliminate kanamycin resistance 
cassette (Figure 4.14A). Digested plasmids were extracted from the gel and the 
purified bands were analysed on gel electrophoresis (Figure 4.14B). pMSA10 and 
pMSA12 products were extracted from the gel, dephosphorylated and ligated to 
the Omega cassette, which was obtained from BamHI-digested pKG130 vector 
(Figure 4.15 C and D).  
 
Figure 4.14. Construction of the mutagenic plasmids pMSA13 and pMSA14. Agarose gel 
analysis of (A) BamHI-digested plasmids. Lane 2, digested pMSA10 to yield 5.713 kb 
and 1.4 kb (kanamycin resistance gene). Lane 3, digested pMSA12 to yield 5.692 kb and 
1.4 kb (kanamycin resistance gene). (B) gel extracted fragments. Lanes: 1, the 5.713 kb 
released from BamHI digested pMSA10. 3, the 5.692 kb fragment released from BamHI-
digested pMSA12. (C) BamHI-digested pKG130 vector. Lane 2 digested pKG130 vector 
to yield 3 kb and 2.2 kb (Omega cassette). (D) gel extracted Omega cassette. 2-kb DNA 
marker is shown in lane 1 in panels A, C and D and in lane 2 in panel B. 
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BamHI-digested pMSA10 and pMSA12 were ligated with the Omega cassette and 
named pMSA13 and pMSA14 respectively. E. coli cells were transformed with 
pMAS13 and pMSA14, isolated colonies were screened by PCR utLOLVLQJ3ǻ-
8I_F and R2 primers (Figure 4.15). 
 
Figure 4.15. PCR analysis of pMSA13 and pMSA14. Schematic diagram demonstrating 
the PCR-amplified fragments from (A) pMSA13 (the 3-kb pGEM-T easy, the 2.2-kb 
Omega cassette and the. 1.1-kb ompP2 plus ca. 0.52 kb upstream and ca. 1.1 kb 
downstream flanking region and (B) pMSA14 (the 3-kb pGEM-T easy, the ca. 2.2-kb 
Omega cassette and the 1.07-kb RPS3¨/ plus ca. 0.52 kb upstream and 1.1 kb 
downstream flanking region) XVLQJ SULPHUV 3¨-8I_F and R2. Both pMSA13 and 
pMSA14 plasmids were derived from pMSA10 and pMSA12 respectively by replacing 
kanamycin resistance cassette with Omega resistant cassette. Agarose gel electrophoresis 
demonstrating amplified PCR-fragments using primers 3¨-8I_F and R2 with pMSA13 
(C) and pMSA14 (D). Panels: C, lanes 3-5 are PCR products of colonies transformed 
with pMSA13. B, lanes 3-5 are PCR products of transformed colonies with pMSA14. 
pMSA10 and pMSA12 used as control and are shown in the lane 2 in both A and B 
respectively. 2-kb DNA marker is shown in lane 1 in both panels. 
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pMSA13 and pMSA14 were confirmed by sequencing and the missing adenine 
nucleotide (known to be missing from their parent plasmids) was again corrected 
by site-directed mutagenesis using a mega primer approach as described above. 
Mutagenesis fragments were amplified using mega primer and mP2R (Figure 
4.16). The amplified fragments were gel-extracted and used to transform H. 
influenzae by natural transformation. Several attempts to transform H. influenzae 
using these amplicons were unsuccessful. 
 
Figure 4.16. Gel agarose electrophoresis of the PCR products amplicons of pMSA13 and 
pMSA14. Lanes: 2, F1 and P2FR primers with pMSA10 template (control). 3, mega and 
P2FR primers with pMSA13. 4, F1 and P2FR primers with pMSA12 template (control). 
5, using mega and R2 primers with pMSA14. 2 kb DNA marker is shown in lane 1. 
4.2.7  Correct the Orientation of Kanamycin Resistance Cassette: 
Construction of Plasmids pMSA15 and pMSA16 
Due to the fact that attempts to transform H. influenzae with plasmids pMSA13 
and pMSA14, which contain the Omega cassette for selection, were unsuccessful, 
we aimed to produce mutants using the kanamycin resistance cassette, but in 
which the resistance gene was in the same orientation as the mutated gene. For 
this purpose, pMSA10 and pMSA12 plasmids, which were already prepared, were 
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employed. Kanamycin resistance cassettes were released from pMSA10 and 
pMSA12 using BamHI restriction enzyme (Figure 4.17). 
 
Figure 4.17. Agarose gel analysis of BamHI-digested pMSA10 and pMSA12 plasmids. 2-
kb DNA marker is shown in lane 1. Lane 2, digested pMSA10 to yield 5.713 kb and 1.4 
kb (kanamycin resistance cassette). Lane 3, digested pMSA12 to yield 5.692 kb and 1.4 
kb (kanamycin resistance cassette).  
The resulting digests were re-ligated with kanamycin resistance cassette and used 
to transform E. coli JM109. Putative positive transformants were subjected to 
PCR analysis using F1 and mP2R primers then were selected and plasmids were 
extracted and designated pMSA15 and pMSA16 (Figure 4.18). 
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Figure 4.18. PCR analysis of pMSA15 and pMSA16 transformed into E. coli JM109. 
Schematic diagram showing the PCR-amplified using F1 and mP2R primers from 
pMSA15 (A) and pMSA16 (B). Gel electrophoresis analysis of PCR-amplified fragment 
by using F1 and mP2R primers from pMSA15 (4.240 kb) is shown in panel (C), and from 
pMSA16 (4.220 kb) is shown in panel D. pMSA15 and pMSA16 were derived from 
pMSA10 and pMSA12 respectively, in which kanamycin resistance cassettes orientation 
were corrected. 2-kb DNA marker is shown in the left. 
The transformants were then scanned using PCR for the desired orientation of the 
kanamycin resistance cassette and plasmids in which the cassette was in the 
correct orientation. Colonies containing plasmids in which the resistance cassette 
was inserted in the desired orientation were identified and plasmids were isolated 
and designated as pMSA15 (3-kb pGEM-T easy, ca. 1.5-kb kanamycin resistance 
cassette and the ompP2 plus 0.52-kb upstream and 1.113-kb downstream flanking 
regions) and pMSA16 (3-kb pGEM-T easy, 1.5-kb kanamycin resistance cassette 
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and the RPS3¨/ plus 0.52-kb upstream and 1.113-kb downstream flanking 
regions) (Figure 4.19). 
 
Figure 4.19. PCR analysis of the kanamycin resistance cassette orientation of pMSA15 
and pMSA16. Schematic diagram representing the PCR-amplified fragments using 
SULPHUV¨3).DQ_CTR and R2 with pMSA15 plasmid (A) and with pMSA16 plasmid 
(B). Agarose gel analysis of PCR products for different primers with pMSA15 (C) and 
pMSA16 (D). Lane 2, Kan_CTR and R2 (ca. 650 bp), lane 3, Kan_&75DQG¨3)QR
products for positive result), lane 4 5DQG¨3) ca. 2377 bp). 2-kb DNA marker is 
shown in lane 1 in A and B. 
4.2.8  Insertion of Single Adenine Nucleotide in the Constructs 
pMSA15 and pMSA16 Using Mega Primer 
The data from the PCR analysis and DNA sequencing indicated that the screened 
colonies harboured the desired construct with the kanamycin resistance cassette in 
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the same orietation as ompP2. However, the constructs obtained from the 
plasmids pMSA15 and pMSA16 were missing a single adenine within the open 
reading frame (ORF) of the ompP2. Hence, a single adenine nucleotide was re-
inserted in the constructs pMSA15 and pMSA16 by PCR using the mega primer 
(0.54-kb) in the PCR as a forward primer with the mP2R reverse primer (Figure 
4.20).  
 
Figure 4.20. Insertion of single adenine nucleotide in the constructs pMSA15 and 
pMSA16 using mega primer. Schematic diagram showing PCR-amplified fragments 
using mega and mP2R primers from pMSA15 (A) and pMSA16 (B). 2-kb DNA marker is 
shown in the lane 1. (C) Agarose gel electrophoresis showing the PCR analysis using 
mega and mP2R primers with pMSA15 (lane 2, ca. 4.240 kb) and with pMSA16 (lane 3, 
ca.4.220 kb). 2-kb DNA marker is shown in the lane 1. 
Next, the corrected constructs were used to mutate loop 2 in vivo in H. influenzae 
as well as to insert the kanamycin resistance cassette into the wild type H. 
influenzae in order to generate an appropriate control isolate. The constructs 
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which were amplified and corrected by mega primer were used as template for 
PCR to amplify the mutagenic fragments using F1 and P2FR (Figure 4.21).  
 
Figure 4.21. Amplifying mutagenic fragments from pMSA15 and pMSA16 using F1 and 
P2FR. Schematic diagram representing the amplified fragment by the PCR using F1 and 
P2FR primers from corrected pMSA15 (A) and pMSA16 (B). (C) Agarose gel analysis of 
PCR-amplified amplicon fragments using F1 and P2FR primers. Lane 2, ca. 4.110 kb 
fragment amplified from corrected pMSA15, lane 3, 4.110 kb fragment amplified from 
corrected pMSA16. 2-kb DNA marker is shown in the left. 
4.2.9  *HQHUDWLRQRI2PS3¨/Mutants in H. influenzae Rd KW20 
Cells 
H. influenzae cells were naturally transformed with the 4.13 or 4.11-kb fragment 
(Figure 4.22). The mutagenic fragment (4.110-kb; derived from corrected 
pMSA16) was used to delete loop 2 of the ompP2 and incorporate the kanamycin 
resistance cassette into the genome. The other amplified mutagenic fragment 
(4.130-kb; derived from corrected pMSA15) was used to insert the kanamycin 
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resistance cassette in the genome generating a control isolate. Putative 
transformant colonies were PCR-screened for the existence of the desired insert 
utilising primers F1 and P2FR (Table 2.1) as shown in figure 4.22A. Further 
checking for the deleted loop 2, was done by digestion reaction of amplified PCR 
products using BglII (Figure 4.22B).  
 
Figure 4.22. PCR and restriction digestion analysis of mutated H. influenzae. (A) PCR 
products of transformed H. influenzae with primers F1 and P2FR. Lanes 2-6: 4.130-kb 
PCR products of transformed H. influenzae, into which the kanamycin resistance cassette 
was inserted. Lane 7 shows the 2.615-kb PCR product of wild type cells. Lanes 8-9: 
4.110 kb-PCR products of transformed cells, into which the kanamycin resistance 
cassette was inserted and loop 2 encoding region of ompP2 was deleted. (B) BglII-
digested PCR product amplified from deleted loop 2 H. influenzae using F1 and 3ǻ-
8I_R primers. Lanes 2, 4, 6, 8: 1.2-kb fragment of PCR product of colonies 1, 2, 3, and 4, 
respectively, before digestion reaction. Lanes 3, 5, 7 and 9 are BglII-digested PCR 
product using F1 and 3ǻ-8I_R primers of colonies 1, 2, 3, 4, respectively, which 
yielded 2 bands: 759 and 380 bp (just colonies 3 and 4; lanes 7, 9; give positive result). 2-
kb DNA markers are shown in the left. 
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4.2.10  Creation of a New Negative Control of ompP2 Mutant 
In order to generate a new ompP2 H. influenzae Rd KW20 mutant, that contains 
NDQDP\FLQUHVLVWDQWFDVVHWWHDQHZSULPHUZDVGHVLJQDWHG¨3)DQGXVHGZLWK
3ǻ,B5primer in inverse PCR with the plasmid pMSA15 as template. This PCR 
resulted in deletion of approximately 796 bp of the ompP2 gene from the start 
codon and amplification of a 6.4-kb amplicon (Figure 4.23). The IPCR product 
was gel-extracted, BglII-digested and self-ligated and used to transform E. coli 
JM109 cells. Putative transformants were selected and analysed by PCR (Figure 
4.23C). The resulting plasmid was designated pMSA17. 
 
Figure 4.23. Generation of pMSA17 plasmid from pMSA15 by IPCR. (A) Schematic 
GLDJUDPGHPRQVWUDWLQJ,3&5RIWKH3ǻ,B5DQG¨3)SULPHUVZLWKS06$SODVPLG
(B) Agarose gel electrophoresis of the IPCR product of pMSA15 plasmid. The 6.445 kb 
UHDFWLRQ SURGXFWV RI D 3&5 XVLQJ 3ǻ,B5 DQG ¨3) SULPHUV LV VKRZQ LQ ODQH  C) 
Agarose gel analysis of the PCR product using the primers F1 and P2FR. Lane 2: 4.130-
kb fragment of PCR product of the plasmid pMSA15 (control); Lane 3: 3.334-Kb 
fragment of the PCR product of the plasmid pMSA17 transformed into E. coli JM109. 
Molecular mass markers are shown in lane1. 
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The band produced using F1 and P2FR primers using plasmid pMSA17 as a 
template (Figure 4.23C, lane 3) corresponding to the expected size of ca. 3.33-kb 
was extracted and used to transform H. influenzae cells to delete the ompP2 
region and introduce the kanamycin resistance cassette by natural transformation. 
DNA sequencing and PCR using F1 and Omg_R primers (Figure 4.24A and B) 
were used to confirm the mutagenesis (Figure 4.24C and D). 
 
Figure 4.24. PCR analysis of knout-out ompP2 H. influenzae. PCR- amplified fragment 
of the mutated H. influenzae cells using F1and Omg_R primers (A) schematic diagram 
(B) Agarose gel analysis. Lane 2, fragment amplified from wild type H. influenzae cells 
(ca. 1.623 kb). Lane 3-6, fragments amplified from ompP2 mutated cells (872 bp). (C) 
Diagrammatic representation of the amplified fragment of the ompP2 mutated H. 
influenzae cells by the PCR using kan_CTR and R2 primers. (D) 1% agarose gel analysis 
of the PCR products of the ompP2 mutated H. influenzae cells using Kan_CTR and R2 
primers. Lane 2-5, fragment amplified from putative ompP2 mutated H. influenzae cells. 
2-kb DNA marker is shown in the lane 1 in B and C. 
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The mutation of ompP2 was confirmed by SDS-PAGE and immunoblotting of 
whole cell lysates (Figure 4.25). Bands corresponding to OmpP2 were only seen 
in the wild type, ompP2::kanR and RPS3¨/ extracts indicating that the OmpP2 
is expressed in the wild type, ompP2::kanR and RPS3¨/ but not in the 
¨RPS3 mutant. The expression levels of OmpP2 and OmpP2¨/were similar. 
Moreover, there were no apparent differences in expression of other proteins in 
the generated mutants. 
 
Figure 4.25([SUHVVLRQRI2PS3DQG2PS3¨/ (A) SDS-PAGE analysis of whole 
cell proteins from the H. influenzae wild type and mutant strains. Lane 2: Wild-type; lane 
3: ompP2::kanR; Lane 4: RPS3¨/ mutant; lane 5: ¨ompP2 mutant. (B) Immunoblot of 
H. influenzae cell lysates probed with anti-OmpP2 antibody. Lanes as for panel A. A ca. 
36-42 kDa band corresponding to OmpP2 is seen in wild type, ompP2::kanR2PS3¨/ 
lysates only. Broad range protein marker (6-175 kDa) is shown in lane 1 in A and B. The 
arrows indicate the position of the OmpP2 protein.  
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4.2.11  Growth Characteristics of H. influenzae and Its Mutant 
Derivatives 
Comparison of the in vitro growth of H. influenzae and its derivative mutants in 
liquid culture was performed before further analysis of the mutant strains. The 
wild-type H. influenzae, ¨ompP2, RPS3¨/ and ompP2::KanR mutant strains 
were grown in BHI broth with an equal starting OD600. Growth curves were 
plotted based on the measurement at OD600 of samples that were removed from 
the culture at hourly intervals. Growth rates of the mutants were not substantially 
different to that observed for the wild-type H. influenzae strain (Figure 4.26).  
 
Figure 4.26. Comparison of the rate of RPS3¨/ ¨/ ¨ompP2, ompP2::kanR 
mutants compared to the wild-type. Cultures were grown at 37°C in 15-ml tubes with 
vigorous aeration and OD600 reading was taken at hourly intervals for 24 h. Mean values 
from triplcate cultures are plotted. 
0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
0 5 10 15 20 25 30 
O
D
 6
00
 n
m
 
 
t (h) 
H. influenzae growth curve 
WT 
WT-kan  
¨/ 
¨2PS3 
  
 
 
127 
 
4.2.12  2PS3ǻ/LVCorrectly Localised to the Outer Membrane 
OmpP2 is an outer membrane protein that is transported from the cytoplasm 
across the inner membrane via the sec secretion system into the periplasm before 
reaching its final destination in the outer membrane. To investigate the sub-
FHOOXODU ORFDOLVDWLRQ RI 2PS3ǻ/ LQ H. influenzae, a previously described 
method of cell fractionation was used to separate inner and outer membrane 
fractions and the sub-cellular location of OmpP2 determined by immunoblotting 
using anti-OmpP2 antibody (Figure 4.27). Bands corresponding to OmpP2 or its 
mutant derivatives were seen in outer membrane fractions of wild type and 
2PS3ǻ/ H. influenzae, respectively, but not in the ompP2-mutant. 
Furthermore, no bands were seen in the inner membrane fraction of any of these 
cells.  
 
Figure 4.27 /RFDOL]DWLRQ RI 2PS3ǻ/ LQ H. influenzae. SDS-PAGE (A) and 
immunoblot (B) of H. influenzae cell fractions. Lane 1: Broad range protein marker (6-
175 kDa); lane 2- 3: IM and OM-enriched fractions, respectively, of Wild-type; lane 4-5: 
IM and OM-enriched fractions, respectively, of RPS3¨/ mutant; lane 6-7: IM and 
OM-enriched fractions, respectively, of ¨ompP2 mutant; lane 8, purified OmpP2. A 36-
N'DEDQGFRUUHVSRQGLQJWR2PS3LVVHHQLQ20IUDFWLRQVRIZLOGW\SH2PS3¨/
and purified OmpP2 only. The arrows indicate the position of the OmpP2 protein. 
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4.2.13  Interaction of H. influenzae and Its Derivative Mutants with 
Laminin Receptor 
To investigate the interaction of wild-type H. influenzae Rd KW20 and the 
constructed mutants (H. influenzae ompP2::kanR, H. influenzae RPS3¨/ and 
H. influenzae ¨ompP2) with LamR, bacteria cells were DIG-labelled and utilised 
in ELISA. rLRP-binding by H. influenzae RPS3¨/ was significantly reduced 
compared to the wild-type (p <  0.01), albeit the reduction in rLRP-binding was 
not as great as that observed for the control strain lacking OmpP2 (Figure 4.28), 
perhaps indicating that additional residues of OmpP2 may play a role in 
optimizing rLRP-binding. The control strain with an antibiotic cassette inserted at 
the ompP2 locus, but no modification to the ompP2 coding sequence, showed no 
significant reduction in rLRP-binding, thus confirming the direct effect of 
removing or truncating ompP2 on binding.  
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Figure 4.28. Deletion of OmpP2 loop 2 significantly reduces bacterial rLRP-binding. 
Binding of H. influenzae (WT), H. influenzae ¨ompP2 (ǻRPS3), H. influenzae 
RPS3¨/ (RPS3¨/) or H. influenzae ompP2::kanR (ompP2::kanR) to rLRP. 
Specific binding of digoxigenin-labeled bacteria to rLRP-coated ELISA plates was 
determined by subtracting the absorbance in BSA-coated wells from that in rLRP-coated 
wells. Data shown are means from three independent experiments; in each experiment 
each sample was tested in triplicate. * p < 0.01 compared to wild-type. Error bars indicate 
SE.  
To further investigate the interaction of wild type H. influenzae and its derivative 
mutants with rLRP, flow cytometry was employed using bacterial cells harvested 
during the logarithmic phase of growth. The rLRP was stained with fluorescein 
using Lightning-LinkTM Atto680 Conjugation Kit (section 2.16). As an additional 
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control, wild type and ¨porA¨ pilQ double knock out N. meningitidis MC58 
mutant cells were also examined using the same conditions. The combination of 
treated and non-treated cells with stained rLRP, demonstrated a clear difference in 
rLRP binding between wild-type cells and the mutants ¨ompP2 and ompP2¨L2 
(Figure 4.29).  
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Figure 4.29. Flow cytometry analysis of treated and non-treated strains with fluorescein-
conjugated rLRP. Panels A, H. influenzae wild-type. B, H. influenzae ompP2::kanR. C, 
H. influenzae RPS3¨/D, H. influenzae ¨ompP2. E, N. meningitidis wild-type. F, N. 
meningitidis ¨porA¨ pilQ. Cells were incubated with fluorescein-conjugated rLRP or 
without rLRP (control). Mid-log phase bacterial samples were washed with PBS and 
adjusted to 2 × 107 CFU ml-1 aliquots. After centrifugation, fluorescein-conjugated rLRP 
was added (untreated cells were used as a control). After being incubated, the samples 
were washed with FACS buffer and finally samples were fixed in 1 ml PBS containing 
0.5% formaldehyde. Samples were analysed for fluorescence using a Coulter Altra Flow 
Cytometer. The cells were detected using forward and log-side scatter dot plots, and a 
gating region was set to exclude cell debris and aggregates of bacteria. A total of 50, 000 
bacteria (events) were analysed for fluorescence signals. The population of fluorescently 
labeled cells was displayed as a histogram. 
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Binding to rLR, expressed as the percentage of labeled cells exhibiting greater 
fluorescence than the cutoff, varied between the bacterial cell populations: 28.4% 
of the wild type H. influenzae bound to rLRP, which was approximately similar to 
the level observed in control cells in which the kanamycin resistance cassette had 
been inserted downstream of an intact ompP2 gene (H. influenzae mutant, 
ompP2::kanR), of which 22.7% bound rLRP. The cutoff was set such that less 
than 2% of the unlabeled population of cells were recorded. The percentages of 
the cells were much lower for the H. influenzae RPS3¨/ and H. influenzae 
¨ompP2 (14.9% and 8.28%, respectively). Similarly, the binding of N. 
meningitidis ǻSRU$ǻSLO4 cells bound rLRP 40.9% less than their wild type 
counterparts (90.1%), which were used as control in this experiment. Interaction 
of the H. influenzae RPS3¨/ and H. influenzae ¨ompP2 mutants with rLRP 
was significantly less than the interaction of either the wild type H. influenzae or 
H. influenzae ompP2::kanR. Binding of the H. influenzae ompP2::kanR, which 
was used for control purposes, was also less than the wild type, but this difference 
did not reach significance (Figure 4.30).  
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Figure 4.30. Interaction of the H. influenzae and its derived mutants with rLRP using 
FACS analysis. Mid-log phase bacteria were adjusted to 2 × 107 cfu/ml aliquots, 
centrifuged and 20 µg of fluorescein- conjugated rLRP was added in a total volume of 0.2 
PODQGLQFXEDWHGIRUKZDVKHGZLWK)$&6EXIIHU¿[HGZLWKSDUDIRUPDOGHK\GHLQ
PBS. Samples were analysed for fluorescence using a Coulter Altra Flow Cytometer. 
6WXGHQW¶V t-test analysis showed that the different of the interaction with rLRP between 
wild type and H. influenzae ompP2::kanR (control mutant) was not significant and p 
value > 0.05. The interaction with rLRP was significantly reduced in the mutants H. 
influenzae RPS3¨/ and H. influenzae ¨ompP2 mutants compared with the wild type 
(WT), *p value < 0.05. The binding of the double mutant N. meningitidis ¨pRU$¨pilQ 
(DM) was significantly less than the wild type N. meningitidis (NM) which was used as a 
control, **p value < 0.05. Experiment was performed in triplicate. The experiment was 
repeated for three times on different occasions using similar conditions. Error bars 
indicate SE. 
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In order to provide confirmatory evidence for the interaction of rLRP with H. 
influenzae and the role of loop 2 of OmpP2 in this interaction, whole cell lysate 
pull-down assays were conducted. Bacterial cells (H. influenzae, H. influenzae 
RPS3¨/, and H. influenzae ¨ompP2 mutants) were incubated with soluble 
purified rLRP, harvested by centrifugation, washed and re-suspended in SDS-
PAGE loading buffer and analysed by SDS-PAGE and immunoblotting with anti-
LR. Bands were scanned and quantitated by densitometry (Figure 4.31A). Bands 
corresponding to protein with an apparent molecular mass of ca. 44 kDa represent 
the rLR bound to the bacteria. A band with an apparent molecular mass of ca. 29 
kDa was consistently observed; the identity of this protein is unknown. Band 
intensity was quantified by multiplying the total area of the band with the average 
density of the band (Figure 4.31B).  
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Figure 4.31. rLRP binding to whole cells detected using a whole cell pull-down assay. 
(A) rLRP bound to whole cells was detected after cell lysis and immunoblotting. Lysates 
of wild-type H. influenzae (1), ompP2::kanR (2), ompP2¨L2 (3), ¨ompP2 (4) were 
probed with anti-LR and the membrane was scanned using a Bio-Rad GS-800 calibrated 
densitometer. rLRP binding was quantified by multiplying the area of the bands with the 
average band intensity. (B) Quantified regions are indicated for each band.  
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The experiment was repeated three times on different occasions with similar 
results (Figure 4.32). The interaction of the H. influenzae RPS3¨/ and H. 
influenzae ¨ompP2 mutants with rLRP was significantly lower than either the 
wild type H. influenzae or H. influenzae ompP2::kanR. 
 
Figure 4.32. The interaction of rLRP to the bacteria determined by whole cell pull-down 
assay. The amount of rLRP interacting to the bacterial cells was determined by 
multiplying the total area of the band by the average band intensity. Values are expressed 
as a percentage RIWKHELQGLQJ¶VSHUFHQWDJHVZHUHFRPSDUHGYHUVXVZLOG-type. Interaction 
of rLRP with the H. influenzae RPS3¨/ and H. influenzae ¨ompP2 mutants was 
significantly lower than with wild type cells (*p value < 0.05). Experiments were 
performed in triplicate. Error bars indicate SE. 
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4.2.14  ,QWHUDFWLRQRI2PS3DQG2PS3¨/Purified under non-
Denatured Conditions with Laminin Receptor 
Previous data demonstrating an interaction of OmpP2 and rLRP and the role 
played by loop 2, in these experiments the proteins were purified under denaturing 
conditions after being expressed in E. coli. In order to further investigate the role 
of OmpP2 and loop 2 in the interaction of the H. influenzae with rLRP, OmpP2 
DQG2PS3¨/ZHUHSXULILHGXQGHUQRQ-denaturing conditions directly from H. 
influenzae using detergent extraction, ion exchange and gel filtration. Overnight 
bacteria cultures were harvested and lysed in lysis buffer (50mM Tris-HCl, 30mM 
Zwittergent 3-12, pH 8.5 and 1:500 DNase I) at 4°C, cell lysates then were 
centrifuged. Supernatants were subjected to Capto Q cation exchange column 
chromatography and proteins then were eluted with a linear gradient of elution 
buffer 1 (50mM Tris-HCl, 30mM Zwittergent 3-12, 2M NaCl, pH 8.5) and 
samples analysed by SDS-PAGE (Figure 4.33). Fractions containing the porin 
(fractions 5 to 10; lanes 5-10 in figure 4.33 A and B) were then successfully 
further purified by gel filtration and again fractions were analysed SDS-PAGE 
and immunoblotting using anti-OmpP2 (Figure 4.34). 
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Figure 4.333XULILFDWLRQRI2PS3DQG2PS3¨/ Fractions eluted from a Capto Q ion 
exchange column loaded with detergent extracts of H. influenzae (A) or H. influenzae 
RPS3¨/ (B) were analysed by SDS-PAGE. In both panels lane 1 contains protein 
marker; lane 2: detergent extract of whole cells; lane 3: flow through; lane 4: wash; lanes 
5-10 are fractions 5 to 10 respectively. Arrows show the expected size of the protein of 
interest. 
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Figure 4.34 *HO ILOWUDWLRQ SXULILFDWLRQ RI 2PS3 DQG 2PS3¨/ Eluted fractions of 
proteins of H. influenzae (A) or + LQIOXHQ]DH RPS3¨/ (B) were analysed by SDS-
PAGE. The fractions then of H. influenzae (C) or + LQIOXHQ]DH RPS3¨/ (D) were 
analysed by blotting (probed with anti OmpP2). In all panels lane 1 contains protein 
marker; lane 2: soluble; lane 3: flow through; lane 4: wash; lane 5: mixture of fraction 6-
10 of ion exchange elution; lane 6-11 are fractions 5 to 10 respectively.  
Purified native OmpP2 (lanes 6 and 7 in panels A and C; figures 4.34) and 
2PS3¨/ (lanes 6 and 7 in panels B and D; figures 4.34) proteins (lanes 6 and 7 
in figures 4.34) were tested in ELISA assays to determine their ability to bind 
rLRP. %RWK 2PS3 DQG 2PS3¨/ ERXQG U/5P but binding by the mutant 
protein was significantly less than the wild type protein (p < 0.01) (Figure 4.35). 
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Figure 4.35. Binding of QDWLYH 2PS3 DQG 2PS3¨/ WR U/53 An ELISA plate was 
FRDWHGZLWKQDWLYH2PS3DQG2PS3¨/DWDFRQFHQWUDWLRQRIJPO-1. BSA-coated 
wells were included as a negative control. Wells were subsequently incubated with rLRP 
ȝJPO-1) followed with rabbit anti-LR and then anti-rabbit IgG-AP. Bound rLRP was 
detected after adding AP substrate in an ELISA plate reader. Specific binding of rLRP to 
2PS3 DQG 2PS3¨/-coated ELISA plates was determined by subtracting the 
absorbance in BSA-coated wells from WKDWLQ2PS3DQG2PS3¨/-coated wells. Data 
shown are the means of three independent experiments, with each sample tested in 
triplicate. *p value < 0.01 compared to wild-type. Error bars indicate SE. 
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4.3  Discussion 
The laminin receptor protein is an important protein in the microbial infection 
pathway of a number of pathogens, which appear to target this protein as a means 
to enter host cells (Nelson et al., 2008). It was demonstrated that 67LR present on 
the human brain microvascular epithelial cells (HBMECs) membrane and serves 
as a cell-surface receptor facilitating E. coli K1 internalization of HBMECs. This 
interaction is mediated by interaction of cytotoxic necrotizing factor-1 (CNF1) 
with the 37/67-kDa laminin receptor (Chung et al., 2003). Many cell-binding and 
internalization studies proved evidence that the LamR has been reported to serve 
as target for many viruses and it is a receptor for the binding and internalization of 
infectious prions into neuronal or non-neuronal cells (Ludwig et al., 1996; 
Gauczynski et al., 2006; Gauczynski et al., 2001). Furthermore, it has been 
reported that LamR acts as the PrPSc receptor at the cell surface in cultured 
neuronal cells (Leucht et al., 2003). 
Porin P2 purified from H. influenzae type b (Hib) contributes to signaling of the 
inflammatory cascade as in the rat model of meningitis and it was revealed that 
inoculation of OmpP2 of Hib into the fourth stimulated the expression of 1L-Į
TNF- ĮDQGPDFURSKDJHLQIODPPDWRU\SURWHLQ0,P-2) (Galdiero et al., 2001). 
Concomitantly, Galdiero et al., found that the release of IL-6 and TNF-Į ZDV
increased in human monocytic cell line THP-1 cells stimulated with Hib porin. 
Moreover, Hib porin-induced IL-6 and TNF-ĮLQ7+3FHOOV LVPHGLDWHGE\ WKH
CD14 and TLR2 pathway (Galdiero et al., 2004). Similarly, stimulation of U937 
cells by synthetic peptides corresponding to externally exposed loops L5, L6, and 
L7 of OmpP2 porin from Hib induced IL-6 and TNF-ĮSURGXFWLRQ0RUHRYHUWKLV
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production mediated by activation of JNK and p38 mitogen-activated protein 
kinase (MAPK) phosphorylation. L7 and L2 induced IL-6 and TNF- cytokine to 
approximately 40% and 20%, respectively, in comparison to the entire OmpP2 
protein. Loop 7 was identified to be the most active derivative among these loops 
(Galdiero et al., 2006; Neary et al., 2001).  
The work described in the previous chapter using purified recombinant OmpP2 
and its derivatives implicated the second extracellular loop of the porin in its 
rLRP binding activity. To extend these observations, a H. influenzae mutant strain 
expressing OmpP2, with the apex of loop 2 removed (Ala91-Phe99) was 
constructed and the binding of this strain to rLRP compared to the binding of the 
cognate wild-type strain. This mutant was constructed using bacterial 
transformation and allelic exchange. Initial attempts to clone ompP2 and its 
flanking region in E. coli JM109 failed; perhaps due to toxicity to the E. coli cells 
and a subsequent clone obtained using a smaller amplicon contained a frameshift 
mutation, suggesting that expression of the full-length porin gene (including the 
N-terminal signal sequence, which was absent in the pQE-based expression 
plasmids) might also be toxic to E. coli. This clone was used to facilitate further 
steps toward construction of the desired mutagenic amplicon and the point 
mutation had to be corrected using site-directed mutagenesis (Chapnik et al., 
2008), this was achieved using a megaprimer (Kammann et al., 1989). Expression 
levels of OmpP2 in the first 2PS3ǻ/ strain constructed were greatly reduced 
compared to wild-type, this could be due to the kanamycin resistance cassette 
which was inserted in the reverse orientation to ompP2; transcription from the 
kanR gene could interfere with transcription of ompP2 and thus reduce ompP2 
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gene expression. The kanamycin resistance cassette was therefore replaced with 
the Omega cassette, but this construct could not be successfully introduced into H. 
influenzae. The reason for this was not clear. Therefore a new mutant, ompP2¨L2 
was created by removing and re-inserting the kanamycin resistance cassette in the 
forward orientation. In addition to the deleted loop 2 H. influenzae mutants, other 
mutants, ¨ompP2 and ompP2::kan, were generated for control purposes.  
Due to the fact that a specific gene manipulation might cause several phenotypic 
changes compared to the parent strain, it was first essential to demonstrate that 
genetic alterations did not significantly affect the growth rate of H. influenzae. All 
generated mutants were tested for their growth with comparison to the wild type. 
All the mutated cells showed similar growth rate to the wild type H. influenzae. In 
contrast, in 2006, Murphy and colleagues showed that during mutation of outer 
membrane protein P6, which plays a structural function in the bacterial cell, 
several changes would resulted including: morphological alteration; larger cell 
size, vesicle formation, and reduction in cell wall integrity compared to the parent 
cells. Moreover, the growth of the mutated cells was slower, susceptibility to the 
antibiotics and complement-mediated killing by human serum increased (Murphy 
et al., 2006).  
OmpP2 is translocated to the outer membrane via the inner membrane and the 
SHULSODVPLF VSDFH 7KHUHIRUH WKH DELOLW\ RI 2PS3ǻ/ to localise to the outer 
membane was checked to exclude this as a possible explanation for reduced LR-
binding. The result obtained from the SDS-PAGE staining and blotting of the cell 
fractions (enriched for the inner and outer membrane proteins) indicated that the 
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mutated protein was still able to localise to the outer membrane as efficiently as 
the wild-type protein. 
Next, the role of OmpP2 L2 in the H. influenzae binding to rLRP was studied by 
flow cytometery analysis and whole cell pull-down assays. Furthermore, the 
QDWLYHSURWHLQ2PS3DQG2PS3¨/ZHUHSXULILHGQDWLYHO\IURPH. influenzae 
directly using ion exchange and gel filtration. Natively purified proteins were 
again investigated for its binding to the rLRP in ELISA. Mutation of the OmpP2 
loop 2 resulted in a marked reduction of binding to recombinant LRP as shown by 
flow cytometry and whole cell lysate pull-down assay as well as ELISA. 
However, the data showed that the ompP2 knockout still had some residual LR 
binding actvity. This may suggest that there is another binding protein that is not 
yet identified and further screening would be needed to identify this protein. 
Taken together, the experimental data presented herein show that loop 2 (Ala91-
Phe99) has an important role amongst the eight loops of OmpP2 in its binding to 
rLRP. 
This work confirms the identification of OmpP2 as a ligand for LamR. 
Furthermore, the second extracellular loop of this protein has been demonstrated 
to be important for binding to the human receptor. This data builds on previous 
reports that indicated some of the surface-exposed loops are involved in 
recognition of ligands, including small molecule nutrients, bacteriophages and 
eukaryotic target cells (Galdiero et al., 2003). Vitiello and colleagues pointed out 
that OmpP2 loops are capable of different biological activities such as activation 
of TNF, MEK1-MEK2/MAP, IL-6 and JNK (Vitiello et al., 2008).  
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In a newborn mouse model, E. coli K1 mutants missing the extracellular loops 1 
and 2 regions from OmpA were unable to cause meningitis. These regions were 
found to be responsible for survival of the pathogen inside neutrophils and 
dendritic cells and loop regions 1 and 3 are needed for survival the pathogen in 
macrophages. Loop 2 (MPYKGSVENGA) was involved in the majority of the 
interactions and represents an interesting target for immunization. Levels of TNF-
Į,/-1, IL-6, and IL-12 were decreased in the brains of mice infected with loop 1 
and loop 2 mutants compared with animals infected with loop 3 and loop 4 
mutants or OmpA+ E. coli K1 (Mittal et al., 2011). The results may lead to a 
better understanding of the mechanism of H. influenzae invading of the BBB and 
then getting access to the HBMECs and in turn to the development of potential 
vaccines to prevent infection.  
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CHAPTER FIVE 
5. ROLE OF THE SECOND EXTRACELLULAR LOOP OF OMPP2 
IN BINDING TO HUMAN MICROVASCULAR ENDOTHELIAL 
CELLS 
5.1 Introduction  
H. influenzae has many virulence factors which contribute to its pathogenicity. 
For example, in a rats bacterial meningitis model it was found that inoculation of 
animals with live H. influenzae, bacterial LPS or outer membrane vesicles 
induced meningeal inflammation and resulted in both dose- and time-dependent 
increases in cerebrospinal fluid (CSF) white blood cells (WBC) and blood-brain 
barrier permeability (Mustafa et al., 1989; Wispelwey et al., 1989). In vivo and in 
vitro model systems were showed that capsular polysaccharide and 
lipopolysaccharide (LPS) are important for the ability of H. influenzae to traverse 
the nasopharynx and localize in the cerebrospinal fluid and meninges. Also it was 
identified that lipopolysaccharide plays a role in enhancing the efficiency of 
bacterial translocation from the nose to the blood, and in facilitating intravascular 
survival (Moxon, 1992). A study of nasopharyngeal carriage in an infant rat 
model indicated that phosphorylcholine (ChoP) plays a role in H. influenzae 
colonization (Weiser et al., 1998). ChoP is present on the cell surface of the major 
pathogens residing in the human respiratory tract including S. pneumoniae, H. 
influenzae, and Neisseria meningitidis (Gould & Weiser, 2002). Studies have 
revealed that ChoP is expressed on H. influenzae lipopolysaccharide (LPS) and it 
is subjected to phase variation (Weiser et al., 1989; Weiser et al., 1998; Lysenko 
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et al., 2000). Moreover, it was verified that the expression and phase variation of 
ChoP on H. influenzae LPS is mediated by four genes in the lic1 locus: licA, licB, 
licC, and licD (Weiser et al., 1997; Weiser et al., 1990a). It was showed that the 
first gene licA is mediated phase variation (Weiser et al., 1998). This gene has 
multiple tandem repeats of the sequence 5'-CAAT-3' within the coding region of 
the first open reading frame which provides a mechanism for phase variable 
expression (Weiser et al., 1997; Weiser et al., 1990a). By shifting the upstream 
initiation codons in or out of phase with the remainder of the open reading frame, 
could switch on or off the translation of downstream genes (Cope et al., 1990). 
Moreover, it was shown that ChoP mediates the interaction of H. influenzae with 
the PAF receptor (Swords et al., 2000). In addition, the phosphorylcholine (ChoP) 
is a target for C-reactive protein (CRP) (Weiser & Pan, 1998; Lysenko et al., 
2000) which, in the presence of complement against H. influenzae expressing 
ChoP, will have bactericidal activity against the organism (Gould & Weiser, 
2002; Weiser et al., 1990b). H. influenzae has the ability to switch off expression 
of ChoP, which eliminates binding of CRP suggesting that the biological role of 
the ChoP+ phenotype might be evasion of CRP-mediated clearance (Weiser et al., 
1997).  
In a study performed by Reddy et al., (1996) to determine the mechanism of 
binding between mucin and OMPs of NTHi, an overlay binding assay was 
performed and the OMPs P2 and P5 of NTHi were found to function as adhesins 
for purified human nasopharyngeal mucin (HNM). Moreover, the sialic acid-
containing oligosaccharides of HNM appear to be the receptors for NTHi 
(Prasadarao et al., 1996). It was demonstrated in a new born rat meningitis model 
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that a prominent outer membrane protein, OmpA, of Escherichia coli is essential 
for interaction with GlcNAcb1-4GlcNAc epitopes of BMEC glycoproteins and 
entry of OmpA+ E. coli into the central nervous system was inhibited by soluble 
*OF1$Fȕ-4GlcNAc oligomers (Prasadarao et al., 1996). 
Outer membrane protein P2 (OmpP2) is the major outer membrane (porin) protein 
of H. influenzae type b (Hansen et al., 1989; Galdiero et al., 2006). The molecular 
mass of OmpP2 is 38.5 kDa and the structure is composed of 16 transmembrane 
regions separating eight large surface-exposed loops on the external surface of the 
bacterial membrane, seven short periplasmic loops and periplasmic N and C 
termini (Munson & Tolan, 1989; Srikumar et al., 1992b; Srikumar et al., 1997; 
Galdiero et al., 2006). There is increasing evidence to show that OmpP2 of H. 
influenzae plays a significant role in the pathogenesis of the H. influenzae (Duim 
et al., 1996; Yi & Murphy, 1997; Murphy & Bartos, 1988; Chong et al., 1993; 
Andersen et al., 2003). In comparison with the wild-type parent strain, the OmpP2 
mutant Hib was unable to generate bacteremia in infant rats after intraperitoneal 
challenge (Cope et al., 1990).  
The mechanisms responsible for microbial invasion and traversal of the 
microvascular endothelial cell of blood±brain barrier are poorly understood. 
However, previous work indicated that these pathogens required interaction with 
LamR on the surface of HBMECs as a first step to initiate invasion of the BBB 
(Orihuela et al., 2009). OmpP2 of the H. influenzae was shown to be the bacterial 
adhesion responsible for interaction with LamR (Orihuela et al., 2009). Notably, 
LamR has been shown to act as a receptor for a number of bacterial ligands (Kim 
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et al., 2005) as well as neurotrophic viruses, such as Sindbis virus and Dengue 
virus (Wang et al., 1992), and is also required for internalization of prion proteins 
(Nelson et al., 2008). 
It was shown that the cytotoxic necrotizing factor 1 (CNF1) of E. coli K1 
interaction with 37/67-kDa laminin receptor (LamR) is the initial step required for 
bacterial uptake into eukaryotic cells including HBMEC and HEp-2 by mediating 
RhoA activation. Exogenous 37-kDa laminin receptor precursor (LRP) or LRP 
antisense oligodeoxynucleotides blocked the CNF1-mediated RhoA activation 
and bacterial uptake, whereas they were increased in LRP overexpressing cells 
(Chung et al., 2003). 
Work described in chapter four identified that recombinant loop 2 of H. influenzae 
OmpP2 as being important for the interaction of H. influenzae and LamR. Hence, 
it is likely that possession of this loop plays an important role in the pathogenesis 
of H. influenzae. To test this hypothesis, the interaction of synthetic peptides 
based on the loop 2 sequence with rLRP and HBMECs was investigated. In 
addition, the potential roles of OmpP2 and loop 2 in H. influenzae adhesion to, 
and invasion of, cultured HBMECs and HEp-2 are discussed. The final aim 
discussed in this chapter was to explore whether OmpP2 or loop 2 have the ability 
to activate RhoA.  
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 5.2  Results  
5.2.1  Binding of Synthetic Peptides Corresponding to OmpP2 Loop 
2 with Laminin Receptor 
The mutagenesis study of H. influenzae indicated that loop 2 of OmpP2 is the 
most important region of this protein for rLRP-binding. Further characterization 
of the role of this loop in interactions with rLRP was undertaken using synthetic 
peptides. The surface-exposed amino acid sequence corresponding to the 9-amino 
acid apical region of OmpP2 loop 2 (residues 91-99) were synthesized including 
additional terminal cysteine residues; under oxidizing conditions cysteine 
sulfhydryl groups spontaneously form disulfide bonds, thus allowing the peptides 
to more closely mimic the native loop structures seen in outer membrane-
embedded proteins. ELISA assays were performed to determine the interaction 
between rLRP and the OmpP2 loop 2 synthetic peptide and another two synthetic 
peptides; the 34-amino acids corresponding to the fourth loop of N. meningitidis 
PorA (residues 185-218) and the 39 amino acids corresponding to the first loop of 
PorA (residues 31-70) served as positive and negative controls, respectively. 
OmpP2 loop 2 and PorA loop 4 both bound rLR to a significantly higher degree 
than PorA loop 1 (Figure 5.1). This observation confirms that H. influenzae 
OmpP2 binding to rLRP is governed by its second loop and this loop directly 
binds to rLRP. 
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Figure 5.1. Binding of synthetic OmpP2 loop 2 to rLRP. Synthetic loop 2 (5 µM) was 
used to coat the wells of an ELISA plate and rLRP was added to the plates (5 µM). 
Following incubation, bound rLRP was detected with rabbit anti-LR and then anti-rabbit 
IgG-AP antibody. PorA loop 4 and loop 1-coated wells were included as comparative 
positive and negative controls respectively. To correct for non-specific background 
binding, the absorbance in BSA-coated wells was subtracted from that in OmpP2 loop 2, 
PorA loop 4 and PorA loop 1-coated wells. Each data point represents the means of three 
independent experiments; in each experiment each sample was tested in triplicate. * p < 
0.01 compared with synthesised OmpP2L2. Error bars indicate SE. 
5.2.2  OmpP2 Loop 2 Interacts with HBMECs  
Synthetic loop 2 interacts with rLRP in the ELISA. Further study was undertaken 
in order to identify whether this loop can bind directly to HBMECs, which are 
known to express LamR on the cell surface. Synthetic loop 2 peptides were 
coupled to micro-beads and the ability of the synthetic loop 2 to mediate 
adherence of the beads to HBMECs was characterised. This showed that 
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interaction of the micro-beads with HBMECs was enhanced if the micro-beads 
were first coupled to synthetic loop 2 compared to BSA-coated control beads 
(Figure 5.2). After being rinsed with PBS, cells were fixed with 4% 
paraformaldehyde, washed and blocked with BSA/PBS. Anti-IHLR and Mluc5 
IgM mouse antibodies were then added to detect the 37LR and 67LR respectively. 
Cells were rinsed with PBS and then incubated with anti rabbit Alexa 488 (to 
detect IHLR), anti-mouse IgM 647 (to detect Mluc5) and Hoechst 33258 (to 
detect dsDNA). Adhesion of loop2-coated micro-beads to HBMECs was viewed 
using the Leica inverted confocal microscope (DM IRE2). Only micro-beads 
coated with loop 2 were observed to bind HBMECs (Figure 5.2). 
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Figure 5.2. Representative confocal microscopy images of (A) BSA- and (B) loop2-
coated micro-bead adhesion to HBMECs. To determine whether loop 2 of OmpP2 binds 
to HBMECs, HBMECs seeded onto sterile coverslips. Synthetic loop 2 coupled-beads 
and BSA-coupled beads (control) were incubated with HBMECs at 4°C for 1 h. 
HBMECs were then rinsed with PBS and fixed with 4% paraformaldehyde. Cells were 
then washed and blocked with BSA/PBS. Localization of 37LR in HBMEC was detected 
with anti-37LR (anti-IHLR) monoclonal antibody, followed with anti-rabbit Alexa-488 
conjugated secondary antibody (green). Localization of 67LR in HBMEC was detected 
with anti-67LR (MLuC5) monoclonal antibody, followed with anti-mouse IgM 647 
conjugated secondary antibody (red). Nuclear DNA was detected with Hoechst 0033258 
(blue). Images were captured using a Leica inverted confocal microscope (DM IRE2).  
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5.2.3  $GKHVLRQRI2PS32PS3¨/DQGLoop 2-coated Micro-
Beads to HBMECs  
Synthetic OmpP2 loop 2 was shown by confocal microscopy to bind to HBMEC 
monolayers. Further experiments were performed to determine the specificity of 
this reaction by comparing the interaction of the synthetic loop 2 with a scrambled 
sequence based on the loop 2 sequence and the N. meningitidis PorA loop 1 
sequence. Moreover, the micro-beads assay was performed to assess whether the 
deletion of loop 2 from intact OmpP2 affects its ability to bind HBMECs. OmpP2 
DQG2PS3¨/ZHUHSXULILHGIURPH. influenzae under non-denatured conditions 
employing detergent extraction, ion exchange and gel filtration. Purified proteins 
and synthetic peptides were utilised to coat micro beads and then coupled protein-
beads were incubated with HBMEC monolayers. Subsequently, the micro-beads 
adhesion assay slides were read and the beads coated with OmpP2, OmpP2¨L2, 
OmpP2L2, PorAL1, scrambled loop 2 and BSA adhering to monolayers were 
counted. All beads interacted with HBMECs except the negative control (BSA-
coated) beads. Loop 2-coated micro-beads adhered at higher levels compared to 
the scrambled loop 2 and PorAL1 coated control beads. In addition, deletion of 
ORRS IURP2PS3 2PS3¨/ UHGXFHG LWVDELOLW\ WRDGKHUH WR WKH+%0(&V
compared to the wild type OmpP2 (Figure 5.3). These findings confirm that loop 
2 of OmpP2 interacts with HBMEC and it is the most important region of this 
protein that facilitates its binding to the HBMECs. 
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Figure 5.3. Adhesion of OmpP2- 2PS3¨/-, OmpP2L2, PorAL1 or scrambled 
OmpP2L2-coated micro-beads to HBMEC monolayers. Human brain microvascular 
endothelial cells were grown in the 12-well plate containing fibronectin-coated covers 
slips. Coupled protein-beads (5 µl per well) were added for 1 h incubation duration at 4°C. 
After being washed with PBS, the cells were fixed with 4% PFA/PBS. Following the 
washing with the PBS and blocking with 4% BSA/PBS the coverslips were then mounted 
on microscopic slides and examined under light microscope. Employing a blind method 
of reading the slides, micro-beads were counted from 15 random fields per slide at 400 × 
magnification. BSA-coated beads were included as negative controls, and the mean value 
obtained from these controls was subtracted from all other data points. The micro-beads 
attached to HBMECs were counted and the mean total adhesion of micro-beads were 
analysed. Data shown are the means of three independent experiments experiments * p < 
0.1 compared to adhering of the OmpP2 and ** p < 0.1 compared to adhering of 
OmpP2L2. Error bars indicate mean SE. 
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5.2.4  Role of OmpP2 in Association and Invasion of HBMECs and 
HEp-2 Cells by H. influenzae 
To investigate the potential role of H. influenzae OmpP2 in general, and its 
second loop in particular, in adhesion and invasion to epithelial and endothelial 
cells, viable counts of bacteria associated with homogenized infected monolayers 
were determined to compare the capacity of wild-type and ompP2 and RPS3¨/ 
mutant strains to associate with and invade either HBME or HEp-2 cells. 
Adhesion and invasion assays were performed essentially based on the previously 
described employing HBME or HEp-2 monolayers (Section 2.23, 2.24) (Oldfield 
et al., 2007). For association assays, confluent monolayers of HBMECs or HEp-2 
cells were grown in a 24-well tissue culture plate format. Cells were infected with 
bacteria and, following the incubation period, non-adherent bacteria were 
removed by washing and monolayers were permeabilised with 0.1% Saponin. 
Dilutions of the homogenized suspensions were plated on chocolate agar plates 
and numbers of colony forming units determined. To determine the number of 
bacteria entering the cells of HBMECs or HEp-2 monolayers, invasion assays 
were performed essentially as described above except that after the initial 3 h 
incubation, monolayers were washed with PBS and incubated for another 2 h with 
culture medium containing gentamicin, a bactericidal antibiotic that is unable to 
enter eukaryotic cells. Therefore, bacteria adherent to epithelial cells are killed, 
whilst internalized bacteria are protected (St Geme & Falkow, 1990). After 
washing, monolayers were disrupted and homogenized as before for plate 
counting (Figures 5.4 and 5.5). To exclude the possibility that any observed 
changes in the ability of the mutants to adhere or invade monolayers might be due 
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to the presence of the kanamycin resistance cassette, which was inserted into the 
H. influenzae genome during generating the mutants, an additional mutant, 
ompP2::kanR, was used as a control. OmpP2-deficient cells had a significantly 
reduced capacity to adhere to monolayers of HEp-2 in comparison to both 
parental strain and the ompP2::kanR mutant. There was also slightly reduced 
adhesion to HBMEC cells but this reduction did not reach statistical significance 
(Figure 5.4). Although it was not statistically significant, the ompP2 and 
RPS3¨/ mutants exhibited a decrease in invasion of both HEp-2 and 
HBMECs. Taken together, the above data demonstrate that OmpP2, and 
specifically its second extracellular loop contribute to the ability of H. influenzae 
to bind and invade HEp-2 and HBMEC.  
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Figure 5.4. Adherence of H. influenzae and its mutants to human HEp-2 and HBMEC 
cell. Bacterial cells, H. influenzae and its mutants, ¨RPS3 RPS3¨/ DQG
ompP2::kanR, were adjusted to 1 × 107 CFU ml-1 (confirmed retrospectively by plating 
out aliquots of serially diluted inoculums) and were allowed to associate with confluent 
monolayers of HEp-2 (A) and HBMEC (B) cells for 3 h. After incubation, monolayers 
were washed with 1 × PBS to remove non adherent bacteria and cells were disrupted and 
homogenized in 0.1% saponin. 10 µl spots of serial 10-fold dilutions of the homogenized 
suspensions, were plated out and incubated overnight. The viable count plates yielded the 
number of cell-associated bacteria per monolayer (CFU/well per strain). Statistically 
significant differences are represented by * for p < 0.05. In (A) mean levels shown from 
five independent experiments, four wells were used in each experiments. Bars denote 
standard error from the mean samples from five experiments. In (B) mean levels shown 
from a representative of one of two repeated experiments on separate occasions using 
quadruplicate wells, with consistent results. Bars denote standard error from the mean of 
quadruplicate samples from one experiment. CFU denotes colony forming units.  
  
 
 
161 
 
 
Figure 5.5. Invasion of H. influenzae strains into human HEp-2 and HBMEC cells. H. 
influenzae and derivatives were incubated with confluent monolayers of HEp-2 (A) and 
HBMEC (B) cells for 3 h. Following washing, the monolayers were then re-incubated for 
2 h with medium containing 100 µg ml-1 gentamycin to kill attacheded bacteria. 
Monolayers then disrupted and homogenized in 0.1% saponin. Dilutions of the 
homogenized suspensions were plated out on a chocolate agar plates and incubated 
overnight. The number of cell-internalised bacteria per monolayer (CFU/well per strain) 
was measured by viable count. In (A) mean levels are shown from three independent 
experiments, each using four wells. Bars denote standard error from the mean samples 
from three experiments. In (B) mean levels shown from one of two repeated experiments 
on separate occasions using quadruplicate wells, with consistent results. Bars denote 
standard error from the mean of quadruplicate samples. CFU denotes colony forming 
units. Bars denote standard error. 
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5.2.5  H. influenzae OmpP2 Contributes to Activation of RhoA in 
HBMECs 
The LR-binding protein CNF1 of E. coli K1 can activate RhoA, which in turn 
induces host cell cytoskeleton rearrangement and enhances bacterial uptake in 
epithelial cells and human brain microvascular endothelial cells (Flatau et al., 
1997; Chung et al., 2003). Moreover, it was identified that the CNF1 interaction 
with LRP is the initial step required for CNF1-mediated RhoA activation and 
bacterial uptake into eukaryotic cells (Chung et al., 2003). The role of OmpP2, 
and specifically its loop 2, in the possible activation of RhoA was investigated in 
HBMECs using the G-LISATM RhoA activation assay. Monolayers of HBMECs 
were allowed to grow to 50-60% confluency, serum starved and treated with 
2PS3 2PS3¨/ or loop 2. Thrombin was also used as a positive control 
(Chung et al., 2003). In addition to the positive control, OmpP2 activated the 
RhoA-*73LQWUHDWHG+%0(&V)LJXUH2PS3¨/DOVRLQGXFHGWKH5KR$
activation; albeit it this activity was lower than the wild type protein. The 
synthetic loop 2 peptide did not induce a statistically significant increase in RhoA 
activation. 
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Figure 5.6. G-LISATM assay showing activation of RhoA-GTP in the HBMECs. 
HBMECs monolayers were incubated with 5 02PS32PS3¨/ORRSRI2PS3
and thrombin (which was used as a positive control) for 30 min. Cells were lysed and 
samples were run employing G-LISA, the amount of RhoA-GTP was detected with anti-
RhoA antibody and measured by microplate spectrophotometer. Non-treated cells were 
used as a negative control. Data shown are the means of three independent experiments, 
with each sample tested in triplicate. * p < 0.01 compared with non-treated cells (free 
cells). Error bars indicate SE. 
 
5.2.6  Binding of Alanine-substituted Synthetic Peptides of L2 to 
Laminin Receptor 
Full length synthetic loop 2 was able to bind rLRP in ELISA experiments. To 
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synthetic peptides (designated L2-1 to L2-9) were synthesized (Table 2.2). In each 
synthetic peptide a single amino acid was substituted with alanine (A). The ability 
of the derivative peptides to bind purified recombinant LRP protein was analyzed 
by ELISA. Synthetic peptides were immobilized in microtitre wells and rLRP 
added. Loops 1 and 4 of N. meningitidis PorA were included as negative and 
positive controls, respectively. After washing, bound rLRP was detected and 
quantified (Figure 5.7). Two of the peptides (L2-4; N94A, and L2-8; N98A) 
showed significantly reduced rLR-binding compared to wild-type loop 2 peptide. 
As expected, the control non-rLRP binding control peptide (PorA loop 1) also 
showed significantly less binding to rLRP compared to loop 2. The highest rLRP-
binding was exhibited by positive control (PorA loop 4). Taken together our data 
suggested the key residue(s) mediating rLRP binding are the two asparagine (N) 
amino acids within the loop 2 sequence. 
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Figure 5.7. Binding of synthetic OmpP2 loop 2 and its derivatives to rLRP. Loop 2 (L2) 
and its alanine substitued varients (5 µM) were used to coat the wells of an ELISA plate 
and rLRP was added (5 µM). Following incubation, bound rLRP was detected with 
polyclonal rabbit anti-LR and then anti-rabbit IgG-AP antibodies. Synthetic peptides L4 
and L1 of PorA were used as positive and negative control respectively. Specific binding 
was determined by subtracting the absorbance in BSA-coated wells from other wells. 
Each data point represents the means of three independent experiments, in each 
experiment each sample was tested in triplicate. * p < 0.01 compared with whole loop 2 
(L2-1). Error bars indicate SE.  
5.2.7 Variability of OmpP2 and its Loop 2 in H. influenzae Strains 
Further analysis of the OmpP2 and loop 2 sequences was performed to determine 
the degree of conservation of these sequences among 50 sequence isolates of H. 
influenzae (Appendix 2A). OmpP2 was at least 62% identical among these 
isolates and 33 isolates were at least 80% identical (Appendix 2B-C). However, 
within the loop 2 region identity of 50% or more was found in only 20 sequences 
(Adppendix 2D-E). Furthermore, 4 typeable and 10 NTHi H. influenzae strains 
were examined; the identity of the loop 2 amino acids sequence was highly 
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conserved (98%) among the typable isolates compared to the NTHi isolates (76%) 
(Table 5.1). 
Table 5.1. Amino acid sequences of loop 2 of OmpP2 among different H. influenzae 
strains 
Strain OmpP2 Loop 2 sequences Ref. 
 H. influenzae type b Rd TKASENGSDNFGDI (Srikumar et al., 1992b) 
Hib DL42 TKASENGSDNFGDI (Hansen et al., 1989) 
Hib ATCC 9795 TKASENGSDNPGDI (Galdiero et al., 2006) 
Minna TKASENGSDNFGDI (Munson & Tolan, 1989) 
Identity percentage for  
typeable strains  98.21% 
 
NTHi 12085 SAQSGTESDNFGHI (Bell et al., 1994) 
NTHi 3232 SAQSGTESDNFGHI (Bell et al., 1994) 
NTHi 2019 SAQSGTESDNFGHI  
NTHi 12 AAQSGTKSDDFGHI (Bell et al., 1994) 
NTHi 12049 SSYDGENTDGFGGI (Bell et al., 1994) 
NTHi 1479 SKASKEKADQFADI (Sikkema & Murphy, 1992) 
NTHi TN106 SAQSGTESDNFGHI (Sanders et al., 1993) 
NTHi H05-19 SDASKNGSDNFGDI (Sanders et al., 1993) 
NTHi H04-06 SDYTKKKSDHFGDI (Sanders et al., 1993) 
NTHi H99-115 SAQSGTESDNFGHI (Sanders et al., 1993) 
Identity percentage 
for NTHi strains 76.43% 
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5.3  Discussion  
Based on experimental data presented in previous chapters OmpP2 was shown to 
harbor a LRP-binding domain within the loop 2 region. Experiments were 
undertaken to further characterize the role of this region. Maximal rLRP binding 
was initially localized to the region between amino acids 91-99 (ASENGSDNF), 
which corresponds to loop 2. The ability of this sequence to bind rLRP and to 
epithelial and endothelial human cell was investigated. This was addressed by 
producing this region synthetically and incorporating a terminal cysteine residue 
at each end to form a bridge between the peptide ends and thus to stimulate the 
loop structure of this region within the native protein. Binding of the synthetic 
loop 2 to rLRP was tested in ELISA. Synthetic loops 1 and 4 of N. meningitidis 
PorA were used as negative and positive controls, respectively, as N. meningitidis 
PorA loop 4 had been shown previously to bind to rLRP, while no such activity 
was demonstrated for loop 1 (N. Abouseada, personal communication). OmpP2 
loop 2 and PorA loop 4 both bound rLRP in these assays. The binding was 
statistically significant in comparison to the negative controls BSA or synthetic 
loop 1 of PorA.  
In this study, HBMEC cells, which are known to express LamR at the cell surface, 
were used to address whether synthetic loop 2 of OmpP2 of H. influenzae was 
able to mediate adherence to these cells in vitro. Initially, confocal microscopy 
images showed that loop 2 but not BSA- coated beads were able to bind HBMECs. 
Furthermore, the loop 2-coated beads co-localised to 37LR or 67LR proteins. 
Subsequently, images were captured by light microscopy and binding of the 
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2PS3 2PS3¨/ DQG V\QWKHWLF SHSWLGH-coated beads to the HBMEC 
monolayers were counted and then the adherence was analysed. Although the 
micro-beads adhesion assay showed that all protein and peptides-coated beads can 
adhere to the HBMECs, there were obvious differences among the adherence of 
these beads. Deletion of loop 2 from OmpP2 significantly reduced the binding to 
the cells. Additionally, the loop 2-coated micro-beads adhered at significantly 
higher levels compared to the negative control PorA loop 1 or scrambled loop 2. 
Taken together, the data suggest that loop 2 has the ability to interact with the 
HBMECs.  
Adherence to respiratory epithelium is generally assumed to be the first step in 
carriage and the pathogenesis of diseases by encapsulated and nonencapsulated H. 
influenzae (van Alphen et al., 1991b). The ability of bacteria to colonize their 
hosts and cause infection is often related to their ability to express several 
different adhesins with different receptor specificities (Scarselli et al., 2006). 
Here, the potential roles of H. influenzae OmpP2 and its second loop in adhesion 
to, and invasion into, host cells was characterised using the HBMEC and HEp-2 
cell models. 
Experiments using HEp-2 cells were carried out five times for adhesion and three 
times for invasion. However, due to time and material constraints, adhesion and 
invasion experiments using HBMECs cells were carried out only twice and 
ideally they should be repeated at least three times at different occasions to allow 
statistical significance to be fully assessed. Wild type H. influenzae and its 
mutants: ¨ompP2, RPS3¨/ and ompP2::kanR (control), were tested for their 
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ability to adhere to and invade HBMEC and HEp-2 cells. In both cell lines models 
the ompP2::kanR mutant strain of H. influenzae did not display a statistically 
significant difference in its ability to association with and invade HEp-2 or 
HBMEC cells compared to the wild type H. influenzae. Adherence of ¨ompP2 H. 
influenzae to monolayers of HEp-2 was significantly attenuated in comparison 
with both the wild type parent and the ompP2::kanR mutant strain (p < 0.05). 
However, adherence of RPS3¨/ to HEp-2 was not statistically significantly 
reduced. This could be explained by the fact that residues outside of the deleted 
loop 2 of OmpP2 region may also play a role in adherence to these cells. While 
the adherence level to HBMECs was also lower than the wild type but this 
difference did not reach statistical significance. No significant changes in invasion 
were observed in either of the mutants. 
Rho guanosine triphosphatases (Rho GTPases) are molecular switches that control 
a wide variety of regulation various cellular processes involving actin filaments, 
signal transduction pathways, and play a key role in the initiation and regulation 
of cell migration (Lemonnier et al., 2007). Rho proteins play essential roles in 
host cell invasion by bacteria and GTP-binding proteins are major targets for 
bacterial toxins acting inside eukaryotic cells, these GTPases appear to be of 
major importance for the entry of bacteria into eukaryotic host cells (Aktories, 
1997). 
Here, the potential role of OmpP2 and its second loop in mediating activation of 
RhoA-GTP in HBMECs was investigated. To assess the activation, OmpP2 and 
2PS3¨/ ZHUH SXULILHG XQGHU QRQ-denaturing conditions from H. influenzae 
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and its RPS3¨/ mutant derivative. HBMECs were treated with the purified 
SURWHLQV DV ZHOO DV WKH V\QWKHWLF ORRS  2PS3 DQG 2PS3¨/ VLJQLILFDQWO\
increased the activated RhoA level. Deletion of loop 2 from OmpP2 decreased 
RhoA activation compared to OmpP2 but the difference was not significant. 
Activation of RhoA by synthetic loop 2 was not statistically significant. These 
data suggest that H. influenzae OmpP2 may contribute to activation of RhoA but 
the mechanism of this induction may not involve LamR, since the removal of the 
LamR-binding domain did not significantly reduce activation. Further work is 
needed to clarify this.  
In the present work, the surface-exposed amino acid sequence of H. influenzae 
OmpP2 loop 2 was identified to be important for OmpP2 interaction with host 
cells. Substitution of amino acids within synthetic peptides corresponding to loop 
2 identified the asparagine residues at positions L2-4 and L2-8 as being important 
for rLRP binding, which was reduced by 23% and 52% respectively in peptides in 
which these residues were replaced by alanine. Substitution of alanine for other 
amino acids within the loop 2 sequence had no significant effect on the binding. 
The surface-exposed epitopes of OmpP2 protein have been shown to vary 
markedly among NTHi strains. Sikkema and Murphy characterized the OmpP2 
proteins from three NTHi strains and indicated that antigenic differences reside in 
four hypervariable regions of the porin protein (Sikkema & Murphy, 1992). In 
contrast analysis of nucleotide sequences of ompP2 genes have demonstrated that 
the OmpP2 proteins of type b strains are conserved among strains (Munson et al., 
1989a; Munson & Tolan, 1989). Although NTHi strains are frequently implicated 
in non-invasive infections, Hib is a major cause of bacterial meningitis and other 
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invasive infection such as epiglottitis, osteomyelitis, septic arthritis, septicaemia, 
cellulitis, and pericarditis (Collee et al., 1996; Peltola, 2000; William et al., 2005). 
Our findings demonstrate that loop 2 is important for OmpP2-rLRP binding and 
this loop was identified to be conserved motif within the OmpP2 of Hib strains.
  
 
 
172 
 
CHAPTER SIX: General Discussion 
  
  
 
 
173 
 
CHAPTER SIX 
6. GENERAL DISCUSSION 
Acute bacterial meningitis is one of the most severe infectious diseases, causing 
an estimated 171,000 deaths worldwide per year and neurologic sequelae in up to 
30% of the survivors (Grimwood et al., 1995; WHO, 2000). Until the introduction 
of conjugated vaccines, the leading agents of bacterial meningitis were 
Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria 
meningitidis (Ceyhan et al., 2008; Harvey et al., 1999; Pong & Bradley, 1999).  
In recent years, the introduction of modern methods of treatment, effective 
antibiotics and approved vaccines that targeted some serogroups of these 
meningeal pathogens has resulted in a significant decline in mortality (Harvey et 
al., 1999; Bilukha et al., 2005; Morris et al., 2008). However, there is still a high 
incidence of meningitis which is caused by S. pneumoniae, Hib, and N. 
meningitidis (McVernon et al., 2003a; Ceyhan et al., 2008; Flores-Cordero et al., 
2003). Currently there is no available vaccine against N. meningitidis serogroup 
B, which is responsible for the majority of cases in the United States and Europe 
(Milonovich, 2007). It was documented that Hib causes at least three million cases 
of serious disease every year as well as approximately 386,000 deaths (WHO, 
2006). 
Hib conjugate vaccines, PRP-HbOC, PRP-OMP, PRP-T, PRP-D, have 
dramatically reduced the incidence of Hib. Nevertheless, failures have been 
reported in fully immunized infants in different areas, such as England, Ireland, 
Wales and Canada (Heath et al., 2000; McVernon et al., 2004a; Scheifele et al., 
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2005). In addition, the vaccine for Hib is directed against its type-specific 
polysaccharide capsule, it has no ability to prevent infections caused by 
nonencapsulated NTHi (Foxwell et al., 1998). Therefore, understanding 
interactions between bacteria and cells of the blood±brain and blood±CSF barrier 
may allow the development of new strategies to prevent meningitis by blocking 
bacterial adherence. 
Hib is the most pathogenic of the six recognised capsular serotypes (a, b, c, d, e 
and f). H. influenzae pathogenesis begins with colonisation of the nasopharynx. 
This colonisation may be transitory or bacteria may remain for several months 
without affecting the host (asymptomatic carriage). Bacterial adherence to the 
respiratory epithelium represents a mechanism to circumvent clearance, whereas 
invasion into host cells and the mucosa of the upper respiratory tract may allow 
evasion of immune function and subsequent entry into the blood. The passage of 
bacteria through mucosal epithelium and penetration of sub-epithelial blood 
vessels represents a key step in the pathogenesis of meningitis. Entry of bacteria 
into the central nervous system requires passage across the blood-brain barrier 
(BBB). The major anatomical sites of the BBB are the cerebral microvascular 
endothelium of the arachnoid membrane and the choroid plexus epithelium (Polin 
& Harris, 2001). The attachment of bacteria to microvascular endothelial cells is 
promoted by receptors for these pathogens on endothelial cells (Stins et al., 1994). 
Following attachment, bacteria gain entry to the central nervous system by 
disrupting tight junctions, active or passive movement across the endothelial cell, 
or carriage by leukocytes entering the nervous system (Leib & Tauber, 1999b; 
Tuomanen, 1996). 
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Outer membrane proteins (OMPs) of Gram-negative bacteria have diverse 
functions and are directly involved in the interaction with various environments 
encountered by pathogenic organisms. Thus, OMPs represent important virulence 
factors and play essential roles in bacterial adaptation to host niches, which are 
usually hostile to invading pathogens (Galdiero, 2007; Srikumar et al., 1992b; 
Vachon et al., 1985). Understanding the structure and functions of bacterial OMPs 
may facilitate the design of novel antimicrobial drugs and vaccines.  
The LamR proteins role as a laminin receptor makes it an important molecule 
both in host cell adhesion to the basement membrane and in signal transduction 
following this binding event. In addition to these functions, LamR has additional 
roles. It was shown that the reduction of LamR expression reduced developing 
tumours in HT1080 human fibrosarcoma cell line (Scheiman et al., 2010). 
Moreover, it was proposed that the suppression of 37LBP/p40 expression reduces 
tumour formation of lung cancer cells in vivo (Satoh et al., 1999). Also, LamR is 
known to be receptor to many virus and bacteria (Wang et al., 1992; Thepparit & 
Smith, 2004; Huang & Jong, 2009). Understanding the molecular basis of these 
interactions will certainly increase our knowledge of bacterial pathogenesis and 
allow the development of new strategies to prevent diseases, such as meningitis 
caused by H. influenzae and others agents by blocking the adherence of the 
pathogens to their receptors. 
The OmpP2 protein is a homotrimeric porin that constitutes approximately one-
half of the total protein content of the outer membrane. Each monomer consists of 
 DQWLSDUDOOHO ȕ VWUDQGV WKDW VSDQQLQJ WKH RXWHU PHPEUDQH HLJKW VKRUW
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periplasmic turns and eight outer loops of variable size (Galdiero et al., 2003). 
The effect of loop 2 on LRP-binding of the whole bacterium was tested by 
deletion of the loop 2-region from ompP2. Flow cytometry, whole cell lysate pull-
down assays and ELISA experiments showed that the interaction of RPS3ǻ/ 
mutant H. influenzae to LamR was significantly reduced compared to the wild 
type. The recent published data showed that pneumococcus, meningococcus, and 
H. influenzae adhere to the BMECs via LamR, and the same study identified that 
the corresponding LamR-binding adhesins were CbpA, PilQ and PorA, and 
OmpP2 respectively (Orihuela et al., 2009; Abouseada, 2009). These species 
target a common carboxy-terminal recognition site on LamR (amino acids 263±
282), since antibodies recognizing this sequence or a peptide corresponding to 
LamR residues 263±282 could inhibit bacterial binding to microvascular 
endothelial cells. Moreover, it was identified that the CbpA LamR-binding region 
mapped to a highly conserved surface-exposed loop (residues 391EPRNEEK397) 
linking the second and third anti-paraOOHO Į-helices of the R2 domain. 
Pneumococci expressing a CbpAP392GR393G derivative showed significantly 
reduced binding to recombinant LamR and endothelial cells. Importantly, in a 
mouse model of pneumococcal meningitis, strains expressing CbpAP392G-
R393G rarely caused meningitis compared to strains expressing wild-type CbpA 
(Orihuela et al., 2009; Abouseada, 2009). Similarly, it was identified that the 
fourth extra-cellular loop of PorA was the LamR-binding domains of this protein 
(Abouseada, 2009). Residues 192-208 (AYTPAYYTKNTNNNLTL) in the apex 
of loop 4 were found to be particularly important for LamR-binding (Abouseada, 
2009). In this study, the second extra-cellular loop of OmpP2 (amino acids 
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ASENGSDNF) was identified as the LamR-binding domain of this protein 
(Abouseada et al., 2012). Increased knowledge of the structural motifs of bacterial 
ligands that interact with LamR may facilitate the design of therapeutic 
interventions which could disrupt or modulate the interaction of neuroinvasive 
bacteria with LamR and engender protection against bacterial meningitis. 
To define the region(s) of OmpP2 that are responsible for binding of the protein to 
LamR, a series of OmpP2 truncated proteins were characterized and assessed for 
rLRP binding. The ompP2 mutant H. influenzae Rd KW20 was provided from a 
different laboratory (J. Reidl and J. McCullers) and, although it was the same 
strain as the wild type available in our laboratory, it is possible that different 
passage histories of these isolates may have led to changes in the genetic 
background in addition to the defined mutation. Therefore, we generated a new 
ompP2 mutant using our own stock of H. influenzae Rd. All the mutated cells 
showed similar growth rate to the wild type H. influenzae. In addition, the 
truncated OmpP2 was still able to localise to the outer membrane. This is in 
agreement with the findings of a study performed to investigate the role of 
surface-exposed loops of OmpA in E. coli, as the deletion of specific loops from 
the whole protein did not hinder its assembling into the outer membrane of the 
bacterial cells (Koebnik, 1999). In the current study, we obtained three lines of 
evidence: flow cytometry and whole cell lysate pull-down assay as well as ELISA 
that the binding domain responsible for adherence of H. influenzae to rLRP 
resides within the second loop 2 of OmpP2. 
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It is known that surface-exposed loops L1, L2, and L4 of OmpP2 of H. influenzae 
are important for monomer-monomer interactions within the porin trimer; loop L3 
is internal; loops L5, L6, and L7 are superficial; loop L8 contributes to form the 
channel opening on the external side (Galdiero et al., 2006; Galdiero et al., 2003). 
In addition, these loops were identified to have several functions during 
pathogenesis. By utilising seven murine monoclonal anti-Hib porin antibodies, the 
surface-exposed epitopes loops 4 and 8 were identified as antigenic determinants 
on Hib porin (Srikumar et al., 1992a). In another study, Haase et al. proposed that 
the surface-exposed loops L5 and L8 of the OmpP2 of the NTHi are potentially an 
immunodominant region of the molecule (Haase et al., 1994). Accordingly, Yi 
and Murphy published that a MAb specific for loop 5 of the OmpP2 molecule was 
bactericidal and a mutant with minor amino acid changes in this loop lost 
susceptibility to this bactericidal activity (Yi & Murphy, 1994). It was shown that 
immunizing rabbits with peptides corresponding to a conserved loop 6 sequence 
of the gene that encodes the P2 porin of NTHi results in bactericidal activity 
against multiple strains (Neary & Murphy, 2006). 
Prior to employing the H. influenzae mutants in association and invasion 
experiments, in vitro assessment of synthetic loop 2 peptide, recombinant OmpP2 
and OmpP2¨L2 was undertaken to determine whether they can bind directly to 
the HBMECs using coated micro-beads in an adhesion assay. Data showed that 
loop 2 is essential for OmpP2 to interact with HBMECs. Since loop 2 peptide-
coated beads adhered to the HBMECs. In addition, deletion of loop 2 from 
OmpP2 significantly reduced its interaction to the HBMECs in comparison to the 
whole OmpP2-coated beads. To investigate OmpP2 and the contribution made by 
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loop 2 to H. influenzae colonization, the various strains of the H. influenzae were 
compared in an in vitro cell infection model for their ability to adhere to and 
invade into HEp-2 and HBMECs. Both H. influenzae PXWDQW VWUDLQV ¨2PS3
DQG 2PS3¨/ ZHUH FRQVLVWHQWO\ LPSDLUHG LQ WKHLU DELOLW\ WR DGKHUH WR DQG
invade into HBMECs and HEp-2 cells compared to H. influenzae wild-type strain. 
7KHDGKHUHQFH OHYHO RI WKH¨2PS3PXWDQts to HEp-2 (but not HBMECs) was 
significantly reduced when compared to the parental strain. Although the invasion 
UDWHRI¨2PS3DQG2PS3¨/PXWDQWVWUDLQVWRHLWKHU+%0(&VRU+(S-2 cell 
lines model was less than the parental strain, it was not statistically significant. It 
is perhaps not surprising since a variety of bacterial factors, such as the 
polysaccharide capsule, the lipooligosaccharide (LOS), pili, HMW1, influence H. 
influenzae adherence to and entry into mammalian cells (van Alphen et al., 1991b; 
van Alphen & van Ham, 1994; Noel et al., 1994; van Alphen et al., 1996).  
Deletion of loop 2 (Ala91-Phe99) from OmpP2 significantly reduced its 
interaction with rLRP (Abouseada et al., 2012). Thus, these amino acids are 
pivotal in the ability of the OmpP2 to bind to rLRP. Therefore, it is likely that 
possession of this loop plays an important role in the pathogenesis of H. 
influenzae. To further study the role of OmpP2 and its loop 2 to activate RhoA in 
HBMECs was investigated using a G-LISATM assay. This was based on the 
previously published data proposing that the CNF1 interaction with 37-kDa LRP 
is the initial step required for CNF1-mediated RhoA activation and E. coli K1 
uptake in HBMECs cells (Chung et al., 2003). Furthermore, in a separate study, 
the region(s) of CNF1 that are responsible for binding to LRP were investigated; 
two receptor-binding domains were identified, the first located in the N terminus 
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(amino acids 135 to 164) and the second located in the C-terminal portion of 
CNF1 (amino acids 683 to 730) (Rieger et al., 1997). G-LISATM assay was 
employed in order to assess the ability of OmpP2 and its loop 2 in activation the 
RhoA-GTP in the HBMECs. Despite the fact that synthetic loop 2 peptide and 
ERWK UHFRPELQDQW2PS3DQG2PS3¨/SURWHLQDFWLYDWHG WKH5KR$-GTP, the 
activation was not statistically significant compared with non-treated HBMECs 
cells. In addition, no significant differences in RhoA activation were observed 
EHWZHHQ +%0(&V FHOOV WUHDWHG ZLWK 2PS3 RU 2PS3¨/ LQGLFDWLQJ WKDW
OmpP2L2 has little effect on RhoA activation. 
Bacterial pathogens utilize several strategies to modulate the organization of the 
actin cytoskeleton. Some bacterial toxins catalyze the covalent modification of 
actin or the Rho GTPases, which are involved in the control of the actin 
cytoskeleton (Barbieri et al., 2002). In one study, invasion of HBMECs by E. coli 
K1 was found to be mediated by RhoA activation and subsequent remodelling of 
the host-cell actin cytoskeleton; a ǻcnf1 mutant caused decreased RhoA activation 
and invasion HBMECs compared to its wild type parent (Khan et al., 2002). CNF-
1 activates Rho, Rac, and Cdc42 by deamidating Gln-63 (of Rho) or Gln-61 (Rac 
and CDC42), converting a Gln to a glutamate (Hopkins et al., 2003). Deamination 
of glutamine 63 or 61 locks the intrinsic or the GTPase activating protein (GAP)-
induced hydrolysis of GTP leading to the permanent activation of the GTPase 
(Boquet, 2001). 
To further determine the exact site of the interaction between the LamR and loop 
2, several synthetic peptides corresponding to OmpP2 loop 2-region were 
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synthesised, in each one a single amino acid was substituted with alanine (Table 
2.2). These synthetic peptides were analysed by ELISA assay for their ability to 
bind rLRP. Two of the mutated loop 2 peptides (L2-4, L2-8), in both of which the 
asparagine was replaced to alanine, showed markedly less interaction to rLRP 
comparing to the original loop 2.  
Extracellular loops of outer membrane porins, including OmpP2, contribute to the 
pathogenesis of bacteria (Neary & Murphy, 2006; Severino et al., 2010; 
Maruvada & Kim, 2011). It was found that loop L7 or porin OmpP2 intravenous 
injection induced an increased release of IL-6 and TNF-Į DQG HOLFLWHG
hyperglycaemia (Vitiello et al., 2008). Thus, OmpP2 loop 2 bears the potential for 
being a suitable vaccine candidate, but the effect of the variability of this loop on 
H. influenzae binding to LamR has to be evaluated before considering loop 2 for 
vaccine production. 
One reason of the fact that the pathogen can reinfect the host despite a prior 
immune response to other strains of the same organism is due to variations within 
the surface-exposed hypervariable regions. Thus the organism can evade the 
immune system (Brunham et al., 1993). The ability of NTHi to cause recurrent 
infections is in part attributable to antigenic variability in several surface-exposed 
loops of major OmpP2 (Bell et al., 1994; Sikkema & Murphy, 1992). The surface-
exposed epitopes of OmpP2 protein are variable among NTHi strains, whereas 
OmpP2 proteins of type b strains are conserved among strains (Munson et al., 
1989a; Munson & Tolan, 1989). The derived amino acid sequences of the OmpP2 
proteins from the eight H. influenzae strains were aligned (7 NTHi and the 
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OmpP2 sequence from the serotype b strain MinnA). The amino acid identity was 
between 76% and 94%. The OmpP2 proteins from the NTHi strains were 79% to 
84% identical to the OmpP2 protein from H. influenzae type b strain MinnA (Bell 
et al., 1994). These amino acid changes resulted in altered reactivity of murine 
monoclonal antibodies directed against a surface exposed epitope in the L4 loop 
of OmpP2 (Bell et al., 1994).  
Work by van Alphen and colleagues, has demonstrated that regions of the ompP2 
gene encoding surface exposed loops undergo point mutations under immune 
selective pressure (van Alphen et al., 1991a). This observation raises the 
possibility that point mutations could occur in conserved loops targeted as vaccine 
antigens and render a vaccine useless (van Alphen et al., 1991a; Duim et al., 
1996). 
Comparison of the sequences of the ompP2 genes of various nonencapsulated H. 
influenzae strains revealed highly conserved sequences coding for the membrane-
spanning regions and highly variable sequences coding for surface-exposed loops 
(Sikkema & Murphy, 1992). Therefore, the antibodies against these peptides will 
be only strain-specific. Using OmpP2 as an immunogen against H. influenzae-
induced infection would likely ultimately prove to be problematic for all the 
above cited reasons. To overcome this obstacle, conserved antigenic domains 
within these proteins and/or use multiple short linear peptides could be used. In 
the current study, sequences of OmpP2 and its second loop from different H. 
influenzae strains were analysed and it was revealed that the amino acid identity 
of OmpP2 was 62% conserved among all analysed strains and more than 80% 
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among 33 of the 50 isolates examined. However, the amino acids sequences of 
loop 2 of OmpP2 among strains were highly variable. Additional analysis showed 
that the amino acid sequences were highly conserved among typeable H. 
influenzae strains (98.21%) while it was more variable among NTHi strains 
(76.43%). The second asparagine residues in loop 2 sequence (L2-8; N98A), 
which was found to be important for rLRP binding, is only present in the 
sequence of around 50% (26 of 50) OmpP2 sequences. Hib is responsible for most 
invasive infections (90%) such as meningitis, but NTHi is responsible for 10% of 
the invasive infections such as epiglottitis, septic arthritis, osteomyelitis, 
pneumonia and cellulitis and it is responsible for about 90% of noninvasive 
diseases such as otitis media, sinusitis and conjunctivitis (Slack, 2007). Hence, 
these findings may be useful in the development of alternative therapies aimed at 
reducing excessive inflammatory responses during Hib infections. 
In conclusion, this study has shown that the second surface-exposed loop of 
OmpP2 is the most significant region that contributes to binding to LRP. 
Moreover, recombinant OmpP2 and its synthesised loop 2 were shown to bind 
directly to HBMECs. We also showed that this loop plays a role in the interaction 
of H. influenzae with rLRP. However, OmpP2 and its second loop did not 
contribute significantly in the adhesion to and invasion of HEp-2 and HBMECs 
cell lines by H. influenzae, suggesting that there are different factors are mediating 
host cells adhering and invasion. The importance of these newly identified results 
may lead to a better understanding of the mechanism of host-pathogen interaction 
and in turn to the development of potential vaccines to prevent infection. 
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Future Directions  
This study has provided greater insights into the role of outer membrane 
extracellular loops of the H. influenzae porin OmpP2 in LamR-binding. Further 
study is needed to map region(s) of LamR to which loop 2 of OmpP2 binds. 
Truncated protein fragments of LamR can be generated and purified and their 
binding to loop 2 studied. Moreover, inhibition assays can be performed to assess 
whether loop 2 can inhibit the LamR-binding of H. influenzae and other 
meningeal pathogens. Two residues of loop 2 were found to be especially 
important for the interaction; to identify whether these residues are important in 
the context of the whole organism, new mutant strains with these two residues 
substituted could be generated and their binding to LamR can be investigated.  
Although this study has demonstrated the central role of OmpP2, and specifically 
its second extracellular loop, for LamR-binding, the ompP2 knockout strain 
retained residual LamR binding activity. This may suggest there is another 
binding protein, reminiscent of the situation in N. meningitidis, in which two 
distinct LamR-binding proteins have been described. In future experiments, 
different independent approaches, such as cross-linking or immunoprecipation, 
may facilitate identification of such protein(s).  
It will be necessary to determine what role loop 2 plays during infection. The in 
vivo mouse model of H. influenzae type b meningitis may be useful in this respect, 
although it should be noted that the murine model will not necessarily reflect the 
situation in human patients in all details. Additional in vitro assays employing 
  
 
 
185 
 
human cells might also be useful in determining the role of this region in 
infection. 
OmpP2 loop 2 region is found to be important for LamR-bacteria binding and 
thus loop 2 bears the potential for being a suitable vaccine candidate as antibodies 
directed against this region may block the LamR-bacterial interaction, which 
could prevent adhesion or invasion of the BBB by the H. influenzae and thus 
prevent bacterial meningitis. As the loop is surface-accessible, it might also be a 
target for bactericidal antibodies. Bactericidal assays should be performed using 
bacteria grown under in vivo conditions (in the mouse model for example) and 
antibodies raised against the loop 2 could be assessed for serum bactericidal 
activity. 
Given that loop 2 is expressed by a wide range of isolates and is highly conserved, 
among Hib strains, but variable among NTHi strains, it will be of interest to 
investigate and compare the LamR-binding of the equivalent loop in different 
strains of typeable H. influenzae and NTHi. Furthermore, further studies are 
required to evaluate the possible consequences of LamR binding by loop 2 in 
signal transduction cascades occurring after bacterial association with host cells. 
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Appendix 1. Formula of Commonly Used Buffers and Solutions 
Sodium dodecyl sulfate (SDS)-resolving buffer; (36.34 g Tris base, 8 ml 10% 
SDS add deionised waster (dH2O) up to 200 ml, pH at 8.8). 
SDS-staking buffer; (12.114 g Tris base, 8 ml 10% SDS) add dH2O up to 200 
ml, pH at 6.8. 
SDS running buffer (10 ×); dissolve 30.3 g (0.25 M) Tris base, 187.7 g (2.5 M) 
Glycine, in 950 ml dH2O, add 10 g SDS (1%), made up to 1000 ml with dH2O, 
mix well. 
SDS-sample buffer (5 ×); 0.62 M Tris-Cl (pH 6.8), 5% SDS, 25% glycerol, 
ȕ-meracaptoethanol, 0.002% Bromophenol blue, or 7.8125 ml (2 M) Tris-
CO  J 6'6  PO JO\FHURO  PO ȕ-meracaptoethanol, tip of pipette 
Bromophenol blue, made up to 25 ml with dH2O. 
Resolving (separating) gel; 1.7 ml SDS-resolving buffer, 2.33 ml 
Acrylamide/Bis-$FU\ODPLGH   PO G+2  ȝO  $PPRQLXP
peUVXOIDWH$36DQGȝO7HWUDPHWK\OHWK\OHQHGLDPLQH7(0(' 
Staking gel; 1 ml SDS-stacking buffer, 0.8 ml Acrylamide/Bis-Acrylamide 
POG+2ȝO$36DQGȝO7(0(' 
Semi-dry blotting buffer; 5.82 g Tris base, 2.93 g Glycine, 3.75ml 10% SDS, 
200 ml methanol and make up to 1000 ml with dH2O.  
Phosphate buffered saline solution (PBS); 1 × PBS was prepared by dissolving 
1 tablet of Phosphate buffered saline (Dulbaco A, Oxoid) in 100 ml dH2O and 
autoclave, this gives Sodium chloride 0.16 mol, Potassium chloride 0.003 mol, 
Disodium hydrogen phosphate 0.008 mol and Potassium dihydrogen phosphate 
0.001 mol with a pH value of 7.3. 
BSA; (Albumin from bovine serum, Sigma A3912) as lyophilized powder (M W 
c. 66 kDa) was prepared in sterile PBS according to the concentration needed. 
Blocking buffer; 2.52 g skimmed milk powder, 50 ml PBS/0.05% Tween-20 
PO3%6ZLWKȝO7ZHHQ-20); or add 1 g BSA to 100 ml of PBS (1% BSA 
in PBS). 
PBS-Tween washing buffer; PO3%6ȝO7ZHHQ-20. 
Buffers used for protein purification under denature condition (Ni-NTA 
column technique); 100 mM NaH2PO4, 10 mM Tris-Cl, and 8 M urea, adjusts 
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the pH, lysis Buffer (buffer B) at pH 8.0, wash Buffer (buffer C) at pH 6.3 and 
elution Buffer (buffer E) at pH 4.3. 
Antibiotics; prepare according to the recommended concentrations, sterilise by 
filtration and store at 4°C. 
Lysogeny broth (LB); Tryptone 10 g, Yeast extract 5 g and Sodium chloride 10 g 
for 1000 ml dH2O. 
LB agar; Tryptone 10 g, Yeast extract 5 g, Sodium chloride 10 g, Microbial 
tested agar 15 g for 1000 ml of dH2O, pH 7.0 ± 0.2 at 25°C. 
LB ampicillin/IPTG/X-gal agar; /%DJDUDW&ȝJPO-1 Ampicillin, 40 
ȝJPO-,37*DQGȝJPO-1 X-JDOPL[DQGSRXUP0,37*DQGȝJPO-1 
X-gal). 
IPTG (Isopropyl-ȕ-D thiogalactopyranoside [FW 238.8]); 1 M solution stock 
solution was prepared by dissolving 0.23 g of IPTG in 1 ml dH2O, sterilize by 
filtration and store at -20°C. 
DNA loading dye (6 ×); 10 mM Tris-HCl (pH 7.6), 0.03% Bromophenol blue, 
0.03% xylene cyanol FF, 60% glycerol, 60 mM Ethylenediamine tetraacetic acid 
(EDTA). 
TAE buffer (50 × stock); 2 M Tris base (242 g) (life technologies), 2 M Acetic 
acid (57.1 ml glacial acetic acid [Fisher chemicals]) 50 mM EDTA (18.6 g) (pH 
8.0) made up to 1000 ml with dH2O. 
Agarose gel; 0.8-1.0 % agarose was prepared by dissolving 0.8-1 g of agarose 
powder (sigma), 2 ml 50 × TAE buffer and made up to 100 ml with dH2O; melt 
DQGDGGȝOHWKLGLXPEURPLGHPJPO-1). 
ELISA coating (carbonate) buffer; 142 mM sodium bicarbonate, 8 mM sodium 
FDUERQDWH>S+@WRȝJPO-1). 
Alkaline phosphatase buffer; 15.7 g Tris-HCl, 5.8 g NaCl , 0.2 g Mgcl2.6H2O , 
1000 ml dH2O, and adjust the pH to 9.5. 
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Appendix 2 
A-OmpP2 Amino Acids Sequences in Different Strains of H. influenzae  
(http://www.uniprot.org/uniprot/?query=ompP2&offset=0&sort=score) 
1- H. influenzae strain: B1, B2, B3, B4 and D1. 
AVVYNNEGTNVELGGRLSIITEQSNSTVDDQEQQHGALRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYPESSSDHFGGITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNKKYIPTNGNTVGYTYKGIDGLDGLVLGANYLLAQSRVPGGPSPFPRKQGEVYPQQISNGVQVGAKYDANNIIAGIAFGRTNYKTAGADFDPYGDFGLGRKEQVEGV
LSTLGYRFSDLGLLVSLDSGYAKTKYYTTTDSSSGSQTITNPAYDEKRSFVSPGFQYELMEDTNVYGNFKYERTSVNQGKNTREQAVLFGVDHKLHKQVLTYIEGAYARTKTNDK
GKTEKTGKEKSVGVGLRVYF 
2- H. influenzae strain: Serotype B. 
AVVYNNEGTNVELGGRLSIIAEQSNSTVDNQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVTKASENGSDNFGDITSKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVLNNSDYIPTSGNTVGYTFKGIDGLVLGANYLLAQKREGAKGENKRPNDKAGEVRIGEINNGIQVGAKYDANDIVAKIAYGRTNYKYNESDEHKQQLNGVLATLGYRFS
DLGLLVSLDSGYAKTKNYKIKHEKRYFVSPGFQYELMEDTNVYGNFKYERTSVDQGEKTREQAVLFGVDHKLHKQLLTYIEGAYARTRTTETGKGVKTEKEKSVGVGLRVYF 
3- H. influenzae strain: D2, D3, D3R and D4.  
AVVYNNEGTNVELGGRLSIITEQSNSTVDDQEQQHGALRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYPGSSSDHFGGITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNKKYILTNGNTVGYTYKGIDGLDGLVLGANYLLAQSRVPGGPGLFPRKQGEVYPQQISNGVQVGAKYDANNIIAGIAFGRTNYKTAGADFDFSDAFGLGRKEQVEGV
LSTLGYRFSDLGLLVSLDSGYAKTKYHTTTTDSDDGRQTITNPAYDEKRSFVSPGFQYELMEDTNVYGNFKYERTSVNQGKNTREQAVLFGVDHKLHKQVLTYIEGAYARTKTN
DKGKTEKTGKEKSVGVGLRVYF 
4- H. influenzae strain: T1 and T2. 
AVVYNNEGSKVELGGRLSVIAEQSNNTVDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFISHYQDNADHFDDITTKYAYVTLGNKAFGEVKLGRAKTIADDITSAE
DKEYGVLNNSKYIRTNGNTVGYTFKGIDGLVLGANYLLAQARDTANPGKKGEVAAQSISNGVQVGAKYDANNIVAGIAYGRTNYRKNIIAPKQNLGRKDQVEGVLSTLGYHFSD
LGLLVSLDSGYAKTKYYEQQQQQRSSPTKPRYDEKRYFVSPGFQYELMEDTNVYGNFKYERTSSDEGKKTREQAVLFGVDHKLHKQVLTYIEGAYARTKTNGKGKAETTGKEKS
VGVGLRVYF 
5- H. influenzae strain: A1/A850043.  
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AVVYNNEGTNVELGGRLSVIAEQSNSTRKDQKQQHGELRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYQSSSDNFGNIITKYAYVTLGNKGFGEVKLGRAKTISDGITSAEDK
EYGVLENKEYIPKDGNSVGYTFKGIDGLVLGANYLLAQKREAYKTATATPGEVIAQVISNGVQVGAKYDANNIIAGIAYGRTNYREDLATQDKSGKKQQVNGALSTLGYRFSDLG
LLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
6- H. influenzae strain: AG30010. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPIDGNTVGYTFKGIDGLVLGANYLLAQERYKYTTAAAAGAAGAAGAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIASPDLGKKQQVNGALS
TLGYRFSDLGLLVSLDSGYAKTKNYKDKHEKSYFVSPGFQYELMEDTNVYGNFKYERDSVDQGKKTREQAVLFGVDHKLHKQVLTYIEGAYARTRTTESKKGVKTEKEKSVGV
GLRVYF 
7- H. influenzae strain: 321GC.  
AVVYNNEGTKVELGGRVSIIAEQSTSNRKDQKHQHGSLRNQGSRFNIKVTHNLGDGYYALGYYETRFINKDIDGNEKNIGSGFGSITTKLAYAGLGNKELGEATFGLQKTIADKIST
AEDKEYGVIEKNSYIPTEGNAIAYTYKGIEGLTLGASYVFGGRNFSDYEITDGKVSNAVQVGAKYDANNIVAGFAYGRTNYKAQQAKTQQVNGALATLGYHFDDLGLLISLDSGY
AKTKNKADKHEKRYFVSPGFQYELMEDTNLYGNLKYERINSVDQGEKVREHAVLFGIDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
8- H. influenzae strain: 3185A.  
AVVYNNEGTNVELGGRLSVIAEQSNSTRKDQKQQHGELRNAGSHFHIKATHNFGDGFYAQGYLETRLVSDYQSSSDNFGNIITKYAYVTLGNKGFGEVKLGRAKTIADGITSAED
KEYGVLENKEYIPKDGNSVGYTFKGIDGLVLGANYLLAQKREAYKTDAATPGEVIAQAISNGVQVGAKYDANNIIAGIAYGRTNYREDLAELGNKSGKKQQVNGALSTLGYRFS
DLGLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKDKTEKTEKEKSVGVGLRVYF 
9- H. influenzae strain: 3224A. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERYKYGGAAGGAGGAGAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYRESIHEKDLGKKQQVNGALST
LGYRFSDLGLLVSLDSGYAKTKNYKDKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREQAVLFGIDHKLHKQVLTYIEGAYARTRTNDKSKAEKTEKEKSVGVGL
RVYF 
10- H. influenzae strain: 3230B. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERNKYGTGVGEVTSQSISNGVQVGAKYDANNIIVGIAYGRTNYREDVSQQDDAGKKQQVNGALSTLGYRFSDLGL
LVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNLYGNFKYERNSVDQGKKEREHAVLFGVDHKLHKQVLTYIEGAYARTRTTTRDTTKNTSTVKTEKEKSVGVGLRVYF 
11- H. influenzae strain: ATCC 51907 / DSM 11121 / KW20 / Rd. 
AVVYNNEGTNVELGGRLSIIAEQSNSTVDNQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVTKASENGSDNFGDITSKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVLNNSDYIPTSGNTVGYTFKGIDGLVLGANYLLAQKREGAKNTNKQPNDKAGEVRIGEINNGIQVGAKYDANDIVAKIAYGRTNYKYNEADEHTQQLNGVLATLGYRFS
DLGLLVSLDSGYAKTKNYKTKHEKRYFVSPGFQYELMEDTNVYGNFKYERTSVDQGEKTREQAVLFGVDHKLHKQLLTYIEGAYARTKTTNGGVKTEKEKSVGVGLRVYF 
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12- H. influenzae strain: 86-028NP. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTTAAGTRAVTVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIVDPDLGKKQQVNGALSTLGY
RFSDLGLLVSLDSGYAKTKNYKDKHEKSYFVSPGFQYELMEDTNVYGNFKYERDSVDQGKKTREQAVLFGVDHKLHKQVLTYIEGAYARTRTTEQAKGVKTEKEKSVGVGLRV
YF 
 
13- H. influenzae strain: 2019. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNFAKGEVKLGRAKTIADGIISAEDK
EYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQQRHKYTAAAAAAAAAGGARAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDITITPADKLGKKQQVNG
ALSTLGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERNSVDQGEKEREQAVLFGIDHKLHKQVLTYIEGAYSRTRTTTVGSKTNASKVKTE
KEKSVGVGLRVYF 
14- H. influenzae strain: 23P2H1. 
AVVYNNEGTKVELGGRVSIIAEQSTSNKKGQKHQHGSLRNQGSRFNIKVTHNLGDGYYALGYYETRFMNKNIDSTENSIGSGFGTITTKLAYAGLGNKELGEATFGLQKTIADIIST
AEDKEYGVIDKKPYIPTEGNAIAYTYKGIEGLTLGASYVFGGRNFYDYEIANGKISNAVQVGAKYDANNIVAGIAYGRTNYKAEQGKTQQVNGALATLGYHFDDLGLLISLDSGY
AKTKNKAAKHEKRYFVSPGFQYELMENTNVYGNFKYERSSVDQGEKEREHAVLFGVDHKLHKQVLTYIEGAYARTRTTE 
 
15- H. influenzae strain: 23P4H1.  
AVVYNNEGTKVELGGRVSIIAEQSTSNKKGQKHQHGSLRNQGSRFNIKVTHNLGDGYYALGYYETRFMNKNIDSTENSIGSGFGTITTKLAYAGLGNKELGEATFGLQKTIADIIST
AEDKEYGVIDKKPYIPTEGNAIAYTYKGIEGLTLGASYVFGGRNFYDYEIANGKISNAVQVGAKYDANNIVAGIAYGRTNYKAEQGKTQQVNGALATLGYHFDDLGLLISLDSGY
AKTKNKAAKHEKRYFVSPGFQYELMENTNVYGNFKYERSSVDQGEKEREHAVLFGVDHKLHKQVLTYIEGAYARTRTTEQAKGV 
 
 16- H. influenzae strain: 5657. 
AVVYNNEGTKVELGGRLTIIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVSKYKDNADHFDSITTKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFEGIDGLVLGANYLLAQQRNAHGSTAGEVVAQVISNGVQVGAKYDANNIIAGIAYGRTNYREDLAAQGDSDKKQQVNGALSTLGYRFSDLGL
LVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
17- H. influenzae Strain: 73P4H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTRKDQKQQHGELRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYESRSDNFGNIITKYAYVTLGNKGFGEVKLGRAKTISDGITSAEDK
EYGVLKNKEYIPKDGNSVGYTFKGIDGLVLGANYLLAQKREAYKTATATPGEVTSQSISNGVQVGAKYDANNIIVGIAYGRTNYREDVPQQNDVGKKQQVNGALSTLGYRFSDL
GLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNLYGNFKYERNSVDQGKKEREQAVLFGIDHKLHKQVLTYIEGAYARTRTTMHDTKKTSTVKTEKEKSVGVGLRVY
F 
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18- H. influenzae strain: 31P12H1.  
AVVYNNEGTNVELDGHLSVIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVSKYKDNADHFDSITTKYAYVTLGNKALGEVKLGRAKTIADGITSAE
DKEYGVLNNSKYIPTNGNTVGYTFEGIDGLVLGANYLLAQQRNAHSGAAGEVVAQAISNGVQVGAKYDANNIIAGIAYGRTNYREDLAIQDKSGKKQQVNGALSTLGYRFSDLG
LLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
19- H. influenzae strain: 14P5H1. 
AVVYNNEGTKVELGGRLSVIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVTNPNGFTHEDRDGFGDITTKYAYVTLGNKALGEVKLGRAKTIADGI
TSAEDKEYGVLNNSKYVPTNGNTAGYTFKGIDGLVLGANYLLAQKYDNAGVNDGEVQKQSISNGVQVGAKYDANNIVAAIAFGRTNYKEDNSPSASKRKEQLKGVLSTLGYRFS
DLGLLVSLDSGYAKTKNHKKHRPAAAAYDEKRYFVSPGFQYELMEDTNVYGNFKYERNSSDQGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNEKGQTEKTEKEKSGG
VGLRVYF 
 
20- H. influenzae strain: 14P14H1. 
AVVYNNEGTKVELGGRLSVIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVTNPNGFTHEDRDGFGDITTKYAYVTLGNKALGEVKLGRAKTIADGI
TSAEDKEYGVLNNSKYVPTNGNTAGYTFKGIDGLVLGANYLLAQKYDNAGANDGEVQKQSISNGVQVGAKYDANNIVAAIAFGRTNYKEDNSPCASKRKEQLKGVLSTLGYRF
SDLGLLVSLDSGYAKTKNHKKHIPAAAAAAAAAAYDEKRYFVSPGFQYELMEDTNVYGNFKYERNSSDQGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNEKGQTEKTE
KEKSVGVGLRVYF 
 
21- H. influenzae strain: 3232.  
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKAFGEVKLGRAKTISDGITSAEDK
EYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERYKYGGAAGGAGAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYRESIHEKDLGKKQQVNGALSTLGYRF
SDLGLLVSLDSGYAKTKNYKDKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREQAVLFGIDHKLHKQVLTYIEGAYARTRTNDKSKAEKTEKEKSVGVGLRVYF 
22- H. influenzae strain: 12085. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTDGNTVGYTFKGIDGLVLGANYLLAQERHKYTGAGAGAVAGEVYQQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIIAGSDSGKKQQVNGALSTLGYRF
SDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREHAVLFGVDHKLHKQVLTYIEGAYARTRTTQATGTKVKTEKEKSVGVGLRVY
F  
23- H. influenzae strain: 13P24H1s. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTDGNTVGYTFKGIDGLVLGANYLLAQERHKYTGAGAGAVAGEVYQQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIIAGSDSGKKQQVNGALSTLGYRF
SDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREHAVLFGVDHKLHKQVLTYIEGAYARTRTTQATGTKVKTEKEKSVGVGLRVY
F 
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24- H. influenzae strain: 1479. 
AVVYNNEGTKVELGGRLSVIAEQSSSTEDNQEQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVSKASKEKADQFADIVNKYAYLTLGNNTFGEVKLGRAKTIADEITTAE
DKEYGLLNSKKYIPTNGNTVGYTFNGIDGLVLGANYLLAQERDLRTLDSRTNPTKSGEVTVGEVSNGIQVGAKYDANNIIVAIAYGRTNYKDSNHSYTQKIPKANAADADTDTTII
YPHHGKKQEVNGALASLGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERNSVDQGEKEREQALLFGIDHKLHKQVLTYIEGAYSRTRTTSV
GDKQVASKVKTEKEKSVGVGLRVYF 
25- H. influenzae strain: 74P4H1. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNNALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTAAAAGGARAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDITITPAYKLGKKQQVNGALST
LGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERNSVDQGEKEREQAVLFGIDHKLHKQVLTYIEGAYSRTRTTTVGSKTNASKVKTEKEKS
VGVGLRVYF 
 
26- H. influenzae strain: 13P36H1. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTDGNTVGYTFKGIDGLVLGANYLLAQERHKYTGAGAGAVAGEVYQQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIIAGSDSGKKQQVNGALSTLGYRF
SDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREHAVLFGVDHKLHKQVLTYIEGAYARTRTTQATGTKVKTEKEKSVGVGLRVY
F 
 
27- H. influenzae strain: 5P30H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTRKDQKQQHGELRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYESRSDNFGNIITKYAYVTLGNKGFGEVKLGRAKTISDGITSAEDK
EYGVLKNKEYIPKDGNSVGYTFKGIDGLVLGANYLLAQERVAYSSNGNTPGEVSTQKISNGVQVGAKYDANNIIAGIAYGRTNYREDLAAPQAKSGKKQQVNGALSTLGYRFSD
LGLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNLYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
 
28- H. influenzae strain: 47P12H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTADDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVTKASENGSDNFGDITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVIKNSKYIPTNGNTIGYTFKGIDGLVLGANYLLAQERYEGEVNPQKISNGVQVGAKYDANNIIAGIAYGRTNYRENTIGIPGLGKKQQVNGALSTLGYRFSDLGLLVSLDSG
YAKTKNYKAKHEKRYFLSPGFQYELMEDTNVYGNFKYERNSVDQGKKTREHAVLFGVDHKLHKQLLTYIEGAYARTRTTSGTNVTTEKEKSVGVGLRVYF 
 
29- H. influenzae strain: 14P1H1. 
AVVYNNEGTKVELGGRLSVIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVTNPNGFTHEDRDGFGDITTKYAYVTLGNKALGEVKLGRAKTIADGI
TSAEDKEYGVLNNSKYVPTNGNTAGYTFKGIDGLVLGANYLLAQKYDNAGVNDGEVQKQSISNGVQVGAKYDANNIVAAIAFGRTNYKEDNSPSASKRKEQLKGVLSTLGYRFS
DLGLLVSLDSGYAKTKNHKKHRPAAAAYDEKRYFVSPGFQYELMEDTNVYGNFKYERNSSDQGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNEKGQTEITEKEKSVGV
GLRVYF 
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30- H. influenzae strain: 48P29H1. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERYKYTAAAAVPGAVPGAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIITGSDSGKKQQVNGALS
TLGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREQAVLFGIDHKLHKQVLTYIEGAYARTRTNDKSKAEKTEKEKSVGVG
LRVYF 
 
31- H. influenzae strain: 12. 
AVVYNNEGTKVELGGRLSIIAEQSNSTVNDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVAAQSGTKSDDFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVLNNSKYIPTDGNTVGYTFKGIDGLVLGANYLLAQDRSKYTASGSVAGEVTPQSISNGVQVGAKYDANNIIIGIAYGRTNYREDIISKQLNNLVGTKQQVNGALSTLGYRF
SDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERDSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTTESKKGVKTEKEKSVGVGLRVYF 
32- H. influenzae strain: 74P15H1. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNNALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTAAAAAAAGGARAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDITITPAYKLGKKQQVNGA
LSTLGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERNSVDQGEKEREQAVLFGIDHKLHKQVLTYIEGAYSRTRTTTVGSKTNASKVKTEKE
KSVGVGLRVYF 
 
33- H. influenzae strain: not presented.  
AVVYNNEGTNVELGGRLSIIAEQSNSTVNDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVADQSGTESDHFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTGVGVGAAGAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDIHKEDLGKKQQVNGALSTLG
YRFSDLGLLVSLDSGYAKTKNYKDKHEKHYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDQGKTEKTEKEKSVGVGL
RVYF 
 
34- H. influenzae strain: 14P23H1. 
AVVYNNEGTKVELGGRLSVIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRLVTNPNGFTHEDRDGFGDITTKYAYVTLGNKALGEVKLGRAKTIADGI
TSAEDKEYGVLNNSKYVPTNGNTAGYTFKGIDGLVLGANYLLAQKYDNAGANDGEVQKQSISNGVQVGAKYDANNIVAAIAFGRTNYKEDNSPCASKRKEQLKGVLSTLGYRF
SDLGLLVSLDSGYAKTKNHKKHIPAAAAAAAAAAYDEKRYFVSPGFQYELMEDTNVYGNFKYERNSSDQGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNEKGQTEKTE
KEKSVGVGLRVYF 
 
35- H. influenzae strain: 48P45H1. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKGQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNKALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERYKYTAAAVPGAGAGAVAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDITGSDLGKKQQVNGAL
STLGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNFYGNFKYERNSVDQGKKEREQAVLFGIDHKLHKQVLTYIEGAYARTRTNDKSKAEKTEKEKSVGV
GLRVYF 
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36- H. influenzae strain: 74P1H1. 
AVVYNNEGTNVELGGRLSIIAEQSNSTIKDQKQQHGALRNQSSRFHIKATHNFGDGFYAQGYLETRLVSAQSGTESDNFGHIITKYAYVTLGNNALGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTAAAAAAAGGARAVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDITITPAYKLGKKQQVNGA
LSTLGYRFSDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERNSVDQGEKEREQAVLFGIDHKLHKQVLTYIEGAYSRTRTTTVGSKTNASKVKTEKE
KSVGVGLRVYF 
 
37- H. influenzae strain: 73P2H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTRKDQKQQHGELRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYESRSDNFGNIITKYAYVTLGNKGFGEVKLGRAKTISDGITSAEDK
EYGVLKNKEYIPKDGNSVGYTFKGIDGLVLGANYLLAQKREAYKTATATPGEVTSQSISNGVQVGAKYDANNIIVGIAYGRTNYREDVPQQNDVGKKQQVNGALSTLGYRFSDL
GLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNLYGNFKYERNSVDQGKKEREQAVLFGIDHKLHKQVLTYIEGAYARTRTTMHDTKKTSTVKTEKEKSVGVGLRVY
F 
 
38- H. influenzae strain: 5P41H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTRKDQKQQHGELRNAGSRFHIKATHNFGDGFYAQGYLETRLVSDYESRSDNFGNIITKYAYVTLGNKGFGEVKLGRAKTISDGITSAEDK
EYGVLKNKEYIPKDGNSVGYTFKGIDGLVLGANYLLAQERVAYSSNGNTPGEVSTQKISNGVQVGAKYDANNIIAGIAYGRTNYREDLAAPQAKSGKKQQVNGALSTLGYRFSD
LGLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNLYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTRTRTNDKGKTEKTEKEKSVGVGLRV
YF 
 
39- H. influenzae strain:18P4H1. 
AVVYNNEGTNVELGGRLSVIAEQSTNTLDDQEQQHGALRNQGSRFHIKATHNLGDGFYAQGYLETRFVTDITKDKSDHFGDITTEYAYVTLGNKAFGEVKLGRAETIAGGITSAE
DKEYGVLNNSKYIPTNGNTAGYTFKGIDGLVLGANYLLAQQRDVYHTVGKPGEVYPQSISNGVQVGAKYDANNIVAGIAYGRTNYRENIRLTALSPSRKEQVEGVLSTLGYHFSD
LGLLVSLDSGYAKTKNHMKPAITTTTTTAAAEPAYDEKRYFVSPGFQYELMEDTNVYGNFKYERTYVNQGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNDKGKAEKTG
KEKSMGVGLRVYF 
 
40- H. influenzae strain: 22P5H1. 
AVVYNNEGTKVELGGRLSIIAEQSTNTEKDQKQQHGTLRNQGSRFHIKATHNFGDDFYAQGYLETRFVADQSGTESDHFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTAGSDTVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDLSTTKDLGKKQQVNGALSTLGYRFS
DLGLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
 
41- H. influenzae strain: not present. 
AVVYNNEGTKVELGGRLSIIAEQSNSTIKDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVAAQSGTGSDDFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGTNYLLAQDRYKYAATGSFAGEVTPQSISNGVQVGAKYDANNIIIGIAYGRTNYREDIVTAPGGDLAGTKQQVNGALSTLGYRFS
DLGLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
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42- H. influenzae strain: 18P1H1. 
AVVYNNEGTNVELGGRLSVIAEQSTNTLDDQEQQHGALRNQGSRFHIKATHNLGDGFYAQGYLETRFVTDITKDKSDHFGDITTEYAYVTLGNKAFGEVKLGRAETIAGGITSAE
DKEYGVLNNSKYIPTNGNTAGYTFKGIDGLVLGANYLLAQQRDVYHTVGKPGEVYPQSISNGVQVGAKYDANNIVAGIAYGRTNYRENIRLTVLSPSRKEQVEGVLSTLGYHFSD
LGLLVSLDSGYAKTKNHMKPAITTTAATTAAEPAYDEKRYFVSPGFQYELMEDTNVYGNFKYERTYVNQGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNDKGKAEKTG
KEKSMGVGLRVYF 
 
43- H. influenzae strain: 31P7H7. 
AVVYNNEGTNVELDGHLSVIAEQSSNTLDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVSKYKDNADHFDSITTKYAYVTLGNKALGEVKLGRAKTIADGITSAE
DKEYGVLNNSKYIPTNGNTVGYTFEGIDGLVLGANYLLAQQRNAHSGAAGEVVAQAISNGVQVGAKYDANNIIAGIAYGRTNYREDLAIQDKSGKKQQVNGALSTLGYRFSDLG
LLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
 
44- H. influenzae strain: 22P1H1. 
AVVYNNEGTKVELGGRLSIIAEQSTNTEKDQKQQHGTLRNQGSRFHIKATHNFGDDFYAQGYLETRFVADQSGTESDHFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAED
KEYGVLNNSKYIPTNGNTVGYTFKGIDGLVLGANYLLAQERHKYTAGSDTVAGEVYPQKISNGVQVGAKYDANNIIAGIAYGRTNYREDLSTTKDLGKKQQVNGALSTLGYRFS
DLGLLVSLDSGYAKTKNYKDKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTNDKGKTEKTEKEKSVGVGLRVYF 
 
45- H. influenzae strain: 12049. 
AVVYNNEGTKVELGGRLSVIAEQSNTTVDDQKQQHGALRNQGSRFHIKATHNFSDGFYAQGYLETRLISSYDGENTDGFGGIVTRYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVLNNSKYIPTNGNTAGYTFKGIDGLVLGANYLLAQKYDTAGVAGEVQRQSISNGVQVGAKYDANNIVAAIAFGRTNYKESSVIALGRKEQLKGVLSTLGYRFSDLGLLVS
LDSGYAKTKNHKELNKPTGAKPAYDEKRYFVSPGFQYELMEDTNVYGNFKYERTSSDEGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNDKNKPEKTGKEKSVGVGLRV
YF 
 
46- H. influenzae strain: 54P24H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTADDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVTKASENGSDNFGDITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVIKNSKYIPTNGNTIGYTFKGIDGLVLGANYLLAQERYEGEVNPQKISNGVQVGAKYDANNIIAGIAYGRTNYRENTIGIPDLGKKQQVNGALSTLGYRFSDLGLLVSLDSG
YAKTKNYKAKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKTREHAVLFGVDHKLHKQLLTYIEGAYARTRTTSGTNVTTEKEKSVGVGLRVYF 
 
47- H. influenzae strain: 54P33H1. 
AVVYNNEGTNVELGGRLSVIAEQSNSTADDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVTKASENGSDNFGDITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVIKNSKYIPTNGNTIGYTFKGIDGLVLGANYLLAQERYEGEVNPQKISNGVQVGAKYDANNIIAGIAYGRTNYRENTIGIPDLGKKQQVNGALSTLGYRFSDLGLLVSLDSG
YAKTKNYKAKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKTREHAVLFGVDHKLHKQLLTYIEGAYARTRTTSGTNVTTEKEKSVGVGLRVYF 
 
 
48- H. influenzae strain: 54P33H1. 
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AVVYNNEGTNVELGGRLSVIAEQSNSTADDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVTKASENGSDNFGDITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVIKNSKYIPTNGNTIGYTFKGIDGLVLGANYLLAQERYEGEVNPQKISNGVQVGAKYDANNIIAGIAYGRTNYRENTIGIPDLGKKQQVNGALSTLGYRFSDLGLLVSLDSG
YAKTKNYKAKHEKRYFVSPGFQYELMEDTNVYGNFKYERNSVDQGKKTREHAVLFGVDHKLHKQLLTYIEGAYARTRTTSGTNVTTEKEKSVGVGLRVYF 
 
49- H. influenzae strain: R2846 / 12. 
AVVYNNEGTKVELGGRLSIIAEQSNSTVNDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVAAQSGTKSDDFGHIITKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVLNNSKYIPTDGNTVGYTFKGIDGLVLGANYLLAQDRSKYTASGSVAGEVTPQSISNGVQVGAKYDANNIIIGIAYGRTNYREDIISKQLNNLVGTKQQVNGALSTLGYRF
SDLGLLVSLDSGYAKTKNYKAKHEKSYFVSPGFQYELMEDTNVYGNFKYERDSVDQGKKAREHAVLFGVDHKLHKQVLTYIEGAYARTRTTESKKGVKTEKEKSVGVGLRVYF 
 
50- H. influenzae strain: R2866. 
AVVYNNEGSKVELGGRLSVIAEQSNNTVDDQKQQHGALRNQGSRFHIKATHNFGDGFYAQGYLETRFVSHYQDNADHFDDITTKYAYVTLGNKAFGEVKLGRAKTIADGITSAE
DKEYGVLNNSKYIRTNGNTVGYTFKGIDGLVLGANYLLAQARDTANPSKEGEVATQSISNGVQVGAKYDANNIVAGIAYGRTNYRKNIITPKQDLGRKDQVEGVLSTLGYHFSDL
GLLVSLDSGYAKTKYYEQQQQSNSTKPRYDEKRYFVSPGFQYELMEDTNVYGNFKYERTSSDEGKKTHEQAVLFGVDHKLHKQVLTYIEGAYARTKTNGKGKAETTGKEKSVG
VGLRVYF 
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B- Variability of OmpP2 Amino Acids in Different Strains of H. influenzae 
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C- Alignments of OmpP2 Amino Acids in Different Strains of H. influenzae 
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D-Variability of OmpP2L2 Amino Acids in Different Strains of H. influenzae 
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E-Alignments of OmpP2L2 Amino Acids in Different Strains of H. influenzae 
 
